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Crystal Engineering of Co-Crystals and their Relevance to Pharmaceutical Forms 
Tanise R. Shattock 
ABSTRACT 
 
 
 
The research presented herein focus upon crystal engineering of co-crystals with 
an emphasis upon the exploration of co-crystals in the context of delineation of the 
reliability of hydrogen bonded supramolecular synthons and their hierarchies. The 
approach involves a combination of systematic Cambridge Structural Database analysis 
and a series of model co-crystal experiments.  In addition, the viability of solid state 
methodologies toward supramolecular synthesis of co-crystals and the effect on 
polymorphism is also addressed. The application of the acquired knowledge is towards 
the crystal engineering of pharmaceutical co-crystals. The rational design and synthesis 
of pharmaceutical co-crystals accomplished by the selection of appropriate co-crystal 
formers facilitated by analysis of existing crystals structures in the CSD will be 
demonstrated. The processing of pharmaceutical co-crystals will also be addressed in 
terms of slurry conversion, solvent drop grinding and solution crystallization.  
 
 
 
 
 
 
 
 
 1
 
 
 
 
1. Introduction 
 
1.1. Introduction 
 
1.1.1. Supramolecular Chemistry   
 
 
Supramolecular chemistry defined by Jean Marie Lehn as “chemistry beyond the 
molecule” is the organization of entities that results from the association of two or more 
chemical species held together by non-covalent interactions.1-7 Early inspiration for the 
construction of supramolecular entities was obtained from nature and focused upon the 
development of macrocyclic receptors for the selective binding of alkali metal cations.8-23  
The selective binding of a substrate by a molecular receptor involves molecular 
recognition, the so called ‘lock and key’ concept enunciated by Emil Fischer.24 
Consequently the principles of self-assembly and molecular recognition are intimately 
associated paradigms of supramolecular chemistry.  
Supramolecular approach to synthesis offers an attractive alternative to traditional 
covalent synthesis, as a consequence the field of supramolecular chemistry has grown 
around Lehn’s analogy that “supermolecules are to molecules and the intermolecular 
bond what molecules are to atoms and the covalent bond”. 25 
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1.1.2. Intermolecular Interactions 
 
The term non-covalent can be applied to a large range of intermolecular 
interactions26 including electrostatic interactions (ion-ion, ion-dipole and dipole-dipole 
interactions), coordinative bonding (metal-ligand), hydrogen bonding, halogen bonding, 
π-π stacking and Van der Waals forces. The utilization of these interactions for directed 
self assembly requires an understanding of their strength, distance and directionality. 
Gaining a basic knowledge of these factors is a primary focus of this dissertation. A 
comparison of selected interactions is presented in Table 1.1. 
 
    Table 1.1 Covalent and Non-covalent Interactions*  
  
Interaction Bond Energies (kJ/mol) 
Building 
blocks Products Features 
Covalent 200 - 400 Atoms Molecules H > TΔS MW: 1 - 1000 Da 
Hydrogen Bond 
Dipole-Dipole 
π-π stacking 
Van der Waals 
4 - 120 
5 - 50 
< 50 
< 5 
Molecules Supermolecules 
ΔH ≈ TΔS 
MW: 1 - 100 kDa 
 
       *Compiled from Steed, J. W.; Atwood, J. Supramolecular Chemistry, Wiley J.; Chichester, 2000. 
 
Hydrogen bonding 27-29 is perhaps the most reliable design element in the directed 
self-assembly of small organic molecules with hydrogen bond donor and acceptor 
functionalities. The ultimate example of a hydrogen bonded array is provided by nature in 
the form of the double helix DNA, which is formed between complementary base pairing 
of cytosine (C) and guanine (G); and adenine (A) and thymine (T). 
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      GC base pair                                           AT base pair 
Figure 1.1. Watson and Crick hydrogen bonding in DNA 
 
Scientists have therefore been inspired by nature to construct supramolecular 
structures and materials utilizing hydrogen bonding. The formation of supramolecular 
assemblies directed by hydrogen bonds has long been studied with respect to molecular 
association both in solution and the solid state. 30-43  In the solid state the hydrogen bond 
has been employed as a design element in the crystal engineering70 of small organic 
molecules.  
Halogen bonding is another paradigm that complements the hydrogen bond.44-45 A 
striking parallelism exists between the properties of these two interactions. Like hydrogen 
bonding, the halogen bond is a relatively strong and directional non covalent interaction 
making it well suited for geometry based design. First reported over 140 years ago,46-47 
the interaction is of the type B⋅⋅⋅XY, where B represents a Lewis base, commonly 
nitrogen, oxygen, sulphur or sellinium with a non bonding electron pair and X, a halogen 
atom commonly iodine. Hassel in his pioneering work used the equivalent term halogen 
molecule bridge48 to describe these interactions however more recently halogen bonds of 
the type X⋅⋅⋅:N have been called X-bonds.49 This interaction has been used to control 
 4
polymorph interconversion 50 and ultimately the generation of numerous supramolecular 
solid-state structures.51-59 
In the solid state the application of these interactions are in the generation of 
multi-component crystals with desired stoichiometry, architecture and ultimately 
properties.  
1.1.3. Crystal Engineering  
 
A crystal can be viewed as a ‘supramolecule par excellence’ an assembly of 
molecules crafted by mutual recognition to an amazing level of precision.60 The sequence 
of events that lead to the formation of an organic crystal from solution is governed by 
thermodynamic and kinetic factors which are intertwined in ways that are still hard to 
understand. As a consequence crystal structure prediction via computational methods 61 
still remains elusive.62-69  
Crystal engineering is defined by Desiraju as “the understanding of 
intermolecular interactions in the context of crystal packing and in the utilization of such 
understanding in the design of new solids with desired physical and chemical 
properties.” 70 It deals most typically with entirely new phases, sometimes, but not 
necessarily, involving well known molecules. Crystal engineering involves the design of 
crystals with well defined non-covalent connectivities and networks based upon pre-
selected molecular components that possess specific functional groups.71-75 The term 
crystal engineering was initially introduced by Pepinski in 1955.76 This contemporary 
area of research however has its origins in Schmidt’s study of topochemical reactions of 
cinnamic acids.77 Technological advances in hardware, software and X-ray 
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crystallographic techniques and the concomitant availability of a large amount of high 
quality structural information triggered significant activity in the-eighties and nineties. 
Pioneering works by Etter 78 and Desiraju 79 focused upon using the Cambridge 
Structural Database (CSD) 80 to analyze and interpret non-covalent bonding patterns in an 
effort to design functional solids. Crystal engineering represents a paradigm for the 
synthesis of new crystalline phases with predictable stoichiometry and architecture.   
1.1.4. Supramolecular Synthons and the Cambridge Structural Database 
 
Supramolecular synthons79 are structure determining patterns81 or motifs78 that 
encode the molecular recognition information during the crystallization process. 
Supramolecular synthons may be divided into two distinct categories: supramolecular 
homosynthons and supramolecular heterosynthons.82 Supramolecular homosynthons 
occur as a consequence of the interaction between identical, complementary functional 
group as in the case of the carboxylic acid dimer 83-84 (Figure 1.2a) and the amide dimer. 
85 Supramolecular heterosynthons result from the interaction between different but 
complementary functional groups. Examples of supramolecular heterosynthons include: 
carboxylic acid···pyridine 82, 86-98 (Figure 1.2b), alcohol···pyridine 99-120 and carboxylic 
acid···amide. 121-130 
Figure 1.2 Examples of supramolecular synthons: a) carboxylic acid homosynthon and  b) carboxylic 
acid···pyridine heterosynthon 
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Supramolecular homosynthons typically exist in single component crystals, even 
though their existence has also been observed in several crystals containing two different 
carboxylic acids.131-134 However when competing or multiple functional groups are 
present the formation of the supramolecular heterosynthon is more likely. Furthermore, if 
supramolecular heterosynthons form preferentially the knowledge can be utilized to 
design and ultimately generate multi-component crystals of structurally more complex 
molecules such as active pharmaceutical ingredients (API’s). General trends observed in 
a series of relevant crystal structures, in terms of the prevalence of specific 
supramolecular synthons as compared to others, would therefore provide valuable insight 
for crystal engineering strategies toward the generation of novel multiple-component 
crystals. 
Analysis of existing crystal structures represents the first step in a crystal 
engineering experiment. As such, “the systematic analysis of large numbers of related 
structures is a powerful research technique, capable of yielding results that could not be 
obtained by any other method.” 135 This is facilitated by the Cambridge Structural 
Database (CSD). The CSD is a depository of crystal structures of over 403,790 organic 
and organometallic compounds (ConQuest v1.9, January 2007 update) and has earned its 
status as one of the most invaluable research tools in crystal engineering.  The wealth of 
crystal structures archived within has aided the evolution of the field by allowing the 
supramolecular retrosynthesis 136 of numerous non-covalent contacts. This has facilitated 
the characterization of robust and reliable synthons and the potential for the elucidation 
of new or perhaps overlooked interactions from existing structures.   
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Etter et al proposed several hydrogen bonding rules, one of which states: “the best 
hydrogen-bond donor and the best hydrogen-bond acceptor will preferentially form 
hydrogen bonds to one another”. 78, 137 The Etter rules describe anticipated hydrogen 
patterns for several well studied functional groups and have been used as a working 
model for the hierarchal application of these rules to the non-covalent synthesis of 
supramolecular structures. 
Attempts to classify hydrogen bonded motifs were also addressed by Etter based 
upon a system of graph-set notation. 138 Hydrogen bonded patterns are described as 
chains (C), dimers (D), rings (R), or intramolecular hydrogen bonds (S). The number of 
donors (d) and acceptors (a) used in each motif are assigned as subscripts and 
superscripts respectively and the number of atoms involved in the pattern is indicated in 
parenthesis. For example, R22(8) graph set notation denotes an eight-membered ring with 
two hydrogen bond acceptors and two hydrogen bond donors, and is exemplified by the 
carboxylic acid dimer (Fig 1.2a). The utility of the graph-set notation lay in the 
evaluation of the frequency of a given hydrogen bonding pattern. However, information 
with respect to the types of proton donors and proton acceptors engaged in the pattern are 
not provided. Therefore the frequency of supramolecular synthon composed of specific 
hydrogen bond donors and acceptors can not be addressed via the graph-set notation 
system.  
The identification of reliable supramolecular synthons is the preliminary step in 
the design and analysis of multi-component crystal structures and is one of the foci of the 
research presented herein.   
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1.1.5. Co-Crystal 
 
The term and the definition of co-crystal is a subject of topical debate. 139-141 
Broad definition such as that given by Dunitz defines a co-crystal as “a crystal containing 
two or more components together.”140 This definition includes molecular adducts, salts, 
solvates/hydrates, inclusion compounds, etc.  More specific perspective taken by others 
142-43 describes a co-crystal as “a multiple component crystal formed between compounds 
that are solid under ambient conditions… at least one component is molecular and forms 
a supramolecular synthon with the remaining components. That all components of a co-
crystal (co-crystal formers) are solids under ambient conditions has important 
implications with respect to the stability of the co-crystal and its susceptibility for 
preparation in the solid-state. Analysis of the literature, reveal that co-crystals have been 
encountered under various terminologies, such as molecular compounds, 144 organic 
molecular compounds, 145 addition compounds, 146 molecular complexes, 147 and solid-
state complexes.148 The prototypal co-crystal quinhydrone formed between hydroquinone 
and quinone was first reported in 1844 by Wöhler149 however the crystal structure was 
not elucidated until the 1960’s.150-151 
 
                                     Figure 1.3. Crystal structure of quinhydrone 
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Although long known, co-crystals represent a relatively unexplored class of 
compounds as compared to single component crystals or solvates. There are ca. 1,722 
hydrogen bonded molecular co-crystals (comprised of components that are solid at room 
temperature) which constitute less than 0.5% of all structures archived in the CSD, as 
compared to 42,589 hydrates (ca. 11%). However, based upon the increasing number of 
relevant literature, it is clear that there is ever-growing interest.  
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Figure 1.4. Hydrogen bonded co-crystal structures in the CSD from 1985-2005 
                          
 
The inherent physical properties of a molecule in part depend on its crystal 
structure. Towards this end the generation of multiple component crystals is therefore of 
great importance. Moreover, co-crystals by nature are composed of two or more 
component therefore the exploration of the competition occurring between 
supramolecular synthons may be afforded. As will become evident the CSD can be used 
to study the competition between supramolecular homosynthon and supramolecular 
heterosynthon. However there is not enough information to address the hierarchy of 
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supramolecular heterosynthons in a competitive environment. Systematic studies 
involving the competition between three hydrogen bonded moieties have only been 
undertaken in a few instances. 152-154 Competitive studies by Aakeröy et al. focused on 
three distinct hydrogen bonding moieties: primary amide, pyridine, and carboxylic acid. 
The study involved co-crystals of iso-nicotinamide and a range of aromatic and aliphatic 
acids. The generated co-crystals revealed consistent hydrogen bonding patterns 
comprised of two robust supramolecular synthons: carboxylic acid···pyridine 
heterosynthon and self-complementary primary amide homosynthon. The reproducibility 
of the hydrogen bonded motifs suggests a dominant tendency of formation of the 
acid···pyridine heterosynthon over the acid···amide heterosynthon, that is formed in acid 
and amide-containing compounds in the absence of pyridines. Studies conducted by Bis 
et al involved alcohol, cyano and aromatic nitrogen moieties. The study involved 
determining the relative tendency of formation of alcohol-aromatic nitrogen 
supramolecular heterosynthon in the presence of competing cyano group. It was found 
that the alcohol-aromatic nitrogen heterosynthon occurred reliably in the presence of the 
cyano moiety. 
1.1.6. Preparation of Co-Crystals 
 
Co-crystals are usually prepared by evaporation from a solution containing 
stoichiometric amounts of components (co-crystal formers). However sublimation, 
blending of powders, sonication, growth from melt, slurries and grinding of the 
components together are suitable methodologies. Grinding 155-160 or milling of solids is 
usually carried out manually using a mortar and pestle or mechanochemically using a ball 
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mill or a Wig L Bug®. Variables that arise are in the control of reaction conditions such 
as pressure exerted by the operator or the machine, grinding time and temperature. The 
aforementioned technique has profound implications with respect to green chemistry161 
which seeks to reduce and prevent pollution via implementation of environment-friendly 
chemical processes.  Solvent drop grinding 162-163 also referred to as kneading164 or more 
recently as liquid assisted grinding 165-166 is another promising method of preparation in 
which a small amount of suitable solvent is added to the ground mixture in order to 
accelerate co-crystallization. Jones et al., have successfully shown that the addition of a 
small quantity of solvent enhances the kinetics of the solid state co-crystallization of    
cis,cis,cis-1, 3, 5-cyclohexanetricarboxylic acid with pyridyl based molecules.167 Solvent-
drop grinding has also been utilized in promoting selective polymorph transformation and 
for polymorph control.168 The role of the solvent is suggested to act as a lubricant for 
molecular diffusion, a sort of ‘solvent catalysis’ for the solid-state process, 164 as well as 
enhancing the opportunity for molecular collision. 164 
A number of factors contribute to the successful synthesis and isolation of a co-
crystal. A detailed understanding of the supramolecular chemistry of the functional 
groups present is a prerequisite for designing a co-crystal since it facilitates the 
appropriate selection of co-crystal formers. However when multiple functional groups are 
present in a molecule, as is often the case with API’s, the CSD rarely contains enough 
information to address the hierarchy of supramolecular synthons. Solvent can also be 
critical in obtaining a particular co-crystal from solution and the relative solubilities of 
the components in a particular solvent also needs to be considered. Moreover, the role of 
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solvent in the nucleation process remains somewhat poorly understood even though 
strides are being made in this area. 169 
The inherent change in physicochemical properties as a consequence of the 
introduction of another component into the crystal lattice and the existence of 
supramolecular synthons affords many potential applications of co-crystals.  Notable 
applications of co-crystals include: non-covalent derivatization, a term that was coined in 
the context of modifying the stability of Polaroid film 73 and the considerable interest 
these compounds have attracted with respect to pharmaceuticals.74-75, 129-130, 142, 170, 193-195 
Co-crystals have also found applications in solid-state solvent free synthesis116, 171, the 
formation of biomolecular complexes172 and may potentially act as precursors to the 
formation of 2D and 3D polymers. Moreover a recent publication reports that a variety of 
supramolecular synthons present within the co-crystal may act as precursors to a number 
of solid state condensation reactions thereby affording solid state synthesis of organic 
molecules.173 
 The main emphasis of the research presented herein however focuses upon the 
application of co-crystals towards the generation of pharmaceutical co-crystals and 
developing strategies to accomplish this goal. 
1.1.7. Pharmaceutical Co-Crystals 
 
Undesirable physicochemical properties, physiological barriers, or issues of 
toxicity often limit the therapeutic benefit of drugs. This has motivated research in API 
form optimization and drug delivery systems for poorly soluble and poorly absorbed 
substances. For orally administered drugs, unless the substance has an aqueous solubility 
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above 10 mg/ml over pH-range 1-7 potential absorption problems may occur. The 
European Pharmacopoeia reports that more than 40% of drug substances have aqueous 
solubility below 1 mg/ml. The primary method presently utilized in enhancing dissolution 
of these ‘low solubility’ substances is the selection of a salt form for weak acids and 
bases 174-176 or covalent modification. An apparently overlooked means to improve drug 
dissolution until recently is to make benefit of the reactive functionalities in the molecule 
and their interactions by hydrogen bonding.  
Crystalline self-assemblies provide a promising modality for improving 
physicochemical properties such as drug solubility, physical stability, dissolution rate and 
bioavailability. The emergence of crystal engineering and the supramolecular design 
approach to modify APIs extends to these issues without changing the pharmacological 
benefit of the API.  Traditional crystalline forms of APIs have been limited to salts, 
hydrates/solvates, polymorphs and the free acid or base form. 177 Hydrates/solvates are 
typically obtained as a result of adventitious uptake of water/solvent upon crystallization 
and like polymorphs they are difficult to be rationally designed. The possibility of 
dehydration/desolvation and subsequent formation of amorphous material, that may occur 
as a function of time and storage conditions is also a concern. 
Pharmaceutical co-crystals are multiple component crystals that are formed 
between an API and at least one or more co-crystal former that are solids under ambient 
conditions.74 This class of compound has gained much interest over the past few years 
since they offer the potential to amend undesirable physicochemical properties without 
covalent modification of the API. Moreover unlike salt forms of API’s, co-crystal 
formation is not restricted to an ionizable (acidic or basic) center on the API and can 
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simultaneously address multiple functional groups on the API. A relative large number of 
non-toxic compounds with hydrogen bonding functionalities exist on the GRAS 
(generally regarded as safe) list that may act as co-crystal formers in comparison to the 
limited number of salt forming counter-ions in use.174 
The presence of multiple functional groups inherent to APIs affords the 
opportunity for the design of pharmaceutical co-crystals. In fact an analysis of the top 
100 prescription drugs178 reveal that 39% of pharmaceutically active ingredients contains 
at least one alcohol and 30% contain at least one carboxylic acid, this is also consistent 
with the percentage alcohol and carboxylic acid moieties in the Merck Index.179 
Consequently addressing the ability of these functional groups to form supramolecular 
synthons would be of great interest. 
 
 
Table 1.2 Percentage Occurrence of hydrogen bonding functional groups in APIs 
 
Functional  
Group 
 
 
Top 100 
Prescription 
Drugs 
% 
 
CSD only 
Organics  
% 
Alcohol 39 20 
3º amine 37 11 
Carbonyl 35 14 
Ether 33 27 
2° amine 31 7 
Carboxylic acid 30 6 
Ester 22 20 
Aromatic N 12 6 
2° amide 11 9 
Sulfonamide 3 1 
 
Analysis of the 1722 co-crystals deposited in the CSD reveal that approximately 
5% contain API molecules.180-192 Whereas, some of the examples are a result of 
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serendipity, the first crystal engineered series of pharmaceutical co-crystals may be 
attributed to works of Caira et al involving the complexation of sulfonamide drugs193-195 
and the extensive research of Whitesides et al. concerning supramolecular assemblies of 
barbiturates and melamine derivatives. 196-199 
 
                        Figure 1.5. Co-crystal of sulfadimidine and acetylsalicylic acid, VUGMIT 
 
 
The crystal engineering approach to APIs based upon the use of reliable 
supramolecular heterosynthons is exemplified by several series of co-crystals involving 
carbamazepine (CBZ),129-130 ibuprofen,82 piracetam,200 fluoxetine hydrochloride201 and 
itraconazole.202 CBZ had four reported polymorphs and two solvates. All forms of CBZ 
                      Figure 1.6. Co-crystal of barbital and N,N’-bis(m-tolyl)melamine  JICVIA10, 
sustained by 3-point recognition supramolecular heterosynthon 
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for which structural data was available were sustained by the primary amide dimer      
(Fig 1.7.) and the peripheral H-bond donors and acceptor pairs remained unused.  
 
Figure 1.7. Crystal structure of carbamazepine sustained by amide dimer 
 
Two strategies based upon information obtained from a CSD analysis of the 
primary amide functional group was employed in designing co-crystals of CBZ. Strategy 
1, involved breaking the amide dimer via the introduction of a carboxylic acid moiety 
thereby, forming the acid-amide supramolecular heterosynthon and strategy 2, utilized 
the peripheral NH2 H-bonding sites while keeping the amide dimer intact. The acid-
amide supramolecular heterosynthon exists in 47% of entries that contain both an acid 
and an amide. Both strategies were successfully implemented to generate several co-
crystals of CBZ.  
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 Figure 1.8. Illustrate the co-crystal of carbamazepine • acetylsalicylic acid sustained by the two point 
recognition acid-amide supramolecular heterosynthon. 
 
Figure 1.9. Crystal structure of (carbamazepine.)2●4,4’-dipyridyl illustrates the intact amide dimer 
and H-bonding of 4,4’-dipyridyl to the peripheral N-H. 
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Although we are unaware of any pharmaceutical co-crystals that have been 
approved by the FDA, there have been several reports related to their physicochemical 
properties. The CBZ•saccharin co-crystal exhibits improved dissolution, chemical 
suspension and, bioavailability to that of the parent compound.203 Moreover based upon 
1,200 high throughput screening experiments the co-crystal also appears to lack the 
relative propensity towards polymorphism as is seen in pure CBZ. 203 
 
 
                                     Figure 1.9. The crystal structure of carbamazepine●saccharin co-crystal 
 
2-[4-(4-chloro-2-flourophenoxy)phenyl]pyrimidine-4-carboxamide  is a sodium 
channel blocker with indications in the treatment or prevention of surgical, chronic or 
neuropathic pain. The glutaric acid• 2-[4-(4-chloro-2-flourophenoxy)phenyl]pyrimidine-
4-carboxamide co-crystal exhibits 18 fold greater intrinsic dissolution rate as compared to 
the parent API in a single dose dog exposure study.204  The co-crystal was also physically 
and chemically stable for storage under stress conditions of 40°C/75% relative humidity 
and 60°C for 2 months.  
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Figure 1.11. Illustrates the hydrogen bonding interaction present in 2-[4-(4-chloro-2-
flourophenoxy)phenyl]pyrimidine-4-carboxamide•glutaric acid co-crystal 
 
Theophylline, a drug used in the treatment of respiratory illnesses such as asthma, 
is known to convert between the crystalline anhydrate and the monohydrous form as a 
function of relative humidity (RH). This represents a challenge in the formulation 
process. A series of dicarboxylic acid co-crystals of theophylline were subjected to 
relative humidity changes in an effort to evaluate their stability in relation to crystalline 
theophylline.205 None of the co-crystals in the study converted into a hydrated form upon 
storage at high humidity. Moreover the theophylline•oxalic acid co-crystal demonstrated 
superior humidity stability as compared to anhydrous theophylline and the other co-
crystals exhibited comparable stability to the theophylline anhydrate. Similar studies 
involving a series of co-crystals of caffeine and dicarboxylic acids have also been 
undertaken.206 The relative stability profiles of the co-crystals differed from that of the 
crystalline caffeine in that no co-crystal hydrate was found. Moreover the co-crystals that 
were unstable relative to RH dissociated into starting components.  
Dissolution studies of pharmaceutical co-crystals of itraconazole, a highly water 
insoluble antifungal drug, with 1,4-dicarboxylic acids, indicate that the co-crystals 
achieve and sustain  4 to 20-fold higher concentrations as compared to the crystalline 
itraconazole. 202 
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                      Figure 1.10. Crystal structure of cis-itraconazole●succinic acid co-crystals 
 
 
A recent study involving co-crystals of fluoxetine hydrochloride (Prozac) an anti-
depressant, with several pharmaceutically acceptable carboxylic acids illustrates the 
dependence of the co-crystal on the aqueous solubility of the utilized co-crystal former.201 
Consequently it is possible to fine-tune the dissolution rate the API. Additionally the 
solubility of the fluoxetine hydrochloride•succinic acid co-crystal is doubled as compared 
to the fluoxetine hydrochloride salt.  
 
 Figure 1.11. The crystal structure of fluoxetine hydrochloride•succinic acid co-crystal sustained by 
charge assisted carboxylic acid⋅⋅⋅Cl- interactions 
 
L-883555 is a phosphodiesterase IV inhibitor with indication in the treatment of 
asthma and chronic obstructive pulmonary disease. Non-stoichiometric, isostructural 
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complexes of L-883555 and L-tartaric acid demonstrated much higher bioavailability in 
rhesus monkeys as compared to the free base form of L-883555. 207 In particular the 2:1 
co-crystal of L-883555•L-tartaric acid exhibited better physical properties and was 
chosen as the viable solid form for safety assessment. 
The aforementioned studies illustrate the potential impact of pharmaceutical co-
crystals on the pharmaceutical industry in terms of both form and properties. 
1.1.8. Polymorphism  
 
Polymorphism can be defined as the existence of more than one crystal structure 
of the same compound.208-210 This phenomenon was recognized as early as 1822.211 
Polymorphs arise as a consequence of different arrangements and/ or conformation of the 
same molecules in the crystal lattice and as such are classified primarily as structural or 
conformational polymorphs. The possibility of homosynthons or heterosynthons, the 
formation of n-point recognition, as well as slight changes in torsion angles are factors 
that can lead to the phenomenon of polymorphism. The topical issue of polymorphism is 
now recognized as being a major scientific challenge quite apart from its chemical and 
legal implications in the pharmaceutical industry.  
Polymorphs may differ in packing, spectroscopic, thermodynamic, kinetic, 
surface and mechanical properties. The polymorphic form that crystallizes from solution 
depends on an inter-play of several factors. The factors include polarity of solvent, initial 
supersaturation and depending on the crystallization method, the rate of cooling or the 
evaporation of the solvent. Impurities can also affect the potential for a polymorph 
crystallizing from solution.   
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The inability to predict the existence of polymorphs or crystal structures in 
general, has important intellectual property and scientific implications. For example, the 
appearance of an undesired polymorph can invoke problems during the formulation 
process and lead to patent litigations.209, 212 On the other hand, a novel polymorph can 
offer an opportunity in terms of improved physicochemical properties and product 
development. Furthermore, since physicochemical properties of a compound can differ 
critically from one form to another, inducing and controlling a specific polymorph is of 
utmost importance. 
Polymorphism in organic compounds is perhaps exemplified by 5-methyl-2-(2-
nitrophenyl)amino] 3-thiophenecarbonitrile (ROY), which has been crystallized as seven 
polymorphic modifications.213-215 The system has been named ROY because to its red, 
orange and yellow crystal colors. The forms crystallize as yellow prisms, red prisms, 
orange needles, orange plates, yellow needles, orange red plates and red plates. 
From a pharmaceutical perspective the stability of the product, the ability to 
process and bioavailability are influenced by the physicochemical properties of the varied 
solid state forms. 216 The impact of polymorphism on drug behavior is perhaps illustrated 
by chloramphenicol palmitate (CAPP). CAPP is a broad-spectrum antibiotic known to 
crystallize in at least three polymorphic forms; and one amorphous form.217-218 The most 
stable form, A, is marketed. Form B, however, has an eightfold higher bioactivity than 
form A, creating the danger of fatal dosages when the unwanted polymorph is 
unwittingly administered because of alterations in process or storage conditions. 218  
The impact of polymorphism with intellectual property implications is 
exemplified by the case of ranitidine hydrochloride.219 GlaxoSmithKline entered a 
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lengthy court case against Novopharm for alleged patent infringement based on its right 
to manufacture and market a different polymorphic form of Glaxo’s best-selling anti-
ulcer drug, Zantac. The polymorphic forms in question were therapeutically equivalent.  
The existence of polymorphism implies that kinetic factors are important during 
nucleation and growth and that the free energy differences between the different 
crystalline forms are small (<10KJmol-1). The phenomenon is still not entirely 
understood, however, recent literature reveal that the solvent-drop grinding approach can 
be utilized as an efficient method to achieve selective transformations between specific 
polymorphs.168 
1.1.9.  Summary  
 
The research presented herein focuses on crystal engineering of co-crystals and 
pharmaceutical co-crystals. Particular emphasis is placed upon the exploration of co-
crystals in the context of: delineation of the reliability of hydrogen bonded 
supramolecular synthons and their hierarchies; exploring the viability of alternatives to 
solution based methods of preparation of co-crystals specifically melts, grinding and 
solvent drop grinding; and evaluation of the susceptibility of co-crystals towards 
polymorphism using the solvent-drop grinding technique.  The rational design and 
synthesis of pharmaceutical co-crystals accomplished by the judicious selection of co-
crystal formers facilitated by analysis of existing crystals structures in the CSD will be 
demonstrated. The processing of pharmaceutical co-crystals will also be addressed in 
terms of slurry conversion, solvent drop grinding and solution crystallization. 
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2. The Reliability of the Carboxylic Acid-Aromatic Nitrogen Supramolecular 
Heterosynthon 
 
2.1. Introduction  
Carboxylic acids represent one of the most ubiquitous functional groups in crystal 
engineering. They possess a hydrogen bond donor as well as an acceptor site and are 
therefore self complementary. Carboxylic acids are known to self associate to form 
centrosymmetric dimers I and catemers II.1 A search of the Cambridge Structural 
Database (CSD)2-5 reveals that there are 7148 crystal structures that contain at least one 
carboxylic acid. Of this number 1683 (23%) entries exhibit the acid dimer I whereas 125 
(1.7%) crystal structures exhibit the catemer motif II. Based upon the analysis ca. 25% of 
the total 7148 crystal structures that contain a carboxylic acid are involved in forming 
either I or II. 
O
O
H
O
O
H
I
O
O
H
O
O
H
O
OH
II  
Analysis of the remaining 75% of carboxylic acid containing compounds not 
involved in forming homosynthon6 I or II reveals that they are engaged in interactions 
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with different complementary functional groups i.e they are involved in forming a variety 
of supramolecular heterosynthons.6 Functional groups that were found to interact with 
carboxylic acids include: aromatic N (defined in the searches as six membered aromatic 
ring containing at least one unprotonated nitrogen), 1° and 2° amides, carbonyls, 
phoshonyls, alcohols, chlorides, bromides, etc.  
In an effort to further investigate the occurrence of supramolecular homosynthon6 
I and II, entries containing carboxylic acids devoid of competing hydrogen bond donors 
and/or acceptors were analyzed. There are 452 crystal structures containing at least one 
carboxylic acid in the absence of competing functional groups, 422 entries (93 %) exhibit 
supramolecular homosynthon I as compared to 30 structures (7%) that form 
supramolecular homosynthon II suggesting that I is favored over II 
In this chapter, the presented research is focused on the ability of carboxylic acids 
and aromatic nitrogen to form reliable carboxylic acid-aromatic nitrogen supramolecular 
heterosynthon III. In order to form a co-crystal between a carboxylic acid and an 
aromatic nitrogen, the basic assumption is that the initial components must engage in the 
formation of supramolecular heterosynthon III that can compete successfully with the 
carboxylic acid homosynthon, otherwise a mixture of starting material results. The 
second part of the study involves evaluating alternative methods such as grinding, solvent 
drop grinding7 and melts towards synthesis of co-crystals and to screen the obtained co-
crystals for polymorphism8 using the solvent-drop grind technique. The application of the 
knowledge obtained from the series of experiments is the rational design and synthesis of 
new multiple-component crystals that contain structurally more complex molecules such 
as active pharmaceutical ingredients (API’s).  
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2.2.  Results and Discussion   
 
A series of mono, di and tri- carboxylic acids were co-crystallized with a set of 
aromatic nitrogen based molecules (Figure 2.1). Single crystal of the following multi-
component crystals were isolated: (benzoic acid)2 ● 1,2-bis(4-pyridyl)ethane, 1;         
(benzoic acid)2● trans-1,2-bis(4-pyridyl)ethylene, 2;  benzoic acid ● 4,4’-bipyridine, 3; 
Sorbic acid● 1,2-bis(4-pyridinium)ethane sorbate, 4; (naproxen)2●trans-1,2-bis(4-pyridyl) 
ethylene, 5; glutaric acid● 1,2-bis(4-pyridyl)ethane, 6, ; glutaric acid● trans-1,2-bis              
(4-pyridyl)ethylene, 7; oxalic acid● tetramethylpyrazine, 8;  isophthalic acid● 1,2-bis            
(4-pyridyl)ethane, 9; (trimesic acid)2●( trans-1,2-bis(4-pyridyl)ethylene)3, 11 ;            
(trimesic acid)2● 1,2-bis(4-pyridyl)ethane)3 Form I, 12a and (trimesic acid)2● 1,2-bis          
(4-pyridyl)ethane)3 Form II, 12b 
 
N
NCH3
CH3 CH3
CH3
N
N
N
N
COOH
COOHHOOC
COOH
HOOC COOH
HOOC COOH
HOOC
COOH HOOC COOH COOH
O
N
N
tetramethylpyrazine (TMP)1,2-bis(4-pyridyl)ethane trans-1,2-bis(4-pyridyl)ethylene
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Figure 2.2.1. Molecular components used in co-crystallization of 1-12 
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2.2.1. CSD Analysis 
Searches were conducted using the 2006 release of the CSD using Conquest 
version 1.9, with the January 2007 update. Filters placed on the searches include 3D 
coordinates determined, R factor < 7.5% and only organics. The visualization package 
Mercury 1.5 was used to analyze the retrieved entries. 
For each supramolecular synthon considered, initial contact distance well beyond 
the sum of the Van der Waals radii of the hydrogen bond donor and the acceptor atoms 
were applied. Contact limits for each interaction was subsequently determined from 
distance distribution plots. Based on visual inspection of the resulting histogram and 
subsequent structural analysis of selected entries, the lower and higher cut offs for 
hydrogen bonds distances were determined. 
In order to distinguish protonated aromatic nitrogen from neutral aromatic 
nitrogen specific restrictions were applied to the CSD searches.  For neutral aromatic 
nitrogen, the nitrogen atom was defined to be uncharged and the number of bonded atoms 
was set to 2. In the case of protonated aromatic nitrogen, hydrogen atoms were placed on 
the aromatic nitrogen, the charge was set to +1 and the number of bonded atoms was set 
to 3. For carboxylate anion the carbon atom was drawn bonded via any/unspecified bonds 
to two oxygen atom, the number of bonded atom for each oxygen atom was set to one 
and no charge was specified. 
There are four supramolecular synthons that can be expected when a carboxylic 
acid and an aromatic nitrogen containing molecule occur within the same crystal 
structure: carboxylic acid supramolecular homosynthon I or II; carboxylic acid-pyridine 
supramolecular heterosynthon III; and the charge assisted form of III, i.e. 
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supramolecular heterosynthon IV (Figure 2.2). As will become clear, both statistical 
analysis and experimental data indicate that the formation of supramolecular 
heterosynthon is favored to that of supramolecular homosynthons I and II.  
 
O
O
H N O
O
N
+
H
III                                                  IV  
Figure 2.2.2. Supramolecular heterosynthons that can be formed between carboxylic acids and  
aromatic nitrogen: carboxylic acid-aromatic nitrogen heterosynthon III and pyridinium-carboxylate 
heterosynthon IV 
 
 
A CSD analysis of compounds that contain at least one carboxylic acid and an 
aromatic nitrogen moiety was conducted in order to determine the occurrence of the 
supramolecular heterosynthon III. The percentage occurrence and hydrogen bond 
distances of supramolecular synthons I-IV are presented in Table 2.1.  
 
Table 2.1. Percentage occurrence, distance ranges, and average distance for supramolecular synthons 
I-VI 
 
 
 
 
 
The CSD contains 684 crystal structures with both a carboxylic acid and an 
aromatic nitrogen containing compound. 447 entries (ca. 65%) exhibit supramolecular 
heterosynthon III as compared to 32 crystal structures (ca. 5%) that display the 
 Number of entries Distance range [Å] Mean  (σ ) [Å] 
Synthon I   1683/ 7148 (23%) O-H···O          2.50-3.00 2.65(3) 
Synthon II 125/7148 (1.7%) O-H···O          2.50-3.00 2.70(9) 
Synthon III  447/684 (65%) O-H···N          2.50-2.90 2.65(3) 
Synthon IV 365/368 (99%) N+-H⋅⋅⋅O-             2.40-3.00 2.67(9) 
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carboxylic acid supramolecular homosynthon I or II. It should be noted that there are 11 
structures that exhibit both carboxylic acid homosynthon and heterosynthon III due to the 
presence of multiple carboxylic acid moieties. In the remaining structures that do not 
exhibit III, the carboxylic acid functionality forms hydrogen bonds with other 
competitive proton donors or acceptors such as amines, amides, water molecules, 
chloride ions etc. The histogram (Figure 2.3) reveal that the COO-H··⋅Narom hydrogen 
bond distances for III occur within the range of 2.50 - 2.90 Å (average 2.65(3) Å). The 
same search was performed in the absence of other strong donors and/or acceptors e.g. 
alcohols, 1° and 2° amides, 1° and 2° sulfonamides, imidazoles, carbonyls, nitriles, nitro-
compounds, phosphine oxides, chloride ions, bromide ions and water molecules. The 
number of structures containing both carboxylic acid and aromatic nitrogen in the 
absence of other competing donor and or acceptor moieties is 109. In this subset, the 
percentage occurrence of III increases to 95% (104/109).   
It should be noted that during the course of this work several reports have been 
published regarding the use of III as a design element in crystal engineering.6,9-29 The 
observation of the robustness of supramolecular synthon III based upon the CSD analysis 
is consistent with the experimental results of the new compounds presented herein. 
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Figure 2.2.3. Histograms of contacts for: a) supramolecular homosynthon I b) O···N contacts in 
supramolecular heterosynthon III 
 
 
 
 
2.2.2. Features of Carboxylic Acid-Aromatic Nitrogen Interaction  
 
The difference in pKa of the carboxylic acid and the aromatic nitrogen base is 
often used as an indicator to determine whether neutral COO-H⋅⋅⋅Narom hydrogen bond or 
proton transfer results [ΔpKa = pKa (base)-  pKa (acid)]. In the pharmaceutical industry the 
rule of thumb for salt formation is a pKa difference greater than 2 or 330 and is typically 
used as a criterion for selecting counterions for salt formation. Johnson and Rumon31 
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however suggests a limit they report that a difference of pKa < 3.75 affords neutral 
COOH⋅⋅⋅Narom interactions whereas ΔpK a >3.75 results in proton transfer. The formation 
of the carboxylic acid-aromatic nitrogen hydrogen bond has also been rationalized in 
terms of the hydrogen bond rules formulated by Etter.32  
It is well known that the geometrical features of a neutral carboxylic acid group 
are different from those of a carboxylate anion.33 Carboxylate anions tend to have similar 
C-O bond distances whereas a neutral carboxylic acid have two distinctly different C-O 
distance.34 Neutral carboxylic acids are known to have average C=O and C-O bond 
distances of 1.21(2) Å and 1.31(2) Å respectively whereas deprotonated carboxylate has 
average C-O bond distances of 1.25(2) Å.35 The C–N–C angle in aromatic nitrogen 
moieties are also known to be sensitive to protonation,75-78  and the cationic form exhibits 
higher values than that of the corresponding neutral molecules. A graphical 
representation of the C–N–C angle distribution in both protonated and unprotonated 
aromatic nitrogens are presented in Figure 2.4. The average C–N–C angle encountered in 
4649 neutral aromatic nitrogen is 117(2)°. In comparison, the set of 963 cationic aromatic 
nitrogen exhibits higher C–N–C angles with an average value of 122(2)°. The structural 
features of the bond distances and bond angles are used in the analysis of the presented 
series of compounds. 
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Figure 2.2.4. Histograms that present the distribution of the C–N–C angle in a) neutral aromatic 
nitrogens and b) protonated aromatic nitrogen moieties 
 
 
The pKa values of the components involved in the formation of 1-12 are presented 
in Table 2.2. The difference in pKa of the base and the acid ranges from -0.93 to 3.15 and 
the co-crystals obtained from this study appear consistent with Johnson and Rumon’s 
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observation. There is an exception however in the case 4 which is sustained by both III 
and IV and the pKa difference between the initial components is 1.54. 
 
Table 2.2. pKa values of the components of 1-12 
 
Melting point is still regarded as a poorly understood phenomenon however it is 
typically considered to arise as a consequence of the dissociation of the solid state 
molecular assembly.36 Melting point alternation and inversion of melting point involving 
co-crystals of homologous series of dicarboxylic acids and n-alkyl carboxylic acid have 
been reported in the literature.37-40 Melting points of the co-crystals involving 
Co-crystal pKa of acid  pKa of 
component 2 
Δ pKa 
[pKa(base)-pKa 
(acid)] 
(Benzoic acid)2 ● 1,2-bis(4-pyridyl)ethane, 1 4.2 6.13 1.93 
(Benzoic acid)2● trans-1,2-bis(4-
pyridyl)ethylene, 2 
4.2 5.50 1.30 
Benzoic acid ● 4,4’-bipyridine, 3 4.2 3.27 -0.93 
(Sorbic acid)2● 1,2-bis(4-pyridyl)ethane, 4 4.59 6.13 1.54 
(Naproxen)2● trans-1,2-bis(4-
pyridyl)ethylene, 5 
4.84 5.50 0.66 
Glutaric acid● 1,2-bis(4-pyridyl)ethane, 6 4.33 6.13 1.80 
Glutaric acid● trans-1,2-bis(4-
pyridyl)ethylene, 7 
4.33 5.50 1.17 
Oxalic acid● tetramethylpyrazine, 8 1.38 2.88 1.50 
Isophthalic acid● 1,2-bis(4-pyridyl)ethane, 9 3.53 6.13 2.60 
(Trimesic acid)2●( trans-1,2-bis(4-
pyridyl)ethylene)3, 11 
2.98 5.50 2.52 
(Trimesic acid)2● 1,2-bis(4-pyridyl)ethane)3, 
12  
2.98 6.13 3.15 
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dicarboxylic acids n = 2-6 carbon atoms show alternation of even series having a higher 
melting point than odd members whereas inversion of the melting point alternation is 
observed within the latter series of co-crystals as compared to the pure n-alkyl carboxylic 
acids. Attempts to make correlation between the melting point of the obtained co-crystals 
and that of the initial components yielded no general conclusions. As is evident from 
Table 2.3, the melting points of co-crystals 6 and 7 were higher than that of both starting 
materials whereas co-crystals 1, 3 and 5 had melting points lower than that of the initial 
components. 2, 9, 8, 11, and 12 all exhibited melting points that were between that of the 
co-crystal formers. 
 
Table 2.3. Melting points of co-crystals 1-12 and corresponding starting materials 
 
Co-crystal M. pt of co-
crystal 
M. pt of 
component 1 
M. pt of 
component 2 
(benzoic acid)2● 1,2-bis(4-pyridyl)ethane, 1 80-81 121-123 107-110 
(benzoic acid)2● trans-1,2-bis(4-pyridyl)ethylene, 2 128-129 121-123 150-153 
benzoic acid ●4,4’-bipyridine, 3 99-102 121-123 111-114 
sorbic acid● 1,2-bis(4-pyridinum)ethane sorbate, 4 110-112 134-135 107-110 
(naproxen)2●trans-1,2-bis(4-pyridyl)ethylene, 5 135-137 152-154 150-153 
glutaric acid●1,2-bis(4-pyridyl)ethane, 6 130-132 95-98 107-110 
glutaric acid● trans-1,2-bis(4-pyridyl)ethylene, 7 180-186 95-98 150-153 
oxalic acid●·tetramethylpyrazine , 8 139-142 189-190 84-86 
isophthalic acid·● 1,2-bis(4-pyridyl)ethane, 9 212-222 341-343 107-110 
(trimesic acid)2●( t-1,2-bis(4-pyridyl)ethylene)3, 11 228-234 378-380 150-153 
(trimesic acid)2●(1,2-bis(4-pyridyl)ethane)3, 12 182-186, 298-
300 378-380 107-110 
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2.2.3. Crystal Structure Description 
 
The crystal structure of benzoic acid forms discrete adducts that are sustained by 
centrosymmetric carboxylic acid dimer I, 41 also coded as R22 (8), graph set notation. Co-
crystallization of benzoic acid and 1,2-bis(4-pyridyl)ethane results in insertion of a 
molecule of 1,2-bis(4-pyridyl)ethane between the carboxylic acid dimer. The crystal 
structure of (benzoic acid)2●1,2-bis(4-pyridyl)ethane 1, reveals discrete 2:1 
suppramolecular adducts sustained by symmetric COOH⋅⋅⋅Narom supramolecular 
heterosynthon III. In addition to IR spectroscopic evidence, the neutral nature of III is 
supported by structural data: the C-O and C=O bond distance within 1 is 1.316 Å and 
1.220 Å respectively and the C-N-C bond angle within the pyridyl ring is 117.56°. The 
COOH⋅⋅⋅Narom hydrogen bond distance (D: 2.5983(19) Å) occurs within the expected 
range for carboxylic acid-aromatic nitrogen interactions (Table 2.1). The benzoic acid 
molecules are coplanar with respect to the pyridyl rings of 1,2-bis(4-pyridyl)ethane 
resulting in planar three component adducts. Such discrete adducts are related by 
translation and are connected via weak C-H⋅⋅⋅O and hydrophobic interactions to generate 
a supramolecular sheet.  Such organization stack as shown in Figure 2.5a and further 
stabilization of the structure is afforded by  π⋅⋅⋅⋅π stacking between adjacent pyridyl rings 
the centroid to centroid distance of which is 3.55Å. 
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(a) 
 
 
(b) 
Figure 2.2.5. Illustrate a) discrete three component adducts of co-crystal 1, b) crystal packing in 1. 
 
 
The asymmetric unit of (benzoic acid)2● trans-1,2-bis(4-pyridyl)ethylene 2,  
consists of one molecule of benzoic acid and a half molecule of trans-1,2-bis(4-
pyridyl)ethylene and adopts the space group P21/c. The components form 
centrosymmetric three component discrete adducts sustained by supramolecular 
heterosynthon III (D: 2.622(2) Å]. The C-O and C=O bond distances of 1.320 Å and 
1.217Å respectively and the C-N-C angle of 117.19° support the neutral nature of III. 
The supramolecular trimer in 2 is planar the dihedral angle between the carboxylic acid 
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group and the pyridyl ring is 0.64°. The structure is also stabilized by π⋅⋅⋅π interaction 
between adjacent rings (Figure 2.6) 
 
a) 
 
 
b) 
Figure 2.2.6 Illustrate a) Discrete adduct sustained by supramolecular heterosynthon III b) packing 
between adjacent trimeric units. 
 
 
Co-crystallization of a 2:1 molar ratio of benzoic acid and 4,4’-bipyridine resulted 
in the 1:1 co-crystal of benzoic acid●4,4’-bipyridine 3.  The crystal structure of 3 
consists of two molecules of benzoic acid and two molecules of 4,4’-bipyridine. The co-
crystal forms two component adducts sustained by supramolecular heterosynthon III [D1: 
2.668(3) Å, D2: 2.655(3) Å]. The dimeric pairs align in an alternating fashion parallel to 
the b axis. The dihedral angles between the planes of the pyridyl rings in the two 
independent 4,4’-bipyidine molecules are 37.30° and 35.16° and in contrast to 1 and 2 the 
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hydrogen bonded adducts are not planar. The plane of the carboxylic acid is slightly 
twisted with respect that of the interacting pyridyl ring of the 4, 4’-bipyidine molecule     
(25.49°and 21.75°). 
The neutral nature of III is supported by structural information: the C-O and C=O 
bond distances are 1.316 Å and 1.203Å; 1.309 Å and 1.206 Å respectively and the 
corresponding C-N-C angles are 116.50° and 116.70°. 
   
 
Figure 2.2.7 Crystal packing of two component units in 3 
 
 
The crystal structure of 4 contains one molecule of sorbic acid, a sorbate ion and a 
half molecule of 1,2-bis(4-pyridyl)ethane as well as a half 1,2-bis(4-pyridinium)ethane 
ion in the asymmetric unit. The crystal structure of 4 reveals discrete non-
centrosymmetric 2:1 adducts that is sustained by either supramolecular heterosynthon III 
or IV. Analysis of the C-O and C=O bond distances within 4 reveal lengths of 1.322 Å 
and 1.208 Å; 1.257 Å and 1.247 Å respectively and corresponding C-N-C bond angles of 
115.96° and 117.29°.   
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                    Figure 2.2.8 Illustrates a discrete three component adduct in 4 
  
Naproxen is a non-steroidal anti-inflammatory drug that used in the treatment of 
mild to moderate pain, fever and inflammation and is marketed under the trade-name 
Aleve®. Naproxen is sustained by the carboxylic acid catemer motif II.42 Co-
crystallization of naproxen with trans-1,2-bis(4-pyridyl)ethylene resulted in the formation 
of co-crystal 5. The asymmetric unit of 5 contains two molecules of naproxen and one 
molecule of trans-1,2-bis(4-pyridyl)ethylene. Analysis of the crystal structure reveals 
discrete non-centrosymmetric three component adducts that are sustained by 
supramolecular heterosynthon III (D1: 2.678(7), D2:2.876(7) Å). Such discrete adducts 
stack along the b axis as shown in Figure 2.10, and π⋅⋅⋅π stacking between the trans-1,2-
bis(4-pyridyl)ethylene molecules in adjacent adducts is observed. The centroid to 
centroid distance for the π stacking is 3.400Å 
The C-O and C=O bond distances of the carboxylic group within the structure are 
1.331 Å and 1.224 Å respectively for molecule 1; 1.311 Å and 1.213 Å for molecule 2 
and the C-N-C angles within trans-1,2-bis(4-pyridyl)ethylene are 117.46 Å and 117.10Å 
respectively. 
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Figure 2.2.9 Illustrates discrete adducts of (naproxen)2 •trans-1,2-bis(4-pyridyl)ethylene, 5 
 
 
Figure 2.2.10 Crystal packing in (naproxen)2 •trans-1,2-bis(4-pyridyl)ethylene, 5 
 
 
The crystal structure of glutaric acid is sustained by carboxylic acid dimer I to 
generate infinite chains that are translationally related.43 Adjacent chains are connected 
via O⋅⋅⋅O contact to generate 2D sheets as shown in Figure 2.11. Insertion of the 1,2-
bis(4-pyridyl)ethane molecules between the acid dimers of glutaric acid (GLURAC03) 
occurs within 6 to generate extended chains sustained by acid-aromatic nitrogen 
supramolecular heterosynthon III.  
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Figure 2.2.11 Crystal packing in pure glutaric acid 
 
The crystal structure of glutaric acid● 1,2-bis(4-pyridyl)ethane 6, contains two 
independent molecules each of 1,2-bis(4-pyridyl)ethane and glutaric acid. 6 is sustained 
by supramolecular heterosynthon III. The COOH⋅⋅⋅ Narom hydrogen bonds occur within 
the expected range based upon the CSD analysis.  Adjacent infinite chains stack parallel 
to the b axis in an ABAB fashion as shown in Fig. 2.12. There are ancillary C-H⋅⋅⋅O 
interactions between the carbonyl oxygen and the C-H groups adjacent to the aromatic 
nitrogen in the ring which further stabilize the structure and the COOH group lies 
generally coplanar with the pyridyl ring (C-O-N-C torsion angle is 3.37°and 6.00°).  
 The C-O and C=O bond distance within 6 are 1.320Å and 1.197Å; 1.314Å and 
1.201Å; 1.316Å and 1.199Å; 1.326Å and 1.194 Å respectively.  The C-N-C angles 
within the two independent molecules of 1,2-bis(4-pyridyl)ethane are 116.97°, 117.26° 
and 116.75°, 117.19° thus supporting the neutral nature of the interaction.  
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Figure 2.2.12  Crystal structure of  glutaric acid● 1,2-bis(4-pyridyl)ethane 6 
 
 
The 1:1 co-crystal of glutaric acid●trans-1,2-bis(4-pyridyl)ethylene 7,  is 
sustained by supramolecular heterosynthon III. As is seen in 6 extended chains are 
generated via symmetric COO-H⋅⋅⋅Narom hydrogen bond [2.612(3) Å, 175.3°]. Auxiliary 
C-H⋅⋅⋅O hydrogen bond contributes to III and helps maintain co-planarity of the 
carboxylic group and the pyridyl ring. Adjacent infinite chains stack orthogonal to -1 1 0 
plane and are connected by weak C-H⋅⋅⋅O interaction to generate 2D sheets. Weak C-
H⋅⋅⋅O interactions also connect chains between adjacent layers. The neutral nature of 7 is 
supported by structural information: the C-O and C=O bond distances are 1.316 Å and 
1.212 Å respectively and the C-N-C angle is 118.09°.   
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Figure 2.2.13  Crystal structure of glutaric acid● trans-1,2-bis(4-pyridyl)ethylene,  7 
 
Oxalic acid crystallizes in orthorhombic α and monoclinic β modifications.44  The 
α polymorph forms carboxylic acid catemer II and generate supramolecular sheets 
whereas the metastable β modification consists of molecules of oxalic acid linked 
through dimer I that extend to generate infinite hydrogen bonded chains. 
Oxalic acid co-crystallizes with TMP in the molar ratio 1:1 to yield crystals of 
oxalic acid●tetramethylpyrazine (TMP), 8. The crystal structure of 8 consists of 
molecules of oxalic acid and TMP residing on centers of inversion. 8 is sustained by 
heterosynthon III [D1: 2.7156(19) Å] to generate infinite chains. Such translationally 
related chains are connected via weak C-H···O interactions to generate supramolecular 
sheets. The C-O and C=O bond distance within 8 is 1.317 Å and 1.196Å respectively and 
the corresponding C-N-C bond angle is 119.75°. The dihedral angle between the plane of 
the oxalic acid and TMP is 53.18°. The deviation from planarity may be attributed to the 
presence of the methyl groups on the TMP molecule which acts as a source of steric 
hindrance. 
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Figure 2.2.14 Crystal packing of oxalic acid● tetramethylpyrazine, 8 
 
 
The crystal structure of isophthalic acid●1,2-bis(4-pyridyl)ethane, 9 contains 
one molecule of isophthalic acid and two half molecules of 1,2-bis(4-pyridyl)ethane in 
the asymmetric unit. Co-crystal 9 is sustained by supramolecular heterosynthon III      
[D1: 2.6470(18), D2: 2.5840(18)] to generate extended zig-zag chains. As is seen in 
XUNGIW, 45 the co-crystal of isophthalic acid and 4,4’-bipyridine translationally related 
chains align parallel to each other forming planar supramolecular 2D sheets via weak C-
H⋅⋅⋅O hydrogen bonds. The C-O and C=O bond distances are 1.306 Å and 1.214 Å; 1.318 
Å and 1.210 Å respectively; and the C-N-C bond angle of 116.98° and 117.81° supports 
the neutral nature of III. As is seen in 1, 2, 3, 4, 5, 6, and 7 auxillary C-H⋅⋅⋅O interactions 
stabilize III and the COOH is relatively planar to the pyridyl ring, the C-O-N-C torsion 
angles within 9 are 7.80° and 10.22°. 
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Figure 2.2.15 Crystal structure of isophthalic acid●1,2-bis(4-pyridyl)ethane, 9 
 
 
As is anticipated when a molecule with one hydrogen bond donor  is co-
crystallized with a molecule containing two hydrogen bond acceptor, discrete hydrogen 
bonded structures results as in the case of 1, 2, 3, 4 and 5. Stoichiometric 2:1 ratios of 
carboxylic acid to aromatic nitrogen are observed in structures involving monoacids with 
aromatic nitrogen having two acceptor sites in all cases except that of benzoic acid and 
4,4’-bipyridine. However the solvent drop grinds of the 2:1 mole ratio yields a 
consistently different X-ray powder diffraction pattern than is observed for the 1:1 
stoichiometry suggesting the possibility of a 2:1 co-crystal as well. 
Extended chains are observed in co-crystals 6, 7, 8 and 9. In all cases the ratio of 
the acid and the aromatic nitrogen is 1:1 and the molecules are linked by supramolecular 
heterosynthon III or IV. The geometry of the resulting chains reflects the geometry of the 
linking acids in a predictable fashion. Two types of chains are seen, linear chains for co-
crystals 6, 7 and 8 while zig-zag in the case of 9. In these structures weak C-H⋅⋅⋅O 
hydrogen bonds link parallel chains to create supramolecular sheets.  
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The multiple component crystals thus far discussed are all sustained by 
supramolecular heterosynthons III or IV to generate predominantly strong hydrogen 
bonded 0D and 1D motifs. However, depending on the multiplicity of the acceptors and 
donors in the crystal structure, and the resulting geometry of the molecules 2D and 3D 
hydrogen bonded networks may also be generated. In fact, in 1977 Wells catalogued 
network structures in crystals46 in a manner that has facilitated the crystal engineering47 
of a wide range of infinite 2D and 3D networks.48- 50 The topology or connectivity of a 
given network is represented in terms of the general symbol (n, p) where n is the number 
of nodes in the smallest closed circuit in the network and p is the number of connections 
to neighboring nodes that radiate from any centre or node.51 The use of either non-
covalent or metal-ligand coordination bonds means that such networks are modular, i.e., 
sustained by complementary combinations of molecules or ions,52  thereby allowing the 
generation of classes of compound once a prototype has been established.  
Trimesic acid (benzene-1, 3, 5-tricarboxylic acid, TMA) forms hexagonal (6, 3) 
networks that are sustained by carboxylic acid homosynthon I.53-54 The diameter of the 
hexagonal rings which consists of six molecules of TMA is 14 x 14Å. The resulting 
cavity is filled via interpenetration of different chicken wire frameworks. As a 
consequence the α-polymorph exhibits 4-fold inclined interpenetration. The 2:3 co-
crystal of TMA and 4,4’-bipyridine, 10, represents a prototypal55 (6,3) honeycomb 
network formed by two components. The co-crystal is sustained by supramolecular 
heterosynthon III whereby 4,4’-bipyridine molecules act as spacers inserting between the 
acid dimer I thereby expanding the 14 × 14 Å TMA cavity to ca. 35 × 26Å. The 
hexagonal cavity is filled by 3-fold parallel interpenetration of independent networks. 
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Co-crystallization of TMA and trans-1,2-bis(4-pyridyl)ethylene results in the 
formation of the (TMA)2● (trans-1,2-bis(4-pyridyl)ethylene)3, 11. There are two 
molecules of TMA and three molecules of trans-1,2-bis(4-pyridyl)ethylene in the 
asymmetric unit. Co-crystal 11 exhibits hexagonal (6, 3) networks that are sustained by 
supramolecular heterosynthon III. An expanded cavity size of 41 x 35 Å dimension is 
observed without changing the network topology of pure TMA. As is seen in the 
prototypal co-crystal 3-fold parallel interpenetration is observed.  
 
      
a)                                                                              b) 
Figure 2.16. Super honeycomb (6, 3) network (a) and Space filling view of triply parallel 
interpenetrated (b) nets of 11 
 
The X-ray crystal structure of (TMA)2● (1,2-bis(4-pyridyl)ethane)3, 12a 
confirms the expected 2:3 stoichiometry and the presence of supramolecular 
heterosynthon, III. However, 12a does not exist as a (6, 3) network. Rather, 12a forms a 
supramolecular isomer48 that is better known in the context of coordination polymers, a 
(10, 3)-a network.46, 49 The scale of the molecular components means that the dimensions 
of the channels in the network are ca. 53 × 30 Å (Figures 2.17). A distinguishing feature 
of (10, 3)-a networks is the presence of 4-fold helices, all of the same handedness, that 
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align parallel to the three cubic axes.  12a contains a set of three (10, 3)-a nets of the 
same handedness that triply interpenetrate as shown in Figure 2.18a. This set in turn 
interpenetrates with two other sets of the same handedness, thereby generating 9-fold 
interpenetration along the b-axis (Figure 2.18b). Further interpenetration between 
oppositely handed sets of nets affords 18-fold interpenetration (Figure 2.18c). To our 
knowledge this is the highest level of interpenetration yet observed in a net, the previous 
record being 11-fold.56-57 
 
        
                                           (a)                                                                        (b) 
  
Figure 2.2.16 Space filling views of a single (10,3)-a network of 12a: the ca. 53 × 30 Å channel viewed 
down the c-axis; a view orthogonal to the c-axis. 
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(a) 
 
 
(b) 
 
(c) 
Figure 2.2.17 Schematic illustrations of the interpenetration in 12a: (a) A set of triply interpenetrated 
(10,3)-a nets; (b) 9-fold interpenetration, each color represents a set of triply interpenetrated (10,3)-a 
nets; (c) The six sets of triply interpenetrated nets that afford overall 18-fold interpenetration 
 
The X-ray crystal structure of (TMA)2● (1,2-bis(4-pyridyl)ethane)3, 12b reveals 
that it exhibits the expected (6, 3) network with linear 1,2-bis(4-pyridyl)ethane molecules 
expanding the 14 × 14 Å TMA cavity to ca. 39 × 27 Å.  The prototypal structure of 10 
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exhibited a similar expansion of ca. 35 × 26 Å.55 Three (6, 3) networks engage in parallel 
interpenetration as illustrated in Figure 3.19. The void left over after catenation is filled 
by interdigitation of TMA and 1,2-bis(4-pyridyl)ethane molecules from adjacent layers. 
Nangia and co-workers have observed similar behavior in another trigonal scaffold, 
cyclohexane-1,3cis,5cis-tricarboxylic acid (CTA) and have generated a related series of 
super honeycomb networks.58-59 The network topology and mode of interpenetration in 
2:3 co-crystals of CTA•1,2-bis(4-pyridyl)ethane59 is closely related to that observed in 
10, 11 and 12b. It should also be noted that TMA•1,2-bis(4-pyridyl)ethane salt structures 
have been reported 60-62 but they do not exhibit interpenetration. That 12a and 12b are 
indeed molecular co-crystals is supported by location of hydrogen atoms in Fourier maps, 
examination of C−O and C=O bond distances, C−N−C angles and IR spectroscopy. 
 
    
(a)                                                                                 (b) 
Figure 2.19 Super honeycomb (6,3) network (a) and Space filling view of triply parallel 
interpenetrated (b) nets of 12b 
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The existence of (10,3) networks and supramolecular isomerism in coordination 
polymers is well documented but to our knowledge there exist only five neutral hydrogen 
bonded (10,3)-a nets that are built from organic molecules and they are not yet known to 
be polymorphic.63-64 Robson and co-workers recently reported a series of non-
interpenetrated (10,3)-a networks in [C(NH2)3][N(CH3)4][XO4](X= S, Cr, Mo).65  
However to the best of our knowledge, 12a  represents the first observation of a hydrogen 
bonded (10,3)-a network in a co-crystal. Polymorphism in co-crystals is also a relatively 
rare phenomenon, especially when compared to single component molecular 
crystals.65Indeed, only three previous examples of concomitant polymorphism in co-
crystals have been reported and are a consequence of conformational effects.66-68  
A number of methodologies were employed in the synthesis of the presented 
series of co-crystals. Co-crystallization experiments were attempted via slow evaporation, 
melting, grinding and solvent drop grinding techniques. The latter synthetic approaches 
can be advantageous from a green chemistry perspective. Additionally, the solvent-drop 
grinding approach has been shown to be useful in addressing the issue of stoichiometry 
and polymorph control in co-crystals.7 Solvent-drop grinding results suggest that it is 
generally possible to find experimental conditions, under which a specific co-crystal form 
exists. With regards to the stoichiometry and the crystal form 1, 2, 3, 4, 5, 6, 7, 8, 9 and 
11 were reproduced using the aforementioned techniques. (TMA)2•(1,2-bis(4-
pyridyl)ethane)3 was found to exist in two polymorphic modifications. While solution 
crystallization afforded concomitant polymorphs form I (12a) and form II (12b), both 
grinding and solvent drop grinding resulted in a mixture of starting materials.   
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A screen for crystal forms of 1-9 and 11 was conducted via solvent drop grinding 
of co-crystal formers involving seven solvents of different polarity. As determined by 
infrared spectroscopy and X-ray powder diffraction, only one form was isolated for 1-9 
whereas 11 was only obtained from solvent drop using dimethyl sulfoxide. The solvent 
drop grinding experiments tend to mirror the co-crystals that were obtained from 
solution. A screen for crystal forms of 12 was conducted using seventeen solvents. 
Solvent drop grinding involving isopropanol, chloroform, dichloromethane, cyclohexane, 
heptane, ethyl acetate, tetrahydrofuran, acetonitrile, isopropyl acetate, methanol, heptane, 
DMA and DMSO resulted in a mixture of starting materials whereas solvent drop grinds 
involving toluene, acetone and yielded a new phase that was different from 12a and or 
12b. The utilization of solid state co-crystallization of 1-9 and 11 indicates that such 
methods are viable means for supramolecular synthesis of co-crystals.  
2.3. Conclusions 
 
Hydrogen bonded supramolecular synthons in a series of co-crystals containing 
carboxylic acids and aromatic nitrogen have been studied using X-ray diffraction. The 
hydrogen bonding in these co-crystals support the statistical analysis that indicate that the 
acid-pyridine supramolecular heterosynthon III is favored over the formation of the 
carboxylic acid supramolecular homosynthons I or II. Consequently the relative ranking 
of these supramolecular synthons can be presented as: III>I>II.  
Co-crystal 12 exhibits concomitant polymorphism and one form exhibits the 
highest level of interpenetration yet observed in an organic or metal-organic network.  
The observation of polymorphism in a co-crystals is of topical interest given the growing 
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relevance of pharmaceutical co-crystals.6, 9, 69-71  The existence of a (10, 3)-a network 
with such large dimensions and the inherent modularity of co-crystals illustrates how co-
crystals of TMA might be worthy of further investigation in the context of open 
framework networks especially as a recent study suggests that interpenetrated metal-
organic networks are of interest in the context of hydrogen gas storage.70   
The majority of API’s in the pharmaceutical industry tend to have low water 
solubility. Particle size reduction by milling or grinding is typically performed as a means 
of improving the dissolution rate and there exists a correlation between particle size 
reduction and bulk properties such as flowability, bulk density, mixing ability etc. That 
the co-crystals within the study and co-crystals in general may be synthesized via 
grinding and solvent drop grinding has significant implication with respect to processing 
of these novel materials and green chemistry. 
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2.4. Experimental Section 
 
All reagents were purchased from Aldrich and used without further purification. 
Single crystals of 1-12 were obtained via slow evaporation of stoichiometric amounts of 
starting materials in appropriate solvents and were isolated from solution before complete 
evaporation of the solvents. 
2.4.1. Co-crystallization via grinding:  
 
Stoichiometric amounts of the starting materials were ground with a mortar and pestle for 
ca.4 minutes. 
2.4.2. Co-crystallization via solvent-drop grinding:  
Stoichiometric amounts of the starting materials were ground with a mortar and pestle for 
ca. 4 minutes with the addition of 10 μL of solvent per 50 mg of co-crystal formers. 
2.4.3. Co-crystallization via melting:  
Stoichiometric amounts of the starting materials were heated until melt and the mixture 
was left to crystallize at ambient conditions. 
2.4.4. Co-crystallization via solution evaporation:  
(Benzoic acid)2 ● 1,2-bis(4-pyridyl)ethane, 1: 1,2-bis(4-pyridyl)ethane (0.037g, 0.20 
mmol) and benzoic acid (0.049g, 0.40mmol) was dissolved in  a 1:1 ethanol/methanol 
solvent mixture (2 mL) . After three days colorless crystals of 1 were obtained,                  
m. pt: 110-112°. 
(Benzoic acid)2● trans-1,2-bis(4-pyridyl)ethylene, 2: To trans-1,2-bis(4-
pyridyl)ethylene (0.039g, 0.21mmol) was added benzoic acid (0.052g, 0.42 mmol) and          
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2 mL  of a 1:1 ethanol/methanol solvent mixture. Colorless rods of 2 were observed 
within five days, m. pt: 80-81°. 
Benzoic acid●4,4’-bipyridine, 3: Benzoic acid (0.049g, 0.40mmol) and 4,4’-bipyridine 
(0.032g, 0.20mmol) was dissolved in of acetonitrile (2 mL). The solution was allowed to 
slowly evaporate at room temperature to yield colorless blocks of 3, m. pt: 128-129° 
Sorbic acid● 1,2-bis(4-pyridinium)ethane sorbate, 4: Sorbic acid (0.022g, 0.20mmol) 
and 1,2-bis(4-pyridyl)ethane (0.018g, 0.10mmol) was dissolved in 1:1 ethanol/methanol 
solution (2 mL). The solution was allowed to slowly evaporate at room temperature to 
yield colorless crystals of 4 after three days, m. pt: 99-103°. 
(Naproxen)2●trans-1,2-bis(4-pyridyl)ethylene, 5: Naproxen (0.080g, 0.34mmol) and 
trans-1,2-bis(4-pyridyl)ethylene (0.032g, 0.17mmol) was dissolved in 1:1 
ethanol/methanol solution (2 mL). The solution was allowed to slowly evaporate at 
ambient temperature to yield crystals of 5, m. pt: 135-137°. 
Glutaric acid● 1,2-bis(4-pyridyl)ethane, 6: Slow evaporation of a 1:1 ethanol/methanol 
solution (2mL) containing glutaric acid (0.027g, 0.20mmol) and 1,2-bis(4-pyridyl)ethane 
(0.034g, 0.20mmol) yielded colorless crystals of 6, after two days, m. pt: 130-132°. 
Glutaric acid●trans-1,2-bis(4-pyridyl)ethylene, 7: Glutaric acid (0.027g, 0.20mmol) 
and trans-1,2-bis(4-pyridyl)ethylene (0.036g, 0.20mmol) was dissolved in a  1:1 
ethanol/methanol solution (2mL). After two days, colorless crystals of 7 were obtained 
upon slow evaporation, m. pt: 180-186°. 
Oxalic acid● tetramethylpyrazine, 8: Tetramethylpyrazine (0.015g, 0.11mmol) and 
oxalic acid (0.0095g, 0.11mmol) was dissolved in ethylacetate (2 mL) on heating.  Upon 
slow evaporation colorless rods of 8 was obtained, m. pt: 139-142°. 
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Isophthalic acid● 1,2-bis(4-pyridyl)ethane, 9: To 1,2-bis(4-pyridyl)ethane (0.048g, 
0.26mmol) was added isophthalic acid (0.044g, 0.27mmol)  and the solid  mixture 
dissolved in DMSO (0.5mL).  Colorless crystals of 9 were observed within four days, m. 
pt: 212-222°. 
 (Trimesic acid)2●( trans-1,2-bis(4-pyridyl)ethylene)3, 11: Trimesic acid (0.077mg, 
0.37mmol) and trans-1,2-bis(4-pyridyl)ethylene (0.100g, 0.55 mmol) was dissolved in 
DMSO (1 mL). After 3 days, small yellow blocks were obtained to yield co-crystal 11, 
m. pt: 228-234°. 
 (Trimesic acid)2● 1,2-bis(4-pyridyl)ethane)3, 12: Trimesic acid (0.030g, 0.14mmol) 
and trans-1,2-bis(4-pyridyl)ethylene (0.039g, 0.21mmol) was dissolved in DMSO (1mL) 
.  The solution was left to slow evaporate at room temperature. Colorless crystals of 12 
were obtained within 3 days, m. pt: 182-186°, 298-300°. 
Polymorphism Screen 
1-12 were subjected to a preliminary polymorph screen using solvent drop grinding (as 
described above) with seven solvents that exhibit a wide range of polarity: cyclohexane, 
toluene, chloroform, ethyl acetate, methanol, dimethyl sulfoxide (DMSO) and water. A 
summary of the results obtained from dry grinding, solvent drop grinding and melts are 
presented in Table 2.4. In addition to the co-crystal, trace amounts of starting material 
was also observed in the case of 1, 2, 3, 8, 9 and 11 
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Table 2.4 Results obtained from solution crystallization, grinding, solvent drop grinding and melting 
experiments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All compounds were analyzed by infrared spectroscopy using a Nicolet Avatar 
320 FTIR instrument. The purity of bulk samples was confirmed by X-ray powder 
diffraction analysis conducted on a Rigaku Miniflex Diffractometer using Cu Kα (λ= 
1.540562), 30kV, 15mA. The data were collected over an angular range of 3° to 40° 2θ in 
continuous scan mode using a step size of 0.02° 2θ and a scan speed of 2.0º/min. 
The X-ray powder diffraction analysis of the powders obtained in the 
polymorphism screens for 1, 2, 3, 4, 6, 7, 8, 9, 11, and 12 were collected on Bruker AXS 
D8 discover X-ray diffractometer equipped with GADDSTM (General Area Diffraction 
Detection System), a Bruker AXS HI-STAR area detector at a distance of 15.05 cm as 
 Solution Grinding Solvent-drop 
grinding 
Melt 
1 1 1 1 1 
2 2 2 2 2 
3 3 3 3 3 
4 4 4 4 4 
5 5 5 5 5 
6 6 6 6 6 
7 7 7 7 7 
8 8 8 8 8 
9 9 9 9 n/a 
11 11 starting material 11* n/a 
12 12 starting 
material 
New form + 
starting 
material 
n/a 
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per system calibration, a copper source, automated x-y-z stage, and 0.5 mm collimator. 
Data were collected over a 2θ range of 2.0-37.0 at a step size of 0.02° 2θ. 
 The melting points were determined on a Mel-temp® apparatus and are presented 
in Table 2.1. Differential Scanning Calorimetry was performed using a TA instrument 
model 2140, 10° step/min. 
 
2.4.5. Crystal structure determination 
Crystals 1-12 were examined under a microscope and suitable single crystals were 
selected for X-ray analysis. Data were collected on a Bruker–AXS SMART APEX CCD 
diffractometer with monochromatized Mo Kα radiation (λ = 0.71073 Å) connected to a 
KRYO-FLEX low temperature device. Data for 1, 4-5, 8-9, 11-12 were collected at 100 
K whereas data for 2-3, 6-7 were collected at 298 K. Lattice parameters were determined 
from least square analysis, and reflection data were integrated using the program 
SAINT+ Version 6.22. Lorentz and polarization corrections were applied for diffracted 
reflections. In addition, the data was corrected for absorption using SADABS.  Structures 
were solved by direct methods and refined by full matrix least squares based on F2 using 
SHELXTL74 software Version 6.10. All non-hydrogen atoms were refined with 
anisotropic displacement parameters. All H-atoms bonded to carbon atoms, except 
methyl groups, were placed geometrically and refined with an isotropic displacement 
parameter fixed at 1.2 times Uq for the atoms to which they were attached. H-atoms of 
methyl groups as well as N or O bonded protons were located from Fourier difference 
map and refined isotropically based upon the corresponding N or O-atom 
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(U(H)=1.2Uq(N, O)). Crystallographic data for 1-12 are presented in tables 2.4 and 2.5 
and selected hydrogen bond distances are presented in table 2.6. 
 
Table 2.4. Crystallographic data and Parameters for 1-12 
 
 
 
 
 
 
 
 
 1 2 3 4 5 6 
Formula C26H24N2O4 C26H22N2O4 C17H14N2O2 C24H28N2O4 C40H38N2O6 C17H18N2O4 
Mol .wt. 428.47 426.46 278.30 408.48 642.72 314.33 
Crystal system Triclinic Monoclinic Triclinic Monoclinic Triclinic Monoclinic 
Space group P-1 P2(1)/c P-1 C2/c P1 C2/c 
a/Å 6.4357(17) 8.8678(13) 7.608(2) 25.377(5) 5.7645(16) 15.562(6) 
b/Å 6.8960(18) 4.9009(7) 11.454(3) 12.669(3) 7.607(2) 10.281(4) 
c/Å 12.412(3) 24.411(4) 16.423(5) 14.754(3) 19.109(5) 9.436(4) 
αº 79.037(5) 90 100.293(5) 90 84.851(5) 90 
βº 80.952(5) 99.524(3) 95.987(6) 98.68(3) 83.797(5) 92.357(7) 
γº 80.144(5) 90 90.521(5) 90 89.241(5) 90 
V /Å3 528.4(2) 1046.3(3) 1399.8(7) 4689.1(4) 829.7(4) 1508.4(10) 
Dc/g cm-3 1.347 1.354 1.321 1.157 1.286 1.384 
Z 1 2 4 8 1 4 
2θ range 3.38-52.74 3.38-49.42 2.54-49.42 4.40-49.58 2.16-50.20 5.24-52.74 
Nref./Npara. 2102/145 1760/145 4679/ 379 3994/324 2928/433 1542/105 
T/K 100(2) 100(2) 298(2) 298(2) 100(2) 100(2) 
R1 [I>2sigma(I)] 0.0516 0.0508 0.0638 0.0681 0.0611 0.0820 
wR2 0.1385 0.1355 0.1649 0.1957 0.1474 0.2258 
GOF 1.083 1.097 1.087 0.995 1.050 1.134 
Abs coef. 0.091 0.092 0.088 0.079 0.087 0.100 
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Table 2.5. Crystallographic data and Parameters for 1-12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 7 8 9 11 12a 12b 
Formula C17H20N2O4 C10H14N2O4 C20H18N2O4 C27H21N3O6 C54H48N6O12 C27H24N3O6 
Mol .wt. 316.35 226.23 350.36 483.47 972.98 486.49 
Crystal system Monoclinic Triclinic Triclinic Monoclinic Orthorhombic Monoclinic 
Space group P2(1)/c P-1 P-1 P2(1)/n Pbca P2(1)/n 
a/Å 12.295(3) 3.8081(9) 6.9526(17) 10.214(3) 19.270(3) 10.344(2) 
b/Å 11.166(2) 8.3558(19) 7.4920(18) 12.391(3) 19.906(3) 12.313(2) 
c/Å 24.421(5) 8.606(2) 17.118(4) 18.630(5) 25.249(3) 18.914(4) 
αº 90 81.950(4) 100.783(4) 90 90 90 
βº 97.102(4) 80.337(4) 90.162(4) 98.129(6) 90 94.309(4) 
γº 90 85.847(4) 101.822(4) 90 90 90 
V /Å3 3326.8(12) 266.97(11) 856.5(4) 2334.2(10) 9685(2) 2402.3(8) 
Dc/g cm-3 1.263 1.407 1.358 1.376 1.335 1.345 
Z 8 1 2 4 8 4 
2θ range 3.34-52.74 4.84-52.74 2.42-52.74 3.96-52.74 3.22-49.42 3.96-49.42 
Nref./Npara. 6760/415 1069/73 3417/235 4761/334 8249/650 4096/ 325 
T/K 298(2) 100(2) 298(2) 100(2) 100(2) 100(2) 
R1 
[I>2sigma(I)] 0.0844 0.0654 0.0514 0.0734 0.0557 0.0626 
wR2 0.2321 0.1792 0.1405 0.1720 0.1262 0.1242 
GOF 1.058 1.061 1.050 1.001 1.062 0.906 
Abs coef. 0.091 0.110 0.096 0.099 0.096 0.096 
 76
Table 2.6. Selected Hydrogen Bond Distances and Parameters for 1-12 
 
 
 
 
 
 
 
 
 Hydrogen Bond d (H···A) /Å D (D···A)/Å θ /º 
1 O-H⋅⋅⋅⋅N 1.68 2.5983(19) 175.0 
2 O-H⋅⋅⋅⋅N 1.65 2.622(2) 170.9 
O-H⋅⋅⋅⋅N 1.73 2.668(3) 171.2 3 
O-H⋅⋅⋅⋅N 1.69 2.655(3) 171.3 
O-H⋅⋅⋅⋅N 1.66 2.678(7) 172.9 5 
O-H⋅⋅⋅⋅N 1.59 2.687(7) 158.1 
O-H⋅⋅⋅⋅N 1.79 2.647(3) 174.9 
O-H⋅⋅⋅⋅N 1.83 2.657(3) 156.2 
O-H⋅⋅⋅⋅N 1.81 2.632(3) 174.2 
6 
O-H⋅⋅⋅⋅N 1.74 2.657(3) 155.4 
7 O-H⋅⋅⋅⋅N 1.74 2.612(3) 175.3 
8 O-H⋅⋅⋅⋅N 1.81 2.7156(19) 174.2 
O-H⋅⋅⋅⋅N 1.74 2.6470(18) 173.7 9 
O-H⋅⋅⋅⋅N 1.61 2.5840(18) 171.2 
O-H⋅⋅⋅⋅N 1.63 2.623(4) 160.9 
O-H⋅⋅⋅⋅N 1.57 2.597(4) 170.5 11 
O-H⋅⋅⋅⋅N 1.66 2.622(4) 168.2 
O-H⋅⋅⋅⋅N 1.64 2.601(3) 174.3 
O-H⋅⋅⋅⋅N 1.67 2.622(3) 161.6 
O-H⋅⋅⋅⋅N 1.59 2.621(3) 178.1 
O-H⋅⋅⋅⋅N 1.33 2.553(3) 175.5 
O-H⋅⋅⋅⋅N 1.64 2.625(3) 167.7 
 
 
12a 
 
O-H⋅⋅⋅⋅N 1.62 2.607(3) 173.5 
O-H⋅⋅⋅⋅N 1.50 2.596(4) 163.7 
O-H⋅⋅⋅⋅N 1.56 2.605(4) 175.2 12b 
O-H⋅⋅⋅⋅N 1.51 2.614(4) 169.9 
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3.1. Introduction 
 
Crystal Engineering is the rational design of functional solids.1 Consequently one 
of the main goals is to control the way in which individual molecules self assemble in the 
solid state, allowing us to affect solid state reactivity and to design new functional 
materials. A pre-requisite in the design process is the identification of reliable, robust 
supramolecular synthons since it affords a certain level of predictability with respect to 
anticipated pattern formation in the crystal structure and allows for the judicious selection 
of co-crystal formers. In a continuing effort to assess how functional groups self-
associate i.e form supramolecular homosynthons2 versus their interactions with different 
complementary groups to form supramolecular heterosynthons, the system of alcohols 
and aromatic nitrogens were chosen. The study involved assessing the reliability of the 
alcohol homosynthon as compared to the alcohol-aromatic nitrogen heterosynthon. 
Alcohols represent one of the most prevalent functional groups found in nature 
and in pharmaceuticals. They are self complementary since they are capable of acting as 
both hydrogen bond donor and hydrogen bond acceptor. Self-association of alcohols 
mediated by hydrogen bonds has been studied3 and they are known to form chains, rings 
(pentemers, hexamers etc) or helices through O-H⋅⋅⋅O hydrogen bonds. Of the 24,995 
 
 
 
 
3. The Reliability of the Alcohol−Aromatic Nitrogen Supramolecular 
Heterosynthon 
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entries that contain an alcohol group in the Cambridge Structural Database (CSD)4-7 6183 
(ca. 25%) self associate via hydrogen bonds to form supramolecular homosynthon V.  
Alcohols are also capable of forming supramolecular heterosynthons with a number of 
different complementary functional groups such as aromatic nitrogen, carbonyls, 
phosphonyls, sulfonyls, etc.  
The utilization of the alcohol-aromatic nitrogen supramolecular heterosynthon VI 
in crystal engineering is certainly not without precedence. In fact several examples of co-
crystals8-24 based upon supramolecular heterosynthon VI exist in the CSD. VI has been 
utilized to build crystals with intricate supramolecular architectures25-31, to synthesize 
host-guest complexes, 31-38 for non-linear optics39 and as supramolecular template to 
direct topochemical reactions.40-41 
In the present study, hydrogen bonded co-crystals formed between aromatic 
nitrogen and alcohols are investigated in the context of the reliability of supramolecular 
synthons formed. 
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Figure 3.1 Molecular structures of components used in co-crystallization of 13-20. 
 
3.2. Results and Discussion 
 
3.2.1. Cambridge Structural Database Analysis 
A statistical analysis of the CSD revealed the percentage of occurrence and the 
parameters of supramolecular synthons V and VI. For each supramolecular synthon 
considered, initial contact distances well beyond the sum of the Van der Waals radii of 
the acceptor and the donor atoms were applied. Contact limits for each interaction was 
subsequently determined from histogram. Crystal structures at the end of the bell curve 
(visual limits) were examined more closely in Mercury. The parameters used to define 
the searches were 3D-coordinates present, only organics and R < 7.5%. 
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Table 3.1 Geometric features of supramolecular homosynthon V and supramolecular heterosynthon 
VI. 
 
Supramolecular 
Synthon 
Percentage Interaction Distance Range 
(Å) 
Mean (Å) 
V 6183/24994 
(24.7%) 
O-H⋅⋅⋅⋅O 2.50-3.07 2.78(8) 
VI 682/1453 (46.9%) O-H⋅⋅⋅⋅Narom 2.50-3.00 2.77(8) 
 
 
 
 
There are 1453 entries that contain both an alcohol and an aromatic nitrogen 
containing molecule in the CSD. Of this number, 682 (47%) entries exhibit 
supramolecular heterosynthon VI as compared to 274 (19%) crystal structures that 
exhibit the alcohol homosynthon V.  517 of the 682 structures exhibiting VI were found 
to occur exclusive of the alcohol homosynthon. A further analysis revealed 208 structures 
in which an aromatic nitrogen and an alcohol are present in the absence of any other 
hydrogen bonding moieties. 203 of these structures (97%) exhibit heterosynthon VI as 
compared to 52 structures (26%) that exhibit V, suggesting that VI is favored over V 
even in the presence of competing functional groups.  
The alcohol-aromatic nitrogen heterosynthon was found to occur within the range 
2.50-3.00 Å with an average O···N hydrogen bond distance of 2.77(8) Å see Table 3.1.  
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                     (a)                                                                                             (b) 
Figure 3.2 Histogram of hydrogen bonds of (a) homosynthon V and (b) heterosynthon VI retrieved 
from the CSD. 
 
3.2.2  Features of Hydroxyl···Aromatic Nitrogen Interaction  
Phenols (pKa 8-11) are more acidic than aliphatic alcohols (pKa 15-17), 
consequently the O-H⋅⋅⋅Narom hydrogen bonds formed between phenols and aromatic 
aromatic nitrogen are expected to be stronger than that formed between aliphatic alcohols 
and aromatic nitrogen. Phenols and aromatic nitrogens can interact via neutral O-
H⋅⋅⋅Narom interaction to form co-crystals or with proton transfer from the hydroxyl oxygen 
to the aromatic nitrogen to form organic salts.39 It has been suggested that proton transfer 
occurs when the difference in pKa is greater than 2.95.39 The ΔpKa values in co-crystals 
13-20 range from -3.27 to -7.45 (Table 3.2) and consequently the O-H⋅⋅⋅Narom 
supramolecular synthons in these compounds would therefore be expected to be neutral 
rather than ionic. 
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Table 3.2 pKa values of components used in co-crystals 13-20 
 
 
 
 
 
 
 
 
 
Structural parameters of ancillary groups, namely the C-N-C angle in the aromatic 
nitrogen and C-O bond length in the phenolic moieties can be used to support the neutral 
or ionic nature of heterosynthon VI. The C–N–C angle in aromatic nitrogen is known to 
be sensitive to protonation, the cationic form exhibits higher values (ca. 121°) than that of 
the corresponding neutral counterpart (ca. 116°).42-43  Histograms  of carbon-oxygen 
lengths in neutral and ionic hydroxyl moieties were generated using the CSD and are 
presented in Figure 3.2 (only good quality crystal structures: ordered, error-free, non-
polymeric with 3D coordinates determined and R< 7.5%). To distinguish neutral C-OH 
from ionic C-O- specific restriction on the oxygen atoms were applied during the CSD 
searches. For neutral C-OH bond the hydrogen atom was defined to be bonded to the 
oxygen atom; the oxygen atom was defined to be uncharged, and the number of bonded 
atoms was set to 2. In the case of ionic C-O- bond, the charge of the oxygen was set to -1 
and the number of bonded atoms was set to 1. The 14,235 crystal structures that contain 
Co-crystal pKa of 
component 1 
pKa of 
component 2 
ΔpKa  
13 9.40 6.13 -3.27 
14 9.40 5.50 -3.90 
15 9.74 6.13 -3.61 
16 9.74 5.50 -4.24 
17 10.33 5.50 -4.83 
18 10.33 2.88 -7.45 
19 9.45 2.88 -6.57 
20 9.14 2.88 -6.26 
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neutral aliphatic hydroxyl moieties exhibit an average bond distance of 1.42(2) Å while 
the 5,150 entries that contain neutral aromatic nitrogen exhibit an average C-OH bond 
length of 1.36(2) Å. There are 539 entries that contain aromatic deprotonated hydroxyl 
moieties which exhibit an average C-O- bond of 1.27(4) Å while the 279 crystal 
structures that contain aliphatic deprotonated hydroxyl groups exhibit average C-O- bond 
distance of 1.26(3) Å. 
    
a)                                                                                 b) 
 
(c)                                                                 (d) 
 
Figure 3.3 Histograms representing the distribution of carbon-oxygen bond lengths in a) neutral 
aromatic hydroxyl moieties (b) neutral aliphatic hydroxyl moieties (c) deprotonated aromatic 
hydroxyl moieties and (d) deprotonated hydroxyl moieties. 
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The neutral nature of supramolecular heterosynthon VI was confirmed by proton 
location in the difference Fourier map, and structural parameters of the C–N–C angle in 
the aromatic nitrogen moieties and C–O bond lengths in the phenolic moieties.44-45 
3.2.3. Crystal Structure Description 
 
The crystal structure of 1-naphthol46-47 consists of molecules linked by 
homosynthon V into chains that run parallel to the b axis as shown in Figure 3.4. 
 
Figure 3.4 Crystal packing in 1-naphthol 
 
1-naphthol co-crystallizes with 1,2-bis(4-pyridyl)ethane in the 2:1 ratio to yield  
(1-naphthol)2●1,2-bis(4-pyridyl)ethane 13. The molecules interact through symmetric 
O-H···Narom hydrogen bond [2.7206(15) Å, 167.03°] to form the expected 2:1 discrete 
adduct as shown in Figure 3.5. Such discrete units interact in a zig-zag fashion through 
C-H···π interactions along the b axis and π···π stacking between molecules of 1,2-bis(4-
pyridyl)ethane in adjacent discrete trimers occurs along the c axis. The C-O bond 
distance in 13 is 1.351Å and the C-N-C bond angle is 116.43° thus supporting the neutral 
nature of the interaction.  The dihedral angle between the planes of the naphthol ring and 
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that of the pyridyl molecule is 66.28°. Similar interactions are also observed in the 
isostructural co-crystal 14.  
 
 
Figure 3.5 Three component adducts present in the crystal structure of 13. 
 
 
Figure 3.6 Crystal packing in 13 
 
In the crystal structure of (1-napthol)2 ●trans-1,2-bis(4-pyridyl)ethylene 14,  
two molecules of 1-naphthol and one molecule of trans-1,2-bis(4-pyridyl)ethylene 
aggregate as discrete trimeric supramolecular adducts through O-H···Narom hydrogen bond 
[2.7350(13)Å, 176.4°]. As is observed in the previous co-crystal such discrete units 
interact in a zig-zag fashion through C-H···π interactions and further stabilization is 
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afforded by π···π stacking between molecules of trans-1,2-bis(4-pyridyl)ethylene. The   
C-O bond distance is 1.353Å and the C-N-C bond angle is 116.57° . The dihedral angle 
between the planes of the 1-naphthol and trans-1,2-bis(4-pyridyl)ethylene  molecules in 
14 is 63.38°. 
 
Figure 3.7 Three component adduct in the crystal structure of 14 
 
 
 
Figure 3.8 Crystal packing in 14 
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Figure 3.9 Crystal structure of 4,4’-biphenol  
 
4,4’-Biphenol is sustained by supramolecular homosynthon V to generate a 2D 
supramolecular sheet.48 Hydrogen bonded adducts formed between the combination of 
double donors such as biphenols and an equal number of acceptors such as diamines are 
anticipated to form chains with the two molecular components alternating along the chain 
as is observed in co-crystal 15. 4,4’-biphenol●1,2-bis(4-pyridyl)ethane 15, crystallizes 
in a monoclinic system and is refined in centrosymmetric P21/c space group. Both 
molecules of 4,4’-biphenol and 1,2-bis(4-pyridyl)ethane reside on centers of inversion. 
The 1:1 co-crystal is sustained by VI via symmetric O-H…N H-bonding [2.7459(15)Å,  
165.5°] to generate infinite zig zag chains.(Figure 3.10) The C-O bond distance is 1.361Å 
and the C-N-C bond angle is 116.57°. Molecules of 1,2-bis(4-pyridyl)ethane can adopt 
different conformations as a consequence of the flexibility afforded by the central C-C 
bond; in 4,4’-biphenol conformational degrees of rotation is afforded about the central  
C-C bonds and the hydroxyl group about the C-O bonds. However molecules of 4,4’-
biphenol and 1,2-bis(4-pyridyl)ethane in co-crystal 15 are planar. 
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Figure 3.10 Crystal structure of 4,4’-biphenol●1,2-bis(4-pyridyl)ethane, 15. 
 
In 4,4’-biphenol●trans-1,2-bis(4-pyridyl)ethylene 16, molecules of 4,4’-
biphenol and trans-1,2-bis(4-pyridyl)ethylene  reside on centers of inversion. As is seen 
in co-crystal 15, 16 is sustained by supramolecular heterosynthon VI, via symmetric O-
H⋅⋅⋅Narom H-bonding [2.7384(17) Å, 165.0°] to generate infinite zig zag chains.  The 
neutral nature of the interaction is supported by structural data: the C-O bond distance is 
1.358 Å and the corresponding C-N-C angle in 16 is 116.66°. 
 
Figure 3.11 Crystal Packing in 4,4’-biphenol●trans-1,2-bis(4-pyridyl)ethylene, 16 
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Figure 3.12  Crystal Packing in 16, viewed down the b-axis 
 
Co-crystallization of a 1:1 mole ratio of hydroquinone and trans-1,2-bis(4-
pyridyl)ethylene  results in the formation of hydroquinone●trans-1,2-bis(4-
pyridyl)ethylene 17. Molecules of hydroquinone and trans-1,2-bis(4-pyridyl)ethylene  
reside on centers of inversion in 17. The resulting 1:1 co-crystal is sustained by VI 
through symmetric O-H⋅⋅⋅Narom hydrogen bonds [O⋅⋅⋅N: 2.7053(18)Å, 167.7°] to form 
infinite chains (Figure 3. 5) similar to that seen in MEKWUU, the co-crystal of 
hydroquinone and 1,2-bis(4-pyridyl)ethane.15 The C-O bond distance in 17 is 1.369 Å and 
the C-N-C bond angle is 116.68° which supports the neutral nature of VI.  
 
Figure 3.13 Crystal structure of hydroquinone● trans-1,2-bis(4-pyridyl)ethylene, 17. 
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Figure 3.14 Crystal Packing in hydroquinone ● trans-1,2-bis(4-pyridyl)ethylene 17. 
 
 
Hydroquinone ●tetramethylpyrazine (TMP) 18, was crystallized in the 
monoclinic crystal system and refined in the P21/c space group. The asymmetric unit 
consists of a half molecule of TMP and a half molecule of hydroquinone. Both molecules 
reside on a crystallographic center of inversion. In this 1:1 co-crystal the hydroxyl groups 
of hydroquinone are hydrogen bonded to TMP via O-H⋅⋅⋅Narom hydrogen bonds 
[O⋅⋅⋅Narom: 2.76(2)Å] to generate infinite chains (Figure 3.15). Such chains are 
translationally related along the b axis. 
The C-O bond distance in 18 is 1.369 Å and the C-N-C bond angle is 118.92°. 
The hydrogen bond distance observed in this co-crystal is consistent with values observed 
in other alcohol-aromatic nitrogen structures (mean 2.78(2) Å).  
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Figure 3.15 Crystal structure of hydroquinone ●TMP, 18 
 
 The crystal structure of resorcinol (RESORA03, RESORA13)49-50 is sustained by 
supramolecular homosynthon V. There are 16 chemically distinct co-crystals of 
resorcinol in the CSD,40, 51-58 in these structures resorcinol adopts three different 
conformations.  Of the three possible conformation, resorcinol –OH groups adopts two 
divergent motifs that may form linear chain a or zig zag chain b. The convergent –OH 
motif c allows resorcinol to build discrete hydrogen bonded adducts rather than infinite 
motifs (ABEKUN and TAHVII). This particular feature has found application in forming 
discrete adducts in which olefins are brought into close proximity such that 2+2-
cycloaddition is achieved upon photo-irradiation.40-41  
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Molecules of resorcinol in (resorcinol)2●(TMP)3  19, adopts conformation c. 
 Surprisingly, co-crystal 19 crystallizes in 3:2 stoichiometry and exhibits discrete five 
component adducts rather than the expected 2:2 discrete adducts or chains through O-
H⋅⋅⋅Narom hydrogen bonds. While both hydroxyl groups of resorcinol molecules act as O-
H⋅⋅⋅Narom donors, only one of the nitrogen in the two exterior TMP molecules of the 
discrete units act as O-H⋅⋅⋅Narom acceptor. The non-participating nitrogen atoms are 
involved in weak C-H⋅⋅⋅Narom interactions with a distance of 3.612Å and 3.712Å. An 
analysis of the crystal structure revealed two independent S-shaped discrete units each 
consists of one independent molecule of resorcinol and two independent TMP molecules, 
one of the TMP molecule reside on a center of inversion. The molecules in the discrete 
unit interact through O-H⋅⋅⋅Narom hydrogen bonds [O⋅⋅⋅Narom: 2.787(3) Å, 2.816(3) Å]. 
The O-H⋅⋅⋅Narom hydrogen bonds in the other discrete unit are 2.777(3) Å and 2.824(3) Å. 
Such independent discrete adducts are connected via weak C-H⋅⋅⋅O hydrogen bond. TMP 
molecules within the five component adducts are involved in weak face to face π-π 
stacking. The C-O bond distances within this structure are 1.362 Å, 1.369 Å, 1.363 Å and 
1.371 Å; the corresponding C-N-C angles are 119.21°, 119.06°, 119.22° and 119.24° 
respectively. 
 
 99
 
Figure 3.16  S-shaped discrete unit in the crystal structure 19  
 
The asymmetric unit of 2,7-dihydroxynaphthalene● (TMP)2 20, consists of two 
molecules of TMP and a molecule of 2,7-dihydroxynaphthalene.. Similar to co-crystal 19 
there is deviation from the expected 1:1 stoichiometry in co-crystal 20. The crystal 
structure reveals that 20 forms a 1:2 discrete unit in which each 2,7-
dihydroxynaphthalene molecule is linked to two TMP molecules through O-H⋅⋅⋅Narom 
hydrogen bonds of 2.806(3) Å and  2.733(3) Å (Figure 3.17). As in co-crystal 19 only 
one nitrogen atom on TMP is involved in O-H⋅⋅⋅Narom hydrogen bonding.  The other 
nitrogen atom is involved in weak C-H⋅⋅⋅N interactions. The C-O bond distances are 
1.363 Å and 1.362 Å and the corresponding C-N-C bond angles are 118.62° and 118.10° 
respectively. π⋅⋅⋅π stacking is also observed 20, the centroid to centroid distance of which 
is 3.688Å. 
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Figure 3.17 Discrete three component adduct of 2,7-dihydroxynaphthalene•(TMP)2  20. 
 
Co-crystals 13-20 have been investigated in the context of their reproducibility 
via grinding, solvent-drop grinding59 and growth from melts. It was observed that 
whereas solvent drop grinding for 4 minutes was efficient at producing the co-crystals or 
achieving partial conversion in most cases, the dry grinding approach did not always lead 
to conversion. As confirmed by PXRD and FTIR analysis, co-crystals 13, 14, 15, 16, 17, 
18, 19 and 20 were reproduced via solvent drop grinding. 13, 14, 15, 16, 19 was obtained 
upon dry grinding for longer periods (8 minutes) whereas a mixture of starting materials 
was obtained in the case of 18, 19 and 20. Melt experiments also proved to be suitable 
methodology in obtaining 14, 15 and 18 and a new phase was obtained from attempted 
melt to produce 13. 
3.3. Conclusions 
 
The study herein utilizes a series of co-crystals to demonstrate that the alcohol-
aromatic supramolecular heterosynthon VI is favored to the alcohol homosynthon V. Co-
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crystals 13-20 are sustained by the alcohol-aromatic nitrogen supramolecular 
heterosynthon VI. This observation is consistent with the supramolecular heterosynthon 
persistency exhibited by the 203/208 (97%) of entries containing only these two moieties 
(no competing hydrogen bonding moiety) archived in the CSD.  The hydrogen bond 
lengths in 13-20 correspond to the expected values of a typical O-H⋅⋅⋅ Narom interaction 
(Table 3.1) and the structural parameters(C-O lengths and C-N-C angles) of the ancillary 
groups suggest a neutral character of VI. Co-crystals 13-20 can be reproduced with little 
or no solvent via solid-state synthesis. 
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Table 3.3 Crystallographic data and structure refinement parameters for co-crystals 13-20 
 
   13  14  15  16  17  18  19 20  
formula C32H28N2O2 C32H26N2O2 C12H11NO C24H20N2O2 C28H36N4O4 C14H18N2O2 C36H48N6O4 C26H32N4O2 
Crystallization 
Solvent 
 
Ethanol 
 
Ethanol Ethanol Ethanol Methanol Acetonitrile Acetonitrile Aacetonitrile 
MW 472.56 470.55 185.22 368.42 292.33 246.30 628.80 432.56 
crystal system Monoclinic Monoclinic Monoclinic Monoclinic Monoclinic Monoclinic Triclinic Monoclinic 
space group P21/c P21/c P21/c P21/c P21/c P21/c P-1 P21/c 
a (Å) 6.961(15) 6.8699(7) 11.6591(16) 11.7712(19) 6.000(2) 7.566(2) 9.0768(11) 15.579(3) 
b (Å) 25.182(5) 25.450(3) 5.9135(8) 5.9268(9) 17.265(6) 9.218(2) 11.7248(14) 8.5123(19) 
c (Å) 7.7714(16) 7.6379(2) 14.087(2) 13.954(2) 7.062(2) 10.001(3) 17.443(2) 17.781(4) 
α (deg) 90 90 90 90 90 90 98.097(2) 90 
β (deg) 111.272(4) 110.106(2) 107.618(2) 108.614(3) 92.296(6) 111.328(5) 98.195(2) 93.686(6) 
γ (deg) 90 90 90 90 90 90 106.019(2) 90 
V /Å3 1270.9(5) 1254.0(2) 925.7(2) 922.6(3) 731.0(4) 649.7(3) 1734.1(4) 2353.19 
Dc/g cm-3 1.235 1.246 1.329 1.326 1.328 1.259 1.204 1.221 
Z 2 2 4 2 2 2 2 4 
2θ range 3.24- 52.74 5.90-52.74 3.66-52.74 3.66-56.76 5.72-52.74 5.78–49.92 2.40 – 52.74 2.62-52.74 
Nref./Npara. 2587/163 2560/164 1897/127 2108/128 1493/100 1036/82 6924/415 4809/289 
T /K 298(2) 298(2) 100(2) 173(2) 100(2) 100(2) 100(2) 100(2) 
R1 [I>2sigma(I)] 0.0455 0.0407 0.0423 0.0489 0.0428 0.0460 0.0656 0.0639 
wR2 0.1196 0.1156 0.1027 0.1232 0.0990 0.1079 0.1593 0.1530 
GOF 1.062 1.079 1.088 1.048 1.060 1.046 1.040 1.021 
Abs coef. 0.077 0.078 0.085 0.085 0.088 0.085 0.080 0.079 
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3.4. Experimental Section 
3.4.1. Synthesis of Co-crystals  
 
All reagents were purchased from Aldrich and used without further purification. 
Co-crystals 13-20 were prepared by dissolving stoichiometric amounts of starting 
materials in an appropriate solvent. Crystals were obtained by slow evaporation of the 
solvent at ambient temperature in an unmodified atmosphere and were isolated from 
solution before complete evaporation of the solvents.  
 (1-Naphthol)2●1,2-bis(4-pyridyl)ethane, 13: 1-Naphthol (0.035g, 0.24mmol) and 1,2-
bis(4-pyridyl)ethane (0.022g, 0.12mmol) was dissolved in ethanol. Slow evaporation of 
the solution yielded X-ray quality crystals, m. pt. 122-124°. 
(1-Naphthol)2●trans-1,2-bis(4-pyridyl)ethylene, 14: 1-Naphthol (0.035g, 0.24mmol) 
and trans-1,2-bis(4-pyridyl)ethylene (0.021g, 0.12 mmol) was dissolved in 2 mL of 
ethanol. The solution was left to evaporate slowly at room temperature, m. pt. 126-128°. 
4,4’-Biphenol●1,2-bis(4-pyridyl)ethane, 15: To 1,2-bis(4-pyridyl)ethane (0.035g, 
0.19mmol) was added 4,4-biphenol (0.035g, 0.19mmol).  To the solid mixture was added 
ethanol (2 mL) and the solution was heated until dissolved.  The solution was then 
allowed to slow evaporate in an unmodified atmosphere. After a few days, a precipitate 
was observed, collected and dried to give yellow blocks of 15, m. pt. 182-186°. 
4,4’-Biphenol● trans-1,2-bis(4-pyridyl)ethylene, 16: Slow evaporation of an ethanol 
solution containing trans-1,2-bis(4-pyridyl)ethylene (0.022g, 0.12mmol) and 4,4-
biphenol (0.023g, 0.12mmol) yielded yellow rods of co-crystal 16 after 3 day, m. pt. 235-
240°. 
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Hydroquinone●trans-1,2-bis(4-pyridyl)ethylene, 17: Trans-1,2-bis(4-pyridyl)ethylene 
(0.028g, 0.15mmol) and hydroquinone (0.017g, 0.15mmol) was dissolved in methanol (2 
mL).  After a few days, brown blocks of 17 were obtained, m. pt. 196-198°. 
Hydroquinone●tetramethylpyrazine (TMP), 18: Colorless crystals of 18 were obtained 
upon slow evaporation of an acetonitrile solution containing tetramethylpyrazine (0.022g, 
0.17mmol) and hydroquinone (0.019g, 0.17mmol), m. pt. 185-190°. 
(Resorcinol)2●(TMP)3, 19 : A 1:1 mixture of TMP (0.026 g, 0.19 mmol) and resorcinol 
(0.020 g, 0.19mmol) was dissolved in acetonitrile. Colorless crystals of 19 were obtained 
after two days upon slow evaporation at room temperature, m. pt. 134-137°. 
2,7-dihydroxynaphthalene●(TMP)2, 20 :  Pale green crystals of 20 were obtained upon 
crystallization of 1:1 mixture of TMP (0.010g, 0.07 mmol) and 2,7-dihydroxynaphthalene 
(0.012 g, 0.07mmol) from acetonitrile solution.  
3.4.1. Co-crystallization via grinding  
Stoichiometric amounts of the starting materials were ground with a mortar and pestle for 
ca.4 minutes. 
3.4.2. Co-crystallization via solvent-drop grinding 
Stoichiometric amounts of the starting materials were ground with a mortar and pestle for 
ca. 4 minutes with the addition of 10 μL of solvent per 50 mg of co-crystal formers. 
3.4.3. Co-crystallization via melting 
Stoichiometric amounts of the starting materials were heated until melt and the mixture 
was left to crystallize at ambient conditions. 
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All compounds were analyzed by infrared spectroscopy using a Nicolet Avatar 
320 FTIR instrument. The melting points were determined on a Mel-temp® apparatus 
and are presented in Table 3.4. 
 
Table 3.4  Melting points of co-crystals 13-20 and corresponding starting materials 
 
13, 14, 15 and 16 have melting points in between that of the starting materials 
while 17, 18 and 19 have melting point higher that that of both co-crystal formers.  
 
3.4.2. Single Crystal X-ray Crystallography 
Co-crystals 13-20 were examined under a microscope and suitable single crystals 
were selected for X-ray diffraction. All single crystal data was collected on a Bruker–
AXS SMART APEX CCD diffractometer with monochromatized Mo Kα radiation (λ = 
0.71073 Å) connected to a KRYO-FLEX low temperature device.  Data sets for co-
crystals 15, 17, 18, 19 and 20 were collected at 100K.Whereas data sets for 13 and 14 
was collected at 298K and 16 at 173K. Lattice parameters were determined from least 
square analysis, and reflection data were integrated using the program SAINT. Lorentz 
Co-crystal M. pt of 
co-crystal 
M. pt of 
component 1 
M. pt of 
component 2 
(1-naphthol)2●1,2-bis(4-pyridyl)ethane, 13 122-124 96 107-110 
1-napthol)2 ●trans-1,2-(bis(4-pyridyl)ethylene, 14 126-128 96 150-153 
4,4’-biphenol●1,2-bis(4-pyridyl)ethane, 15 182-186 278     107-110 
4,4’-biphenol●trans-1,2-bis(4-pyridyl)ethylene, 16 235-240 278 150-153 
Hydroquinone● trans-1,2-bis(4-pyridyl)ethylene, 17 196-198 170 150-153 
Hydroquinone ●tetramethylpyrazine (TMP ), 18 185-190 170 90 
(Resorcinol)2● (TMP)3,  19, 134-137 110 90 
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and polarization corrections were applied for diffracted reflections. In addition, the data 
was corrected for absorption using SADABS.60 Structures were solved by direct methods 
and refined by full matrix least squares based on F2 using SHELXTL.61 Non-hydrogen 
atoms were refined with anisotropic displacement parameters. All H-atoms bonded to 
carbon atoms, except methyl groups, were placed geometrically and refined with an 
isotropic displacement parameter fixed at 1.2 times Uq for the atoms to which they were 
attached. H-atoms of methyl groups as well as N or O bonded protons were located from 
Fourier difference map and refined isotropically based upon the corresponding N or O-
atom (U(H)=1.2Uq(N, O)). Crystallographic data for 13-20 are presented in Table 3.3 and 
selected hydrogen bond distances are listed in Table 3.5. 
 
Table 3.5 Geometrical parameters of intermolecular interactions for co-crystals 13-20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Co-crystal Interaction d (H···A) /Å d (D···A)/Å θ /º 
13 O-H⋅⋅⋅N 1.78 2.7206(15) 176.0 
14 O-H⋅⋅⋅N 1.80 2.7350(13) 176.4 
15 O-H⋅⋅⋅N 1.86 2.7459(15) 165.5 
16 O-H⋅⋅⋅N 1.81 2.7384(17) 165.0 
17 O-H⋅⋅⋅N 1.79 2.7053(18) 167.7 
18 O-H⋅⋅⋅N 1.79 2.760(2) 166.6 
O-H⋅⋅⋅N 2.07 2.816(3) 153.7 
O-H⋅⋅⋅N 1.86 2.787(3) 156.9 
O-H⋅⋅⋅N 1.87 2.777(3) 176.8 
19 
O-H⋅⋅⋅N 1.97 2.824(3) 156.6 
O-H⋅⋅⋅N 1.91 2.806(3) 178.5 20 
O-H⋅⋅⋅N 1.76 2.733(3) 160.0 
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4. Delineating the Hierarchy of Supramolecular Heterosynthons: Carboxylic 
acid-Aromatic Nitrogen versus Alcohol-Aromatic Nitrogen 
 
4.1. Introduction 
Alcohols and carboxylic acids are functional groups that occur commonly in 
nature and are well represented in the Cambridge Structural Database (CSD.1-2 Moreover 
65% of the top 100 prescription drugs3 and 35 % of those compounds possessing 
biological activity in the Merck Index4 contain at least one alcohol or carboxylic acid. 
However, despite the prevalence of alcohols and carboxylic acids there are only 71 
entries in the CSD that contains an alcohol, an acid and an aromatic nitrogen moiety in 
the same structure.  As a result reliable information on the relative tendency of formation 
of the supramolecular heterosynthons based upon existing crystallographic information 
could not be ascertained.  A systematic study of the competition between carboxylic acids 
and alcohols for aromatic nitrogen was therefore undertaken to determine whether a 
hierarchy exists with respect to the tendency of formation of the acid-aromatic nitrogen 
supramolecular heterosynthon III to that of the alcohol-aromatic nitrogen supramolecular 
heterosynthon VI.   
Each supramolecular heterosynthon in the study has proven to be robust when 
compared to the tendency of formation of the corresponding supramolecular 
homosynthon. Whereby, the carboxylic acid-aromatic nitrogen supramolecular 
heterosynthon III is exhibited in 95% crystal structure containing only an acid and an 
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aromatic nitrogen as compared to 6% of entries that exhibit the carboxylic acid 
homosynthon I or II. The alcohol-aromatic nitrogen supramolecular heterosynthon VI 
exists in 97% crystal structures compared to 17% entries that exhibit the alcohol 
homosynthon V for molecules comprised exclusively of alcohols and aromatic nitrogen.   
Competitive studies involving three moieties have been previously conducted by 
Aakeroy et al5-6 and Bis et al.7 Aakeröy et al. presented systematic studies of the 
competition between three distinct hydrogen bonding moieties: primary amide, pyridine, 
and carboxylic acid. The study involved co-crystals of iso-nicotinamide and a range of 
aromatic and aliphatic acids.   The generated co-crystals revealed consistent hydrogen 
bonding patterns comprised of two robust supramolecular synthons: carboxylic 
acid···pyridine heterosynthon III and self-complementary amide homosynthon VIII. The 
reproducibility of the hydrogen bonded motifs suggests a dominant tendency of 
formation of the acid···pyridine heterosynthon over the acid···amide heterosynthon, that is 
formed in acid and amide containing compounds in the absence of pyridines.8-14 The 
latter study conducted by Bis et al  involved alcohol, cyano and aromatic nitrogen 
moieties. The study involved determining the relative tendency of formation of alcohol-
aromatic nitrogen in the presence of competing cyano group. It was found that the 
alcohol-aromatic nitrogen supramolecular heterosynthon VI occurred reliably in the 
presence of the cyano moiety. 
In the research presented herein co-crystallization experiments were designed 
such that the co-crystal formers contained different permutations of carboxylic acid, 
aromatic nitrogen and alcohol as shown in Scheme 4.1. Co-crystal formers were selected 
based on the criteria that the molecules had the functional group(s) of interest void of 
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other competing hydrogen bond donors and/or acceptors. These functional group(s) were 
also sterically accessible and not involved in intramolecular interactions. The co-
crystallization experiments were designed such that one co-crystal former contained two 
of the three moieties (eg. alcohol and acid; or alcohol and aromatic nitrogen; or acid and 
aromatic nitrogen) and the second possessed the remaining moiety e.g aromatic nitrogen 
or carboxylic acid or alcohol. Accordingly individual pairs of co-crystal formers were 
combined as follows: (1) a molecule possessing both an acid and an aromatic nitrogen 
with molecule containing a hydroxyl group; (2) molecules comprising an alcohol and a 
carboxylic acid with those having aromatic nitrogen moieties and (3) molecules 
possessing an alcohol and an aromatic nitrogen with molecules containing a carboxylic 
acid. This approach is premised on the assumption that a co-crystal will be favored if the 
synthon between the co-crystal formers is stronger than the interactions within the pure 
component. Consequently a co-crystal is not expected to be formed if a dominant 
supramolecular synthon already exists within one of the pure components.  
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Research Strategy utilized in the competitive studies involving carboxylic acids, alcohols and 
aromatic nitrogens. 
 
Small organic molecules that contain alcohol, aromatic nitrogen, and carboxylic 
acid moieties used in this study are shown in Figure 4.1. Co-crystallizations of these 
chemicals afforded the following crystalline compounds: (3-hydroxybenzoic acid)2 
•.pyrazine 21; 4-hydroxybenzoic acid•1,2-bis(4-pyridinium)ethane 4-hydroxybenzoate 
22; : (4-hydroxybenzoic acid)2•tetramethylpyrazine (TMP) 23;  4-hydroxybenzoic acid• 
4-phenylpyridine 24; (4-hydroxybenzoic acid)2•pyrazine 25; (4-hydroxybenzoic acid)2 
•tetramethylpyrazine acetonitrile solvate 26; 3-hydroxybenzoic acid•(4-phenylpyridine)2 
27; 3-hydroxybenzoic acid•1,2-bis(4-pyridyl)ethane 28; 3-hydroxybenzoic acid •        
4,4’-bipyridine 29; 3-hydroxybenzoic acid•quinoxaline 30;  (3-hydroxybenzoic acid)2• 
(tetramethylpyrazine)3 31; 6-hydroxy-2-naphthoic acid•trans-1,2-bis(4-pyridyl)ethylene 
32; 4-hydroxybenzoic acid•trans-1,2-bis(4-pyridyl)ethylene 33;   3-hydroxybenzoic 
OH/COOH1: 4-hydroxybenzoic acid N1: 4-phenylpyridine 
N/COOH1: nicotinic acid 
 If Co-crystal forms  
 
OH··· Narom and or  COOH···Narom ? 
 
single crystal XRD 
 
If co-crystal forms: 
OH···Narom dominant 
N/OH1: 3-hydroxypyridine 
If co-crystal forms:  
COOH···Narom dominant 
COOH2: benzoic acid 
OH1: 1-naphthol  
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acid•trans-1,2-bis(4-pyridyl)ethylene 34; 3-hydroxypyridinium benzoate 35; 3-
hydroxypyridinium isophthalate 36. 
N
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COOH
COOH
COOH
HOOCHOOC COOH
HOOC COOH
OH
OH OH
OH OH OH OH
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N NN
N
N
N
N
N
N
N
N
                  
3-Hydroxypyridine        5-Hydroxyisoquinolone 3-Hydroxybenzoic acid
4-Hydroxybenzoic acid
Nicotinic acid
Isonicotinic acid
Benzoic acid                   Sorbic acid Glutaric acid
Isophthalic acid                        Trimesic acid
1-Naphthol                                       4,4'-Biphenol                                          Resorcinol                              Phloroglucinol
4-Phenylpyridine             Pyrazine                    4,4'-Bipyridine
1,2-Bis(4-pyridyl)ethane Trans-1,2-bis(4-pyridyl)ethylene
Tetramethylpyrazine
 
Figure 4.1 Molecules used in Co-crystallization Experiments 
 
4.2. Results and Discussion 
4.2.1. CSD Analysis  
 
A number of supramolecular synthons are possible when all three moieties 
(carboxylic acid, alcohol, aromatic nitrogen) exist within the same crystal structure. The 
possibilities include: a carboxylic acid homosynthon I and/or II, carboxylic 
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acid···aromatic nitrogen supramolecular heterosynthon III, charge assisted verson of III 
i.e. IV, alcohol supramolecular homosynthon V, alcohol···aromatic nitrogen 
supramolecular heterosynthon VI, alcohol···carbonyl supramolecular heterosynthon VII 
(Scheme 4.3). 
O
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H O
O
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O
O
H
O H NO H O
H
OO H
C
O
O
H N O
O
N
+
H
O
OH
I
II
C
VIV
C C
VII
    III                                                    IV
C
 
Figure 4.2 Possible supramolecular synthons that can form when OH, Narom and COOH are present 
in the same structure  
 
Of the 71 entries in the CSD that contain all three moieties: 2 entries exhibit 
carboxylic acid homosynthon I or II, 9 entries contain alcohol homosynthon V, 41 
structures exhibit carboxylic acid-aromatic nitrogen spramolecular synthon III and 20 
entries exhibit alcohol-aromatic nitrogen supramolecular synthon VI. Furthermore there 
exists 10 structures that exhibit both III and VI.  In the absence of competing hydrogen 
bond donors and/or acceptors the total number of entries containing  these three moieties 
decreases to 11.15 Within this subset, GEHROB, SOFHIE and XAPMAC exhibit acid-
aromatic nitrogen heterosynthon III; MOBZUY exhibits both III and V; and HAKVEV 
and GUTSAP form acid dimer I and alcohol-aromatic nitrogen heterosynthon VI. The 
remaining structures BEQWAV, IDUBUF, VEFVEI, VEFVIM and WEPDIF exhibits 
both III and VI. 
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 Herein, a series of compounds that help to evaluate the relative hierarchy of III 
and VI is presented and analyzed in the context of supramolecular synthons formed. 
 
Table 4.1 CSD statistics on supramolecular synthons that occur in structures containing only COOH, 
Narom, and OH 
Moieties present 
in  structure 
No. of 
structures 
Supramolecular 
synthon 
Structures 
with synthon 
D···A 
[Å] 
Mean (σ) 
[Å] 
COOH and Narom 109 
COOH···Narom 
O–H···O 
104 (95%) 
6 (5%) 
2.50-2.90 2.65(3) 
OH and N 208 O–H···N O-H ···O 
203 (97%) 
52 (26%) 
2.50-3.00 2.77(8) 
COOH, Narom and 
OH 11 
COOH···Narom (alc) 
O–H···N 
O–H···O  
 
9 
7 
2 
2.50-2.90 
2.50-3.00 
2.50-3.00 
2.65(3) 
2.77(8) 
2.65(3) 
         
        
4.2.2 Features of the O-H⋅⋅⋅Narom interaction 
 
 Structural information obtained from single crystal X-ray analysis can be used to 
determine the extent of proton transfer by analyzing proton location, bond distances of 
carboxylic or hydroxyl groups and C-N-C bond angles. Neutral carboxylic acids tend to 
have dissimilar C=O and C-O bond distances that average 1.21(2)Å and 1.31(2)Å 16 
respectively whereas deprotonated carboxylates have average C-O bond distances of 
1.25(2)Å.16 Likewise neutral phenolic alcohol groups have average C–O bond lengths of 
1.36(2)Å. whereas the calculated average for ionic C–O- bond length is 1.28(4)Å.16 The 
C-N-C angle within the aromatic nitrogen moiety is also known to be sensitive to 
protonation.16-20 and the cationic form typically exhibits higher values (ca. 122(2)°)  than 
that of the corresponding neutral molecules (ca. 117(2)°). The structural features of the 
bond distances and bond angles are used in the analysis of the presented series of 
compounds. 
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In the pharmaceutical industry, it is generally accepted that the reaction of an acid 
and a base is anticipated to form a salt if the ΔpKa [pKa (base)- pKa (acid)] is greater than 
2 or 3.21 This criterion is often used as a guide when choosing appropriate counterions for 
salt selection. With respect to neutral COOH⋅⋅⋅Narom and charge-assisted N+-H⋅⋅⋅-O 
hydrogen bonds, Johnson and Rumon22 suggests that a pKa difference less than 3.75 
affords neutral COOH⋅⋅⋅N interactions whereas ΔpKa greater than 3.75 results in proton 
transfer.  In a recent article however the predictive utility of ΔpKa in the solid state is 
scrutinized.23 The authors report that although pKa values tend to be reliable indicators of 
salt formation when ΔpKa >3, and likewise co-crystal formation is depicted when ΔpKa < 
0, there exists a salt-co-crystal continuum between ΔpKa range of 0 to 3.  Within this 
range the reaction between an acid and a base can result in salt or co-crystal formation or 
can contain shared protons, or mixed ionization.23 Within the presented series of 
compounds, 21, 25 and 30 all have ΔpKa < 0, and based upon structural information and 
IR spectroscopy contain neutral components and therefore form co-crystals (Table 4.2).  
23, 24, 27, 28, 29, 31, 32, 33 and 34 have ΔpKa values ranging from 0.86 to 2.05 and also 
form co-crystals. 35 and 36 however form salts having ΔpKa of 4.31 and 4.98 
respectively.  Furthermore based upon the ΔpKa argument the yet isolated compounds 
within the series in which 3-hydroxypyridine and 5-hydroxyisoquinoline are co-
crystallized with carboxylic acids are expected to yield salts (See Appendices).    
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Table 4.2  pKa  data for 21-36 
 
4.2.3. Crystal Structure Descriptions   
The asymmetric unit of 3-hydroxybenzoic acid• pyrazine 21, consists of a half 
molecule of pyrazine and a molecule of 3-hydroxybenzoic acid. The resulting 2:1 co-
crystal form trimeric adducts that are sustained by centrosymmetric COOH⋅⋅⋅Narom 
 
pKa (acid) pKa (base) 
Δ pKa [pKa 
(base)- pKa 
(acid)] 
21 4.08± 0.10 1.00± 0.30 -3.08 
22 4.57± 0.10 6.13± 0.10 1.56 
23 4.57± 0.10 2.88± 0.50 1.69 
24 4.57± 0.10 5.44±0.10 0.87 
25 4.57± 0.10 1.00± 0.30 -3.57 
26 4.57± 0.10 2.88± 0.50 1.56 
27 4.08± 0.10 5.44±0.10 1.36 
28 4.08± 0.10 6.13± 0.10 2.05 
29 4.08± 0.10 3.27± 0.26 0.81 
30 4.08± 0.10 0.59±0.28 -3.49 
31 4.08± 0.10 2.88± 0.50 1.20 
32 4.34± 0.30 5.50± 0.26 1.16 
33 4.57± 0.10 5.50± 0.26 0.93 
34 4.08± 0.10 5.50± 0.26 1.42 
35 8.51± 0.10 
4.86± 0.10 
4.2 
4.2 
4.31 
0.66 
36 8.51± 0.10 
4.86± 0.10 
3.53 
3.53 
4.98 
1.33 
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supramolecular heterosynthon III. Such three component adducts are interconnected via 
alcohol-carbonyl supramolecular heterosython VII (Fig. 4.4) As a consequence, the 
overall hydrogen-bonding pattern in 21 can therefore be described as a corrugated 2D 
network consisting of interconnected trimeric supramolecular adducts that align nearly 
perpendicularly with respect to each other. The dihedral angle between the planes parallel 
to the interacting trimeric adducts is 89.91°. 
In addition to spectroscopic evidence, the neutral nature of III is supported by 
structural data: the C=O and the C-O bond distances are 1.228 Å and 1.313Å respectively 
and the C-N-C angle within the aromatic nitrogen ring is 117.15°. The COOH⋅⋅⋅Narom 
hydrogen bond distance (D: 2.675(2) Å) is within the expected range for carboxylic acid-
aromatic nitrogen interactions and the dihedral angle formed between the carboxylic acid 
group and the pyrazine ring is 9.60°.  
 
Figure 4.3 Crystal packing in (3-hydroxybenzoic acid)2 •pyrazine, 21 showing corrugated sheet 
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 Figure 4.4 Interdigitation of independent 2D networks in the crystal structure of 21 
 
 
In the crystal structure of 4-hydroxybenzoic acid●1,2-bis(4-pyridinium)ethane● 
4-hydroxybenzoate 22, there is ambiguity with regards to the location of the proton on 
one of the two crystallographically independent molecules of  4-hydroxybenzoic acid. 
The carbon-oxygen bond distance on this particular molecule of 4-hydroxybenzoic acid is 
1.249 Å and 1. 283 Å and the associated C-N-C angle is 119.2°. The O⋅⋅⋅Narom hydrogen 
bond distance of 2.546(2) Å is significantly shorter than the average distance for the acid-
aromatic nitrogen interaction [2.65 (3) Å]. This suggest partial proton transfer in which 
the proton is shared between the Narom atom and the oxygen atom.24 The C=O and C–O 
bond distances in the second independent molecule of 4-hydroxybenzoic acid are 1.237 Å 
and 1.308 Å respectively and the associated C-N-C angle is 117.68°. The crystal structure 
of 22 is sustained by III and IV, alcohol-carbonyl supramolecular heterosynthon VII as 
well as alcohol-carboxylate supramolecular heterosynthon. The basic hydrogen bonding 
components are the 1:1:1 adduct as shown in Figure 4.5, such adducts are connected via 
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VII to generate corrugated sheets along the bc plane (Figure 4.6). The supramolecular 
sheets stack along the a axis as shown in Figure 4.7. 
 
Figure 4.5 Supramolecular synthon in 22 
 
 
Figure 4.6 Crystal packing of 22, showing corrugated sheet 
 
 
Figure 4.7 Crystal packing of adjacent 2D networks in 22 
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The crystal structure of (4-hydroxybenzoic acid)2•TMP 23,  is sustained by  the 
carboxylic acid-aromatic nitrogen heterosynthon III [O⋅⋅⋅N: 2.674(6) Å] and the alcohol-
carbonyl (acid) heterosynthon VII [O⋅⋅⋅O: 2.68(5) Å] hydrogen bond. As is observed in 
21 and 22, the nitrogen atoms in TMP are hydrogen bonded to carboxylic acids via 
heterosynthon III. The hydroxyl group and carbonyl on adjacent 4-hydroxybenzoic acid 
molecules interacts via heterosynthon VII resulting in an eight component rectangular 
grid as shown in Figure 4.8a. The molecules interact to form a hydrogen bonded 
herringbone network with an angle of 110° between the planes of 4-hydroxybenzoic acid 
and TMP; and 78° between adjacent 4-hydroxybenzoic acid. The hydrogen bond 
distances are consistent with that observed from the CSD analysis.  
  
 
 
 
 
 
(a) 
 
(b) 
 
Figure 4.8 a) Eight membered molecular rectangular grid formed by six 4-hydroxy benzoic acid and 
two TMP molecules. b) 2-dimensional herringbone network in the crystal structure of (4-
hydroxybenzoic acid)2•TMP co-crystal 23. 
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 Figure 4.9 Crystal packing of adjacent 2D networks in 23 
 
 
21, 22 and 23 are related in terms of their composition, hydrogen bond motifs and 
packing modes. The difference in the molecular structure of the components is not large 
enough to disrupt the 2D corrugated packing mode.  
4-hydroxybenzoic acid●4-phenylpyridine 24, contains one molecule of each 
component in the asymmetric unit. Analysis of the crystal structure reveals discrete 
tetrameric units which are sustained by alcohol-aromatic nitrogen heterosynthon VI     
(D: 2.703 (3) Å) as well as carboxylic acid homosynthon I (D: 2.630(3) Å) as shown in 
Figure 4.10. The neutral nature of VI is supported by structural data: the C-O (alcohol) 
bond distance is 1.352Å and the C–N–C angle within the aromatic nitrogen ring is 
116.99°. Stabilization of the structure is also afforded by face to face π-stacking between 
neighboring 4-phenylpyridine molecules as shown in Figure 4.12. The centroid to 
centroid distances between the aromatic rings are 3.684 Å and 3.862 Å. The torsion angle 
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between the benzyl ring and the pyridyl ring in the 4-phenylpyridine molecule is 41.06° 
and the dihedral angle formed by 4-phenylpyridine and 4-hydroxybenzoic acid is 66.51°.  
 
Figure 4.10 Crystal structure of 4-hydroxybenzoic acid•4-phenylpyridine 24  
 
 
Figure 4.11 Crystal packing of 24 showing translationally related carboxylic acid dimer and face to 
face π-stacked aromatic rings of  adjacent 4-phenylpyridine. 
 
 
The asymmetric unit of the (4-hydroxybenzoic acid)2 •pyrazine 25, consists of 
one molecule of 4-hydroxyybenzoic acid lying in a general position and a half molecule 
of pyrazine lying on a center of inversion. Similar to that seen in HAKVEV and in the 
previous structuure, 24 is sustained by alcohol-aromatic nitrogen supramolecular 
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heterosynthon VI as well as carboxylic acid dimer I. The 4-hydroxybenzoic acid 
molecules interact with each other via 2-point recognition acid dimer I and the hydroxyl 
portion of the molecule is hydrogen bonded to the pyrazine molecule through O-H⋅⋅⋅Narom 
hydrogen bonds to generate zig zag chains. Translationally related chains align parallel to 
the ab plane. The neutral nature of VI is supported by spectroscopic evidence as well as 
structural data: the C–O (alcohol) bond distance is 1.357 Å and the C–N–C angle within 
the aromatic nitrogen ring is 116.5(2)°.  The O–H···Narom hydrogen bond distance         
(D: 2.7739(17) Å) is within the expected range for hydroxyl···aromatic nitrogen 
interactions (Table 4.1) and the O-H⋅⋅⋅O hydrogen bond of the centrosymmetric acid 
dimer is 2.6282 (15) Å. 
 
Figure 4.12 Crystal structure of (4-hydroxybenzoic acid)2 •pyrazine, 25, showing centrosymmetric 
acid dimers and alcohol-aromatic nitrogen heterosynthons. 
 
Surprisingly the acetonitrile solvate of co-crystal 23, does not exhibit the 
carboxylic acid-aromatic nitrogen supramolecular heterosynthon III and the alcohol-acid 
supramolecular heterosynthon VII, as seen in the unsolvated form. Rather the crystal 
structure of (4-hydroxybenzoic acid)2 ●TMP acetonitrile solvate 26, reveals infinite 
chains sustained by carboxylic acid dimer I and alcohol-aromatic nitrogen 
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supramolecular heterosynthon VI. The O-H⋅⋅⋅Narom hydrogen bond distance (D: 
2.739Å(2) Å) is within the expected range for alcohol-aromatic nitrogen interactions 
(Table 4.1) and the hydrogen bond distance of the centrosymmetric carboxylic acid dimer 
I is 2.617 Å. The dihedral angle between the 4-hydroxybenzoic acid and the TMP ring is 
75.92 Å. The acetonitrile molecule is within the structure is not involved in any strong 
hydrogen bond interaction. 
 
Figure 4.13 Crystal structure of (4-hydroxybenzoic acid)2 ●TMP acetonitrile solvate, 26 
 
The asymmetric unit of 3-hydroxybenzoic acid●(4-phenylpyridine)2 27, contains 
one molecule of 3-hydroxybenzoic acid and two molecules of 4-phenylpyridine. The 
resulting 1:2 co-crystal is sustained by both supramolecular heterosynthon III               
(D: 2.596(2) Å) and VI (D: 2.685(2) Å) to generate discrete trimeric adducts. The 
observation of a C=O bond distance of 1.220Å and the C-O (acid) of 1.315Å coupled 
with the C-N-C bond angle within the aromatic nitrogen molecule of 117.14° suggests a 
neutral acid-aromatic nitrogen hydrogen bond.  The C-O (alcohol) bond distance of 
1.349Å and the C-N-C angle of 116.75° support the neutral nature of the alcohol-
aromatic nitrogen hydrogen bond. Adjacent trimeric adducts within the structure are 
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involved in π-π interactions wherein both face to face π-stacking between adjacent 4-
phenylpyridine molecules and edge to face interaction between the 3-hydroxybenzoic 
acid and the pyridyl molecule is observed. The centroid to centroid distances are 3.726Å 
and 3.703Å respectively. The dihedral angle between the pyridyl and benzyl ring within 
the 4-phenylpyridine molecules is 27.88°. 
 
Figure 4.14 Crystal structure of 3-hydroxybenzoic acid.(4-phenylpyridine)2, 27 
 
 
Figure 4.15 Crystal packing in 3-hydroxybenzoic acid•.(4-phenylpyridine)2,  27. 
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The 1:1 co-crystal of 3-hydroxybenzoic acid•1,2-bis(4-pyridyl)ethane 28, is 
sustained by both carboxylic acid-aromatic nitrogen supramolecular heterosynthon III 
(D: 2.590(4)Å) and alcohol–aromatic nitrogen supramolecular heterosynthon V            
(D: 2.663(4)Å) which alternate to generate infinite chains.  The neutral nature of III and 
VI is supported by structural evidence: C=O and C-O bond distance of the carboxylic 
acid group is 1.219 Å and 1.325 Å; the C–N–C angle within the aromatic nitrogen ring is 
117.07 and 117.28° respectively and the C-O (alcohol) bond distance was found to be 
1.357 Å. Face to face π-stacking between pyridyl moieties in adjacent chains, the 
centroid to centroid distance of which are 3.793 Å and 3.721 Å is also observed in this 
structure.   
 
 
Figure 4.16 Crystal structure of 3-hydroxybenzoic acid•1,2-bis(4-pyridyl)ethane, 28. 
 
The asymmetric unit of 3-hydroxybenzoic acid●4,4’-bipyridine 29, consists of 
one molecule of 3-hydroxybenzoic acid and one molecule of 4,4’-bipyridine. The 1:1 co-
crystal is sustained by both supramolecular heterosynthons III (D: 2.6881(19) Å) and VI 
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(D: 2.7898(19) Å) to generate infinite chains.  As is seen in 28, supramolecular 
heterosynthons III and VI alternate along the length of the chains.  
The neutral nature of the interactions is supported by structural evidence: the C=O 
and C-O bond distance of the carboxylic acid group is 1.216 Å and 1.325 Å respectively; 
the C–N–C angles within the aromatic nitrogen rings are 116.86 and 117.00° respectively 
and the C-O (alcohol) bond distance was found to be 1.356 Å. The dihedral angle 
between the planes of the pyridyl rings in 4,4’-bipyridine is 28.51°. 
 
Figure 4.17 Crystal Packing in 3-hydroxybenzoic acid●4,4’-bipyridine, 29 
 
The crystal structure of 3-hydroxybenzoic acid●quinoxaline 30, reveals infinite 
chains that are sustained by two supramolecular heterosynthons: carboxylic acid-aromatic 
nitrogen III and alcohol-aromatic nitrogen VI. As seen in 28 and 29 these interactions 
alternate along the length of the chain. There are two independent molecules of each 
component in the asymmetric unit.  
The C=O and C-O bond distances of the carboxylic acid groups are 1.217 Å and 
1.329 Å; 1.214 Å and 1.335 Å respectively and the C-O (alcohol) bond distances was 
found to be 1.362 Å and 1.365 Å. π⋅⋅⋅π stacking is also observed within this structure. 
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Figure 4.18 Crystal Packing in 3-hydroxybenzoic acid quinoxaline  30. 
 
 
The crystal structure of (3-hydroxybenzoic acid)2 ●(TMP)3  31, exhibits both 
acid-aromatic nitrogen III and alcohol-aromatic nitrogen VI supramolecular 
heterosynthons. Surprisingly 31, does not generate extended chains as is anticipated but 
rather forms discrete five component adducts as shown in Figure 4.19. Consequently 
there are two nitrogen acceptor sites that are not involved in any strong hydrogen bond 
interactions. These sites are however involved in weak C-H⋅⋅⋅N interactions. 
 
Figure 4.19  Discrete 5-component adduct in the crystal structure of (3-hydroxybenzoic acid)2 
●(TMP)3, 31 
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As seen in the previous co-crystal, 6-hydroxynaphthoic acid.•trans-1,2-(4-
pyridyl)ethylene 32, is sustained by both supramolecular heterosynthons III                    
(D: 2.691(2) Å) and  VI ( D: 2.756Å). However unlike 29, 30 and 31, heterosynthons III 
and VI, alternate in a different manner. Trans-1,2-bis (4-pyridyl)ethylene molecule is 
hydrogen bonded  at both nitrogen acceptor sites to carboxylic acids, then the subsequent 
trans-1,2-bis (4-pyridyl)ethylene molecule in the chain is hydrogen bonded to alcohols. 
This sequence is repeated along the chain. The observed hydrogen bonds are symmetric 
about the trans-1,2-bis(4-pyridyl)ethylene molecule.  
The C=O and C-O (acid) bond distances are 1.216Å and 1.323Å respectively.  
The C-N-C angle within the pyridyl rings are 117.34° and 116.4° and the C–O (alc) 
distance is 1.356Å thus supporting the neutral nature of the O–H···Narom hydrogen bonds.  
 
 
 
 
 
 
Figure 4.20 Crystal structure of (6-hydroxynaphthoic acid • trans-1,2-(bis(4-pyridyl)ethylene 32 
 135
 
 
Figure 4.21 Crystal packing in 6-hydroxynaphthoic acid•trans-1,2-bis-(4-pyridyl)ethylene, 32  
 
 
The asymmetric unit of 4-hydroxybenzoic acid●trans-1,2-bis(4-yridyl)ethylene 
33, consists of a molecule of 4-hydroxybenzoic acid and two half molecules of trans-1,2-
bis(4-pyridyl)ethylene. The resulting 1:1 co-crystal is sustained by both supramolecular 
heterosynthon III and VI. The components assemble in the alternate manner seen in 32 to 
generate zig-zag infinite chains. Molecules of trans-1,2-bis(4-pyridyl)ethylene are 
hydrogen bonded at both Narom sites to carboxylic acids,  the subsequent trans-1,2-bis(4-
pyridyl)ethylene molecule in the chain is hydrogen bonded to alcohols and the sequence 
repeated along the chain. 
The C=O and C-O (acid) bond distances are 1.236Å and 1.316Å respectively.  
The C-N-C angle within the pyridyl rings are 116.34° and 117.43° and the C–O (alc) 
distance of 1.354Å supports the neutral nature of the O–H···Narom hydrogen bonds. π⋅⋅⋅π 
stacking is also observed, which affords further stabilization of this structure. 
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Figure 4.22 Crystal packing in 4-hydroxybenzoic acid●trans-1,2-(4-pyridylethylene, 33 showing 
translationally related zig-zag chains. 
 
 
The crystal structure of 3-hydroxybenzoic acid●trans-1,2-bis(4-
pyridyl)ethylene 34, exhibits both supramolecular heterosynthon III and VI. The 1:1 co-
crystal generates chains that hydrogen bond in a manner as seen in co-crystals 32 and 33. 
The C=O and C-O bond distances of the carboxylic group are 1.222Å and 1.328 Å 
respectively whereas the C–O bond distance for the hydroxyl group is 1.361Å.  The C-N-
C angle within the pyridyl rings are 117.03° and 116.65° thus supporting the neutral 
nature of III and VI. 
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Figure 4.23 Crystal packing in 3-hydroxybenzoic acid●trans-1,2 (4-pyridyl)ethylene, 34 
 
The crystal structure of 3-hydroxypyridine is sustained by O-H⋅⋅⋅Narom 
supramolecular heterosynthon VI to generate extended chains.25 The 3-hydroxy proton is 
capable of adopting two conformations: antiplanar or synplanar.26 (The antiplanar 
conformation is seen in the pure form. 
N
O
H
N
O
H
antiplanar synplanar  
There are twelve compounds in the CSD in which 3-hydroxypyridine is combined 
with a carboxylic acid.27 In the reported structures proton transfer result between the acid 
and the base to form organic salts. The 3-hydroxy group of the 3-hydroxypyridinium in 
IDUNIE, IDUNOK, IDUNUQ, JOJJUN, PAHZAA, VITXUR and YETLUE adopts 
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antiplanar conformation while the synplanar conformation is exhibited by IDUNEA, 
KUFBOC, OCAKAF and RACBED.  
Attempts to co-crystallize 3-hydroxypyridine and benzoic acid results in proton 
transfer between the acid and the aromatic nitrogen, thereby generating the charge-
assisted hydrogen bonded salt of 3-hydroxypyridinium benzoate 35. The asymmetric 
unit consists of one ion of each component. The crystal structure exhibits 2-component 
adducts that is sustained by charge assisted pyridinium-carboxylate supramolecular 
heterosynthon IV (Figure 4.25a). These adducts are connected orthogonally via alcohol-
carboxylate interaction to generate infinite chains. The 3-hydroxyl group of the 3-
hydroxypyridinium in 35 adopts the syn-conformation in this structure. 
The bond distances for the carboxylate group are 1.286Å and 1.260 Å; and the 
corresponding C-N-C angle is 121.41°. The dihedral angle between the plane of the 
carboxylate group and that of the pyridinium ring is 8.05°. 
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(a) 
 
(b) 
Figure 4.24  (a) Charge-assisted pyridinium-carboxylate supramolecular heterosynthon IV in 35 (b) 
Crystal packing in 3-hydroxypyridinium benzoate, 35 
 
 
The asymmetric unit of 3-hydroxypyridinium isophthalate 36, consists of one 
3-hydroxypyridinium ion and one isophthalate ion. Similar to that seen in OCAKAF,28 
proton transfer is only observed at one site on the isophthalic acid molecule. 36 is 
sustained by the charge-assisted pyridinium-carboxylate heterosynthon IV, one point 
recognition charge assisted carboxylic acid (OH)-carboxylate interactions and alcohol-
carboxylate heterosynthons. As a result of these three significant hydrogen bond 
interactions supramolecular sheets are generated as seen in Figure 4.25. The 3-hydroxyl 
group of the 3-hydroxypyridinium in 36 adopts the anti-conformation in this structure. 
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Figure 4.25 Crystal packing in 3-hydroxypyridinium isophthalate 36 
  
The crystal structures of isonicotinic acid and nicotinic acid are sustained by 
supramolecular heterosynthon III and generate extended chains.29-30 An analysis of the 
CSD yielded no examples of co-crystals containing isonicotinic acid.  However there are 
five examples of organic salts involving the isonicotinate ion in the CSD31 (Refcodes: 
AWUDEB, HAFZIY, PAZHOO, SATLUV and YERXUP). The counter-ions in the 
aforementioned compounds are derived from molecules that are either more basic or 
acidic than isonicotinic acid. A similar observation is made in the case of nicotinic acid. 
Nicotinic acid forms several organic salts 32 and a co-crystal with 4-aminobenzoic acid. 33  
Solution and solvent drop grinding34 attempts to co-crystallize isonicotinic acid 
and nicotinic acid with a series of alcohols resulted in a mixture of starting materials as 
evidenced by XRPD.  The negative results perhaps is suggesting that the carboxylic acid-
aromatic nitrogen supramolecular heterosynthon in the pure nicotinic acids is more 
dominant than the alcohol-aromatic nitrogen heterosynthon that would exist if a                   
co-crystal were to form. 
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Rationalization of Crystal Structures 
3-Hydroxybenzoic acid exists as two polymorphic modifications. Form I exhibits 
the commonly occurring carboxylic acid dimer I as well as the chain motif of the alcohol 
homosynthon V, to generate corrugated 2D sheets (Figure 4.26a and b). In the second 
polymorph the acid dimer motif is abandoned in favor of a new motif which consists of 
1-point recognition alcohol homosynthon V and alcohol-carbonyl (acid) interaction VII, 
to generate a molecular tape (Fig 4.26b).35 This structural pair illustrates that the same 
compound can exist in both centrosymmetric and non-centrosymmetric structures and can 
perhaps help to explain why different supramolecular motifs are adopted in the structures 
containing 3-hydroxybenzoic acid.  
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 (a) 
 
 
  
(b) 
Figure 4.26 Crystal structures of the polymorphic forms of 3-hydroxybenzoic acid: (a) Form I and( 
b) Form II 
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Figure 4.27 Chain motifs generated in 21-34 rationalized via synthons occurring in the pure 
carboxylic acid. 
 
4-Hydroxybenzoic acid is also known to be polymorphic, 36 there is however only 
one reported form in the CSD.37 The crystal structure of Form II of 4-hydroxybenzoic 
acid was determined by exploiting synchrotron X-ray microcrystal diffraction techniques. 
38-39 The crystal structure of 4-hydroxybenzoic acid Form I exhibit carboxylic acid dimer 
I and alcohol homosynthon V. Similar to that seen in Form I of 3-hydroxybenzoic acid, 
the hydroxyl groups engage in forming homosynthon V, constructing chains that extend 
through the crystal. The reported crystal structure of Form II of 4-hydroxybenzoic acid 
also contains centrosymmetric carboxylic acid dimer I, however there is no interacton 
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between adjacent hydroxyl groups as seen in Form I. Rather the hydroxyl group in Form 
II is involved in the formation of alcohol-carbonyl supramolecular heterosynthon VIII, 
which serves to link adjacent dimers consequently generating a supramolecular sheet. 
  It should also be noted that the co-crystals of 3-hydroxybenzoic acid with meta 
and para nicotinamide also exhibits different supramolecular synthons and crystal 
packing.5,40 LUNMEM the co-crystal of 3-hydroxybenzoic acid with isonicotinamide 
exhibits III and VIII and the hydroxyl group interacts with the carbonyl of the amide 
moiety.  XAQQIQ exhibits alcohol-aromatic nitrogen VI and acid-amide 2-pt recognition 
supramolecular synthon X. These structures may perhaps also be rationalized based upon 
the crystal packing in the pure components. 
In summary, sixteen crystal structures were isolated in the study involving the 
competition between alcohol and carboxylic acid for aromatic nitrogen. 21-23 were 
sustained by carboxylic acid-aromatic nitrogen supramolecular heterosynthon III as well 
as alcohol-carbonyl(acid) synthon VII, 24-26 exhibited alcohol-aromatic nitrogen 
supramolecular heterosynthon VI and carboxylic acid dimer I. 27-34 exhibit both acid- 
aromatic nitrogen III and alcohol-aromatic nitrogen VI supramolecular heterosynthons 
whereas 35 and 36 exhibited the charge-assisted pyridinium-carboxylate supramolecular 
heterosynthon IV. Of the eight structure that exhibit both III and VI: 27, 28, 29 and 30 
exhibit chain type 1 whereas 31, 32, 33, and 34 exhibit chain type 2 (Figure 4.27) The 
chain types observed and consequently the crystal structures may be rationalized in terms 
of the synthons present in the pure carboxylic acids. 
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Table 4.3 Summary of supramolecular synthons present in 21-36 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.4 Methods of Preparation 
 
Co-crystallization experiments were attempted utilizing grinding, solvent-drop 
grinding and melting techniques. Solvent drop grinding and melt experiments of 3-
hydroxypyridinium benzoate 35, 3-hydroxypyridinium isophthalate 36, 3-
hydroxypyridine •sorbic acid, (3-hydroxypyridine)2•glutaric acid and                                       
(3-hydroxypyridine)3•trimesic acid yielded new phases as characterized by XRPD and 
DSC. Moreover grinding, solvent drop grind and melt afforded the same phase as 
obtained from solution in the case of 35 and 36.   
Solution co-crystallization attempts to obtain crystals of: 5-hydroxyisoquinoline • 
benzoic acid, 5-hydroxyisoquinoline •sorbic acid, (5-hydroxyisoquinoline)2•glutaric acid 
 I 
O
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H N
IV 
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O
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H
VI 
O H N
C  
VII 
O H
C
O C
 
21  √   √ 
22  √ √  √ 
23  √   √ 
24 √   √  
25 √   √  
26 √   √  
27  √  √  
28  √  √  
29  √  √  
30  √  √  
31  √  √  
32  √  √  
33  √  √  
34  √  √  
35   √   
36   √  * 
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and  (5-hydroxyisoquinoline)2 • isophthalic acid, were unsuccessful. However as indicated 
by XRPD and DSC new phases were obtained upon solvent drop grinding and 
subsequent melting. 
Solution and solvent drop grinding attempts to obtain co-crystals of nicotinic acid 
and isonicotinic acid with carboxylic acids were unsuccessful; the IR spectroscopy and 
PXRD spectra of the solid obtained revealed a mixture of starting materials. 
21-34 were also investigated in the context of their accessibility via grinding and 
solvent drop grinding methodologies. Initial 4-minute grinds and solvent drop grinds 
resulted in a mixture of starting materials in most cases with the exception of 23, 27 and 
30.  Co-crystals 21, 23, 28, 29, 30 and 31 were reproduced by solvent drop grinding. 29, 
30 and 31 was also obtained from the melt. Attempts to reproduce 21, 22, 23 and 25 from 
the melt resulted in the formation of new phases that differ from the isolated compounds 
and their respective starting materials. 
No proper theory on melting exists to date. However in general para isomers 
almost invariably have higher melting points than meta isomers the observation is a true 
solid state effect.41 The series of compounds presented all have melting points that occur 
in between that of the initial components and no general correlations with respect to 
melting points could be made between the co-crystals of 3-hydroxybenzoic acid versus 
those of 4-hydroxybenzoic acid within this series of compounds (Table 4.4).  
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Table 4.4  Melting point comparison for 21-36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3. Conclusions 
In summary, the study presented herein involves a series of model co-crystals that 
adds to the limited information within the CSD related to the frequency of occurrence of 
supramolecular heterosynthon III in the presence of the competing alcohol functional 
group. That both III and VI occurs when an acid, an alcohol and an aromatic nitrogen are 
co-crystallized suggests that the COO–H···Narom III hydrogen bond is comparable to the 
 O–H···Narom hydrogen bond VI. However the crystal structures obtained may be 
rationalized based upon the synthons existing in the pure components. Single crystals of 
 M. pt of compounds M. pt of component 1 M. pt of component 2 
21 178 199-203 52-55 
22 194-198 214-217 107-110 
23 150-154 214-217 84-86 
24 90-96 214-217 69-73 
25 160-164 214-217 52-55 
26 178-182 214-217 84-86 
27 115-118 199-203 69-73 
28 180-184 199-203 107-110 
29 176-179 199-203 111-114 
30 100-104 199-203 29-32 
31 139-142 199-203 84-86 
32 184-187 237-241 150-153 
33 184-186 214-217 150-153 
34 180-184 199-203 150-153 
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3-hydroxypyridinium benzoate, 35 and 3-hydroxypyridinium isophthalate 36, exhibit 
proton transfer between the carboxylic acid and the aromatic nitrogen and was sustained 
by charge assisted interaction IV.  The charge assisted heterosynthon IV results perhaps 
as a consequence of the pKa difference existing between the components. The negative 
results obtained within the series of compounds involving isonicotinic acid and nicotinic 
acid with alcohols, coupled with the positive results obtained within the series involving 
OH/Narom with COOH suggests that the formation of the carboxylic acid-aromatic 
nitrogen supramolecular heterosynthon III appears to dominate over that of the alcohol-
aromatic nitrogen supramolecular heterosynthon VI.   
This conclusion is particularly relevant to co-crystals of APIs, since they are 
relatively complex molecules that often contain either OH or COOH moieties. 
Modification of the physicochemical properties that is associated with the co-crystal 
formation may lead to interesting opportunities toward new formulations for the 
improved performance of an API.  
 
4.4. Experimental Section 
4.4.1. Syntheses 
Reagents were purchased from Aldrich and used without further purification. 
Single crystals of compounds 21-36 were obtained via slow evaporation of stoichiometric 
amounts of starting materials in appropriate solvents and were isolated from solution 
before complete evaporation of the solvents in all cases except 26.  
 (3-Hydroxybenzoic acid)2 • pyrazine, 21: To 3-hydroxybenzoic acid (0.015 g, 
0.13 mmol) was added pyrazine (0.020 g, 0.13 mmol). The solid mixture was dissolved 
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in chloroform (2ml) and the solution was left to evaporate slowly at room temperature. 
After 4 days colorless crystals of 21, mp = 178 °C, were observed.  
4-Hydroxybenzoic acid•1,2-bis(4-pyridinium)ethane 4-hydroxybenzoate, 22: To 
4-hydroxybenzoic acid (0.026 g, 0.22 mmol) was added 1,2-bis(4-pyridyl)ethane (0.020 
g, 0.11 mmol) and the mixture dissolved in methanol (2 ml). The solution was allowed to 
evaporate at ambient temperature and after 8 days colorless crystals of 22, mp = 194-198 
°C, were obtained.  
 (4-Hydroxybenzoic acid)2•tetramethylpyrazine, 23: To 4-hydroxybenzoic acid 
(0.026 g, 0.22 mmol) was added tetramethylpyrazine (0.020 g, 0.11 mmol) and the solid  
mixture dissolved in methanol (2ml). The solution was allowed to evaporate to dryness to 
obtain crystals of 23, mp = 150-154 °C.  
4-Hydroxybenzoic acid•4-phenylpyridine, 24: A solution of 4-hydroxybenzoic 
acid (0.015 g, 0.13 mmol) and 4-phenylpyridine (0.020 g, 0.13 mmol) in 2 mL of  
acetone/ethyl acetate (1:1) solvent mixture was left to evaporate at ambient conditions.    
After 3 days, colorless crystals of 24, mp = 90-94°C were obtained.   
 (4-Hydroxybenzoic acid)2 • pyrazine, 25: To 4-hydroxybenzoic acid (0.041g, 
0.30 mmol) was added pyrazine (0.012g, 0.15mmol). The solid mixture was dissolved in 
acetonitrile (2 ml) and allowed to evaporate undisturbed at room temperature. After 4 
days colorless crystals of 25, mp = 160-164°C, were observed.  
 (4-Hydroxybenzoic acid)2•tetramethylpyrazine acetonitrile solvate, 26: To 4-
hydroxybenzoic acid (0.026 g, 0.22 mmol) was added tetramethylpyrazine (0.020 g, 0.11 
mmol) and the mixture was dissolved in 2 mL of acetonitrile. After 8 days colorless 
crystals of 26, mp = 178-182°C, were obtained.  
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3-Hydroxybenzoic acid•(4-phenylpyridine)2, 27: To 3-hydroxybenzoic acid 
(0.015 g, 0.13 mmol) was added 4-phenylpyridine (0.020 g, 0.13 mmol) and 2 mL of 1:1 
of acetone and ethyl acetate solvent mixture. Slow evaporation of the solution afforded 
colorless crystals of 27, mp = 115-118 °C after 3 days.   
3-Hydroxybenzoic acid•1,2-bis(4-pyridyl)ethane, 28: To 3-hydroxybenzoic acid 
(0.026 g, 0.22 mmol) was added 1,2-bis-(4-pyridyl)ethane (0.020 g, 0.11 mmol) and the 
mixture was dissolved in 2 mL of acetone. After 3 days colorless crystals of 28,            
mp =180-184 °C, were observed.  
3-Hydroxybenzoic acid• 4,4’-bipyridine, 29: To 3-hydroxybenzoic acid (0.031 g, 
0.26mmol) was added 4,4’-bipyridine (0.020 g, 0.13 mmol). The solid mixture was 
dissolved in 2 mL of methanol and the solution was left undisturbed to evaporate under  
ambient conditions. After 12 days yellow needles of 29, mp = 176-179° C, were formed.  
3-Hydroxybenzoic acid•quinoxaline, 30: To 3-hydroxybenzoic acid (0.032g, 
0.23mmol) was added quinoxaline (0.030g, 0.23 mmol) and 2 mL of ethanol. After 2 
days colorless crystals of mp = 100-104°C, were obtained.  
 (3-Hydroxybenzoic acid)2• (tetramethylpyrazine)3, 31: To 3-hydroxybenzoic 
acid (0.020g, 0.14mmol) was added tetramethylpyrazine (0.20 g, 0.14 mmol). The solid 
mixture was dissolved in 2 mL of acetonitrile and the solution was left undisturbed to 
evaporate under ambient conditions. After 12 days yellow needles of 31, mp = 139-142 
°C, were formed.  
6-Hydroxy-2-naphthoic acid•trans-1,2-bis(4-pyridyl)ethylene, 32: To 6-hydroxy-
2-naphthoic acid (0.025g, 0.13 mmol) was added 1,2-bis(4-pyridyl)ethylene (0.024g, 
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0.013 mmol). The solid mixture was dissolved in 2 mL of methanol. After 2 days 
colorless crystals of 32, mp = 184-187°C were observed 
4-Hydroxybenzoic acid•trans-1,2-bis(4-pyridyl)ethylene, 33: To 4- 
hydroxybenzoic acid (0.012g , 0.12 mmol) was added trans-1,2-bis(4-pyridyl)ethylene 
(0.023g, 0.13 mmol). The solid mixture was dissolved in 2 mL of methanol. After 2 days 
colorless crystals of 33, mp = 184-186°C were observed.  
3-Hydroxybenzoic acid•trans-1,2-bis(4-pyridyl)ethylene, 34: To 3- 
hydroxybenzoic acid (0.013 g, 0.10mmol) was added trans-1,2-bis(4-pyridyl)ethylene 
(0.018g, 0.10 mmol). The solid mixture was dissolved in 2 mL of ethanol. After 2 days 
colorless crystals of 34, mp = 180-184°C were observed. 
3-Hydroxypyridinium benzoate, 35: To 3-hydroxypyridine (0.020g, 0.21 mmol) 
was added benzoic acid (0.026g, 0.21 mmol) and 2 mL of a 1:1  methanol and ethanol  
mixture. The solution was left to evaporate at ambient temperature and after 8 days 
colorless crystals of 35 were obtained.  
3-Hydroxypyridinium isophthalate, 36: To 3-hydroxypyridine (0.025g, 0.26 
mmol) was added isophthalic acid (0.022g, 0.13 mmol) and the mixture was dissolved in 
0.5 mL of dimethylsulfoxide. After 6 days colorless crystals of 36 were observed. 
Co-crystallization via grinding: Stoichiometric amounts of the starting materials were 
ground with a mortar and pestle for ca.4 minutes. 
Co-crystallization via solvent-drop grinding: Stoichiometric amounts of the starting 
materials were ground with a mortar and pestle for ca. 4 minutes with the addition of 10 
μL of solvent per 50 mg of co-crystal formers. 
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Co-crystallization via melting: Stoichiometric amounts of the starting materials were 
heated until melt and the mixture was left to crystallize at ambient conditions. 
All co-crystals were analyzed by infrared spectroscopy using a Nicolet Avatar 
320 FTIR instrument. The purity of bulk samples was confirmed by X-ray powder 
diffraction. Co-crystals were analyzed on a Rigaku Miniflex Diffractometer using Cu Kα 
(λ = 1.54056 Ǻ), 30 kV, 15 mA. The data was collected over an angular range of 3° to  
40° 2θ in continuous scan mode using a step size of 0.02° 2θ and a scan speed of 
2.0º/min. Compounds and were analyzed on Bruker AXS D8 discover X-ray 
diffractometer equipped with GADDSTM (General Area Diffraction Detection System), a 
Bruker AXS HI-STAR area detector at a distance of 15.05 cm as per system calibration, a 
copper source, automated x-y-z stage, and 0.5 mm collimator. Data were collected over  
2.1-37.0 2θ range at a step size of 0.02 2θ.  Melting points of 21-34 were determined on a  
MEL-TEMP® apparatus, and the comparison of the melting points of 21-34 and the 
corresponding constituents is summarized in Table 4.4. 
4.4.2. Single-crystal X-ray diffraction. 
 
The single crystal x-ray diffraction data were collected on a Bruker–AXS 
SMART APEX CCD diffractometer with monochromatized Mo Kα radiation (λ = 
0.71073 Å) connected to a KRYO-FLEX low temperature device. Data for 21-36 were 
collected at 100 K. Lattice parameters were determined from least square analysis, and 
reflection data were integrated using the program SAINT. Lorentz and polarization 
corrections were applied for diffracted reflections. In addition, the data was corrected for 
absorption using SADABS.42 Structures were solved by direct methods and refined by 
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full matrix least squares based on F2 using SHELXTL.43 Non-hydrogen atoms were 
refined with anisotropic displacement parameters. All H-atoms bonded to carbon atoms, 
except methyl groups, were placed geometrically and refined with an isotropic 
displacement parameter fixed at 1.2 times Uq of the atoms to which they were attached. N 
or O bonded protons, as well as H-atoms of methyl groups, were located from Fourier 
difference map and refined isotropically based upon the corresponding N, O or C atom 
(U(H)=1.2Uq(N, O)).  
Crystallographic data for 21-36 are presented in Table 4.7. and 4.8. and selected 
hydrogen bond distances are listed in Table 4.5 and 4.6. 
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Table 4.5  Hydrogen Bond Distances and Parameters for 21-36 
 Hydrogen Bond d (H···A) /Å D (D···A)/Å Θ /º 
O-H⋅⋅⋅⋅N 1.74 2.675(2) 169.0 
21 
O-H⋅⋅⋅ O 1.82 2.7540(19) 176.5 
O-H⋅⋅⋅⋅N 1.54 2.590(2) 173.5 
O-H⋅⋅⋅⋅O 1.81 2.6455(19) 167.8 
O-H⋅⋅⋅⋅N 1.72 2.546(2) 177.6 
O-H⋅⋅⋅⋅O 1.90 2.7411(19) 171.6 
22 
N-H⋅⋅⋅⋅O 1.59 2.546(2) 177.8 
O-H⋅⋅⋅⋅N 1.60 2.674(6) 168.2 
23 
O-H⋅⋅⋅⋅O 1.65 2.680(5) 154.2 
O-H⋅⋅⋅⋅O 1.59 2.630(3) 170.4 
24 
O-H⋅⋅⋅⋅N 1.79 2.703(3) 167.0 
O-H⋅⋅⋅⋅N 1.87 2.7739(17) 169.9 
25 
O-H⋅⋅⋅⋅O 1.76 2.6282(15) 169.6 
O-H⋅⋅⋅⋅N 1.92 2.739(2) 163.7 
26 
O-H⋅⋅⋅⋅O 1.78 2.617(2) 175.4 
O-H⋅⋅⋅⋅N 1.64 2.596(2) 166.6 
27 
O-H⋅⋅⋅⋅N 1.74 2.685(2) 169.3 
O-H⋅⋅⋅⋅N 1.48 2.590(4) 172.4 
28 
O-H⋅⋅⋅⋅N 1.66 2.663(4) 167.8 
O-H⋅⋅⋅⋅N 1.76 2.6881(19) 168.0 
29 
O-H⋅⋅⋅⋅N 1.81 2.7898(19) 175.0 
O-H⋅⋅⋅⋅N 1.85 2.720(2) 170.0 
O-H⋅⋅⋅⋅N 1.89 2.782(2) 170.6 
O-H⋅⋅⋅⋅N 1.77 2.699(2) 169.5 
30 
O-H⋅⋅⋅⋅N 1.86 2.762(2) 163.1 
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Table 4.6  Hydrogen Bond Distances and Parameters for 21-36 (cont.) 
 
 Hydrogen Bond d (H···A) /Å D (D···A)/Å Θ /º 
O-H⋅⋅⋅⋅N 1.77 2.673(2) 177.2 
31 
O-H⋅⋅⋅⋅N 1.81 2.755(2) 162.2 
O-H⋅⋅⋅⋅N 1.70 2.756(3) 176.7 32 
O-H⋅⋅⋅⋅N 1.71 2.640(2) 172.5 
O-H⋅⋅⋅⋅N 1.54 2.617(4) 168.8 
33 
O-H⋅⋅⋅⋅N 1.79 2.756(4) 163.8 
O-H⋅⋅⋅⋅N 1.64 2.6482(16) 168.6 
34 
O-H⋅⋅⋅⋅N 1.80 2.7358(16) 174.8 
N-H⋅⋅⋅⋅O 1.43 2.559(10) 176.1 
O-H⋅⋅⋅⋅O 1.74 2.569(9) 169.0 35 
N-H⋅⋅⋅⋅O 2.41 3.065(10) 115.1 
O-H⋅⋅⋅⋅O 1.76 2.662(3) 165.8 
O-H⋅⋅⋅⋅O 1.80 2.662(2) 174.0 36 
N-H⋅⋅⋅⋅O 1.74 2.647(2) 172.4 
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Table 4.7 Crystallographic data and structure refinement parameters for compounds 21-36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  21 22 23 24 25 26 27 28 
formula C9H8NO3 C26H24N2O6 C11H12NO3 C18H15NO3 C9H8NO3 C13H15N2O3 C29H24N2O3 C19H18N2O3 
MW 178.16 460.47 206.22 293.31 178.16 247.27 448.50 322.35 
crystal system Monoclinic Monoclinic Monoclinic Monoclinic Triclinic Monoclinic Monoclinic Triclinic 
space group P21/n P21/c P21/c C2/c P-1 P21/c P21/n P-1 
a (Å) 5..2006(11) 7..3666(3) 10.379(3) 26.780(4) 5..9424(9) 11.693(4) 9..2032(16) 7..9810(15) 
b (Å) 14.568(3) 23.716(3) 10.307(3) 7.4445(13) 6..8175(10) 8.694(3) 20.819(4) 8..9312(17) 
c (Å) 10.994(3) 12.5523(15) 10.134(3) 19.471(3) 10.6376(16) 12.722(4) 11.827(2) 11.209(2) 
α (deg) 90 90 90 90 102.963(3) 90 90 97.585(3) 
β (deg) 100.450(5) 103.033(2) 110.257(6) 131.101(2) 97.383(2) 94.920(7) 93.487(3) 90.745(4) 
γ (deg) 90 90 90 90 100.057(3) 90 90 90.665(4) 
V /Å3 819.1(3) 2136.5(4) 1017.0(5) 2925.1(8) 407.16(11) 1288.5(7) 2261.9(7) 791.9(3) 
Dc/g cm-3 1.235 1.432 1.347 1.332 1.453 1.275 1.317 1.352 
Z 4 4 4 8 2 4 4 2 
2θ range 4.70- 50.04 3.44-52.74 4.18 -45.04 4.04-50.14 4.00-52.74 3.50–50.14 3.92 – 52.74 4.60-56.48 
Nref./Npara. 1417/118 4356/307 1260/136 2477/199 1635/118 2198/163 4628/307 3126/217 
T /K 100(2) 100(2) 100(2) 100(2) 100(2) 100(2) 100(2) 100(2) 
R1 [I>2sigma(I)] 0.0418 0.0472 0.0823 0.0495 0.0456 0.0461 0.0534 0.0810 
wR2 0.1007 0.1082 0.1771 0.1222 0.1213 0.1110 0.1085 0.2240 
GOF 1.066 1.032 1.063 1.020 1.068 1.037 1.047 1.186 
Abs coef. 0.110 0.103 0.099 0.091 0.111 0.092 0.086 0.093 
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Table 4.8 Crystallographic data and structure refinement parameters for compounds 21-36 (cont) 
 
 
 
  29 30 31 32 33 34 35 36 
formula C17H14N2O3 C15H12N2O3 C19H24N3O3 C23H18N2O3 C19H16N2O3 C19H16N2O3 C12H11NO3 C13H11NO5 
MW 294.30 268.27 342.41 370.39 320.34 320.34 217.22 261.23 
crystal system Triclinic Triclinic Monoclinic Triclinic Triclinic Triclinic Monoclinic Monoclinic 
space group P-1 P-1 P21/c P-1 P-1 P-1 Pc P21/n 
a (Å) 8.1965(12) 7.2850(9) 9.4609(14) 5.9682(8) 6.1928(19) 7.9011(13) 5.007(15) 10.218(5) 
b (Å) 8.8828(12) 12.1470(15) 17.807(3) 8.7387(12) 6.957(2) 10.3101(16) 9.93(3) 11.001(6) 
c (Å) 10.3613(15) 14.4319(18) 11.0809(17) 17.938(3) 18.499(5) 10.8629(17) 10.30(3) 10.412(5) 
α (deg) 72.213(3) 87.837(2) 90 78.473(2) 95.046(6) 114.081(2) 90 90 
β (deg) 72.213(2) 85.937(2) 92.184(3) 82.090(3) 94.058(7) 103.883(3) 100.07(9) 99.983(9) 
γ (deg) 86.773(3) 80.916(2) 90 88.921(3) 103.928(6) 93.041(3) 90 90 
V /Å3 685.25(17) 1257.4(3) 1865.5(5) 907.9(2) 767.1(4) 772.8(2) 504(3) 1152.6(10) 
Dc/g cm-3 1.426 1.417 1.219 1.355 1.387 1.377 1.430 1.505 
Z 2 4 4 2 2 2 2 4 
2θ range 4.82- 49.42 2.84-52.74 4.88 -52.74 2.34-56.36 2.22-50.18 4.40–49.42 5.74 – 50.16 5.48-52.74 
Nref./Npara. 2311/199 5006/361 3804/229 3632/253 2508/217 2591/217 607/145 2340/172 
T /K 100(2) 100(2) 100(2) 100(2) 100(2) 100(2) 100(2) 100(2) 
R1 [I>2sigma(I)] 0.0442 0.0498 0.0576 0.0564 0.0682 0.0416 0.0437 0.0566 
wR2 0.1109 0.1194 0.1303 0.1282 0.1366 0.1112 0.0802 0.1359 
GOF 1.092 1.058 1.033 1.040 0.999 1.088 0.804 1.038 
Abs coef. 0.100 0.101 0.084 0.091 0.095 0.095 0.104 0.117 
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5. Pharmaceutical Co-Crystals of Stavudine 
 
5.1. Introduction 
N
N
H
O O
O OH
  
Stavudine 
Stavudine [1-(2,3-dideoxy-β-D-glycero-pent-2-enofuranosyl)thymine] is a 
synthetic thymidine nucleoside  analogue with inhibitory activity against HIV/AIDS. A 
review of the literature reveals three polymorphic modifications of stavudine.1-4 This 
includes a monoclinic (Form I), a triclinic (Form II) and an orthorhombic form (Form 
III).  The crystal structures of all three forms are sustained by amide dimers and alcohol-
alcohol interactions as shown in Figure 5. 1 and therefore exhibits persistent 
supramolecular synthons. These conformational polymorphs5 differ in the three 
parameters that are typically used to describe the conformation of the nucleoside 
molecule: the geometry of the glycosylic link, the furanose ring puckering and the 
orientation of the 5’ hydroxyl group.6 Structural analysis of all three polymorphs have 
been reported, several solvates and a hydrate have also been described in the literature.7-12 
However we are unaware of any attempts to generate co-crystals of stavudine. In this 
chapter we exploit the remarkable diversity afforded by the imide moiety and utilize the 
robust three point recognition supramolecular heterosynthon IX, the alcohol−pyridine 
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heterosynthon VI and the acid-amide heterosynthon X to generate pharmaceutical co-
crystals of stavudine. 
 
Figure 5.1 Crystal structure of stavudine (Form I)  
 
OH
COOH COOH
OH
N
N
N
NH2
NH2 NH2 N
N
NH2
NH2 NH2
N
NH2
melamine 2, 4, 6-triaminopyrimidine
       (2,4,6-TAP)
2-aminopyridine
4-hydroxybenzoic acid
salicylic acid
 
Schematic of co-crystal formers 
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5.2. Results and Discussion  
N
O
H
O
O
H
X
N
O
H
O
N
N
N
H
H
H
H
IX
O H N
VI
 
The imide moiety exhibits remarkable diversity in terms of its supramolecular 
chemistry, it is self complementary and capable of forming 3-point, 2-point and 1-point 
recognition13 supramolecular synthons. Self association typically occurs via two point 
recognition coupling such as that seen in pure stavudine. Of the many supramolecular 
heterosynthons that the imide moiety can engage in synthon IX is one of the more robust. 
In fact a database analysis suggests that heterosynthon IX has the highest probability of 
occurrence observed in bimolecular hydrogen bonded ring motifs in organic crystals.14 
The three-point recognition heterosynthon IX has some analogy with nucleotide 
recognition in DNA,15 and has been utilized to generate numerous co-crystals in a 
predictable fashion.16-21 An analysis of the Cambridge Structural Database (CSD)22-25 
retrieved 74 structures containing both  the imide moiety and the 2-aminopyridine 
functional groups. Of these, 46 (62%) structures exhibit the three point supramolecular 
heterosynthon IX. The hydrogen bond distances of supramolecular synthons VI, XI and 
X are presented in Table 5.1. 
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Table 5.1 Geometrical Features of Supramolecular Synthons 
Supramolecular 
Synthon  
Supramolecular 
synthon 
D···A 
[Å] 
Mean (σ) 
[Å] 
IX 
N–H···Oa 
N–H···N 
2.50-3.25 
2.50-3.25 
2 50-3 15
2.77(8) 
2.78(8 
VI O–H···N 2.50-3.00 2.78(8) 
 
The alcohol-aromatic nitrogen supramolecular synthon VI is a robust, reliable 
heterosynthon in crystal engineering, occurring in 682/1453 (47%) entries as compared to 
274/1453 (19%) crystal structures that exhibit the alcohol homosynthon V. As shown 
previously in Chapter 3 heterosynthon VI has been utilized in generating co-crystals in a 
predictable manner.26-42 
5.2.1. Crystal Structure Description 
 
Co-crystallization of a 3:1 mole ratio of stavudine and melamine resulted in the 
formation of (stavudine)3•melamine 37. The asymmetric unit of 37 consists of two 
melamine and six stavudine molecules. The presence of multiple molecules in the 
asymmetric unit has often been associated with identifiable packing problems or 
conflict.43-44 Melamine has three 2-aminopyridine recognition sites and stavudine has one 
complementary functional group. Therefore it is anticipated that each melamine and three 
stavudine molecules complementarily hydrogen bond via robust three-point 
supramolecular heterosynthon IX [two R22 (8)] in a trigonal fashion (Figure 5.2a). As is 
observed such trigonal four component adducts are hydrogen bonded via stavudine 
O−H···O interactions to generate hexagonal sheet parallel to (001) plane (Figure 5.2b). 
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The hexagonal sheets are connected through O−H···O hydrogen bonds between the 
layers. The supramolecular sheets stack along the c axis. All the hydrogen bond lengths 
and angles are in the normal range (Table 5.1). 
 
 
 
(a) 
 
(b) 
Figure 5.2  (a) Triangular four component supramolecular adduct in co-crystal 37 (b) Hexagonal 
packing of 3:1 co-crystal of stavudine and melamine, 37  
 
 Co-crystallization of a 2:1 mole ratio of stavudine and 2, 4, 6-triaminopyrimidine 
(2, 4, 6-TAP) 38, results in the formation of a 1:1:1 crystal structure in which water is 
incorporated in the crystal lattice. 38 contains one molecule each of stavudine, 2, 4, 6-
TAP and water present in the asymmetric unit and crystallizes in the orthorhombic P212121 
space group. The three point recognition heterosynthon IX is observed, however instead 
of the anticipated 2:1 stoichiometry, we observe stavudine O-H⋅⋅⋅N hydrogen bond 
(2.7688(19)Å, 167°) to the 2,4,6-triaminopyrimidine at the second potential hydrogen 
bonding site. As a result right-handed helices are formed through 3-point recognition 
heterosynthon IX (N-H⋅⋅⋅O 2.947(2) Å, 166.8°; N-H⋅⋅⋅N: 2.945(2), 174.2°, N-H⋅⋅⋅O  
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2.896, 167.4°) and O-H⋅⋅⋅N heterosynthon VI. Subsequently there are two amino groups 
NH2 that are not involved in strong H-bond interactions. The hydroxyl groups of adjacent 
primary helix are involved in cooperative hydrogen bonding to generate channels parallel 
to the a axis as shown in Fig 5.3. The O-H⋅⋅⋅O hydrogen bond distance within the primary 
helix is 2.894(2) Å whereas the O-H⋅⋅⋅O hydrogen bond that bridge adjacent helix is 
3.095(3) Å.  
  
a)  
 
b) 
 
Figure 5.3 Crystal Packing of 38 showing right handed helices formed through supramolecular 
heterosynthons VI and IX. 
 
Stavudine also forms a co-crystal with 2 -aminopyridine, 39. The co-crystal 
contains one molecule of stavudine and a 2-aminopyridine molecule in the asymmetric 
unit. The presence of the hydroxyl group on the conformationally flexible stavudine 
molecule precludes the formation of the two point 2-aminopyridine-amide synthon. The 
crystal structure reveals that the alcohol group bridges the aminopyridine-amide synthon 
as shown in Fig 5.4. Consequently stavudine molecules interact with 2-aminopyridine 
molecules through terminal O−H···N hydrogen bonds. (2.6715(16) Å, 172.6°) as  
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illustrated in Figure 5.5. Stavudine molecules interact with each other via N−H···O 
(2.7549(16) Å, 165.4º) hydrogen bonds to generate infinite chain along the b-axis. The 
structure is further stabilized by the bifurcation of the amino groups by adjacent carbonyl 
moieties on two different stavudine molecules: one within the chain (N-H⋅⋅⋅O 3.274(17) 
Å and the other in the adjacent chain (N-H⋅⋅⋅⋅O 3.2056(18) Å) as a consequence a two 
dimensional corrugated supramolecular sheet is generated. 
 
Figure 5.4 Illustrates the supramolecular synthons present in co-crystal 39, the insertion of the 
hydroxyl group precludes the formation of the two-point recognition amide-2-aminopyridine 
supramolecular heterosynthon. Please note that portions of the stavudine molecule have been deleted 
for clarity. 
 
 
Figure 5.5 Hydrogen bonded infinite chains of stavudine molecules form terminal O−H···N hydrogen 
bonds with pyridyl moiety of 2-aminopyridine in co-crystal 39. 
 
A recent study involving the association of nucleobases with carboxylic acids led 
to the complexation of adenine and cytosine with mono and di-carboxylic acids. The  
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authors observed no complexation with guanine, thymine or uracil.45 Herein we report the 
co-crystallization of stavudine, a thymine derivative with monocarboxylic acids.  A 
review of the CSD reveals no examples of two point recognition between an imide and a 
carboxylic acid. However based upon our experience exploiting the acid-amide 
supramolecular heterosynthon46-47 to generate pharmaceutical co-crystals, stavudine was 
co-crystallized with a series of monocarboxylic acids. As anticipated stavudine forms a 
1:1 co-crystal with 4-hydroxybenzoic acid 40. The asymmetric unit of 40 contains one 
molecule of stavudine and one molecule of 4-hydroxybenzoic acid. Co-crystal 40 is 
sustained by the 2-point recognition carboxylic acid-amide supramolecular heterosynthon 
X (N-H⋅⋅⋅O 2.814(2) Å, 171.1° and O-H⋅⋅⋅O 2.649(2); 173°). The alcohols of stavudine 
and 4-hydroxybenzoic acid forms right handed cooperative helices through O-H⋅⋅⋅O 
hydrogen bonds48 of 2.831(2) Å and 2.676(2) Å (see Fig 5.6).  
 
Figure 5.6 Carboxylic acid-amide supramolecular heterosynthon in stavudine•4-hydroxybenzoic acid 
40 
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Figure 5.7 Crystal packing of stavudine●4-hydroxybenzoic acid, 40 
 
Stavudine also forms a 1:1 co-crystal with salicylic acid 41, however the expected 
carboxylic acid-amide heterosynthon X is not observed. Instead stavudine molecules 
form one point recognition O-H⋅⋅⋅O hydrogen bonds with salicylic acid molecules. A 
further analysis of the crystal structure reveals that stavudine molecules are connected to 
each other in a linear fashion through N-H⋅⋅⋅O hydrogen bonds (2.917(2) Å, 164.5°) as 
shown in Fig 5.8. Adjacent chains of stavudine molecules are linked together by salicylic 
acid molecules through O-H⋅⋅⋅O hydrogen bonds. 
 
Figure 5.8 Illustrates supramolecular synthons present in stavudine• salicylic acid 41 
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37, 39, 40 and 41 were also investigated in the context of their susceptibility to 
solid state preparation i.e grinding and solvent drop grinding. With regards to 
stoichiometry and crystal form, 39, 40 and 41 were reproducibly obtained using the 
aforementioned methods. Grinding and solvent drop grinding however yielded a mixture 
of starting materials in the case of 37. The syntheses of 38, 39, 40 and 41 were also 
accomplished via slurry conversion of stoichiometric amounts of the starting materials in 
water. However as was the case with the grinding and solvent drop grinding, a mixture of 
starting materials result in the case of 37. 
It has been demonstrated that solvent drop grinding can invoke polymorphic 
transformations. A search for crystal forms of 37, 39, 40 and 41 via solvent drop grinding 
of co-crystal formers involving seven solvents of different polarity: cyclohexane, 
chloroform, dimethyl sulfoxide, ethyl acetate, methanol, toluene and water, was also 
conducted. As determined by FT-IR spectroscopy and X-ray powder diffraction only one 
form that same as was obtained from solution was isolated for co-crystals 37, 38, 40 and 
41.  
5.3. Conclusions 
 
Five novel forms of stavudine were presented, four co-crystals and a co-crystal 
hydrate.These results further illustrate the diversity that may be obtained using a 
supramolecular approach with respect to API forms. 37-41 exhibit a range of 
supramolecular synthons including:  the one point recognition alcohol- aromatic nitrogen 
heterosynthon VI, two point recognition acid-amide X as well as three-point recognition 
synthon IX. The syntheses of 39, 40 and 41 were also accomplished via solvent-drop  
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grinding49 of the starting material and 38, 39, 40 and 41 was also obtained via slurry 
conversion. These results suggests that solid state methodologies such as grinding and 
solvent drop grinding; and slurry conversions are viable means for synthesis of 
pharmaceutical co-crystals. 
5.4. Experimental Section 
5.4.1 Synthesis 
Stavudine was obtained from Transform Pharmaceutical Inc and used as received. 
Reagents used to synthesize co-crystals 37-41 were obtained from commercial sources 
with purity ca. 98% and used as received. Crystals suitable for single crystal X-ray 
diffractometry were obtained by slow evaporation of the solvent under ambient 
conditions. 
(Stavudine)3•melamine, 37: Stavudine (0.132g, 0.58 mmol) and melamine (0.034g, 0.27 
mmol) were dissolved in 2 mL of ethanol/water mixture upon warming. Slow 
evaporation of the solvent at room temperature yielded colorless crystals of 37 within 4 
days, m. pt: 186-190º. 
Stavudine•2,4,6-triaminopyrimidine hydrate, 38: Stavudine (0.078g, 0.35 mmol) and 
2,4,6-triaminopyrimidine (0.022 g, 0.17 mmol) was dissolved in 2ml of 1:1 ethanol / 
water solvent mixture. Slow evaporation of the solvent yielded colorless crystals of 38.  
Stavudine •2-aminopyridine, 39:  Stavudine (0.040g, 0.18mmol) and 2-aminopyridine 
(0.017g, 0.18mmol) were dissolved in 2 mL of 1:1 ethanol/water solvent mixture upon 
warming. Slow evaporation of the solvent afforded colorless crystals of 39, m. pt = 120-
122°C. 
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Stavudine •4-hydroxybenzoic acid, 40: Stavudine (0.035 g, 0.16 mmol) and 4-
hydroxybenzoic acid (0.22 g, 0.16 mmol) was dissolved in ethanol (2 mL). The solution 
was allowed to evaporate slowly under ambient conditions to yield colorless crystals of 
40.  
Stavudine• salicylic acid, 41: Stavudine (0.035g, 0.16mmol) and salicylic acid (0.022 g, 
0.16 mmol) was dissolved in ethanol (2 mL). The solution was left to evaporate slowly at 
room temperature to yield colorless crystals of 41.  
For grinding experiments: stoichiometric amounts of starting materials were 
processed for 4 minutes in a mortar and pestle. The resulting powders were analyzed by 
IR spectroscopy and X-ray powder diffraction. Solvent-drop grinding and slurry 
conversion afforded the same phase as that obtained from solution in all cases except 37.  
X-ray powder diffraction (XRPD) analyses were conducted on a Rigaku Miniflex 
diffractometer using Cu Kα radiation (λ=1.540562, 30 kV and 15Ma). The powder data 
was collected over an angular range of 3° to 40° 2θ in a continuous mode using a step 
size of 0.02° 2θ and a scan speed of  2°/min. Differential Scanning Calorimetry (DSC) 
analyses were performed on a TA instruments 2920 differential scanning calorimeter. 
The sample cell was equilibrated at 25° and heated under a nitrogen purge at a rate of 
10°C/min. Indium metal was used as the calibration standard. Infrared Spectroscopy was 
conducted using a Nicolet Avatar 320 FTIR. 
5.4.2. Single-crystal X-ray diffraction 
The single crystal x-ray diffraction data were collected on a Bruker–AXS 
SMART APEX CCD diffractometer with monochromatized Mo Kα radiation (λ = 
0.71073 Å) connected to a KRYO-FLEX low temperature device.                                   
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Data for 37-41 were collected at 100 K. Lattice parameters were determined from least 
square analysis, and reflection data were integrated using the program SAINT. Lorentz 
and polarization corrections were applied for diffracted reflections. In addition, the data 
was corrected for absorption using SADABS.50 Structures were solved by direct methods 
and refined by full matrix least squares based on F2 using SHELXTL.51 Non-hydrogen 
atoms were refined with anisotropic displacement parameters. All H-atoms bonded to 
carbon atoms, except methyl groups, were placed geometrically and refined with an 
isotropic displacement parameter fixed at 1.2 times Uq of the atoms to which they were 
attached. N or O bonded protons, as well as H-atoms of methyl groups, were located from 
Fourier difference map and refined isotropically based upon the corresponding N, O or C 
atom (U(H)=1.2Uq(N, O)).  
Selected hydrogen bond distances are listed in Table 5.2 and 5.3 and crystallographic 
data for 37-41 are presented in Table 5.4. 
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Table 5.2 Geometric Parameters of Intermolecular Interactions for (stavudine)3●melamine, 37 
Interaction d (H...A)/ Å D(D...A) /Å θ /° 
O-H⋅⋅⋅⋅Oa 2.05 2.900(5) 137.3 
N-H⋅⋅⋅⋅Na 1.95 2.905(5) 153.8 
O-H⋅⋅⋅⋅Ob 2.02 2.820(4) 165.8 
N-H⋅⋅⋅⋅Nb 2.03 2.904(5) 166.5 
O-H⋅⋅⋅⋅Oc 2.00 2.830(5) 157.0 
N-H⋅⋅⋅⋅Nc 1.91 2.893(5) 150.5 
O-H⋅⋅⋅⋅Od 2.09 2.838(4) 134.6 
N-H⋅⋅⋅⋅Nd 1.99 2.893(5) 168.7 
 O-H⋅⋅⋅⋅Oe 1.95 2.734(4) 149.1 
N- H⋅⋅⋅⋅Ne  1.91 2.912(5) 166.2 
O- H⋅⋅⋅⋅Of  2.11 2.807(5) 132.3 
N- H⋅⋅⋅⋅Nf  2.02 2.884(5) 155.2 
N-H⋅⋅⋅⋅Oa  1.97 2.913(5) 169.4 
N-H⋅⋅⋅⋅Ob 2.24 2.875(5) 131.6 
N-H⋅⋅⋅⋅Oc 2.12 2.923(4) 174.5 
N-H⋅⋅⋅⋅Od 2.06 2.937(5) 163.9 
N-H⋅⋅⋅⋅Oe 2.10 2.933(4) 161.7 
N-H⋅⋅⋅⋅Of 2.06 2.972(5) 153.3 
N-H⋅⋅⋅⋅Og 2.07 2.915(4) 173.1 
N-H⋅⋅⋅⋅Oh 2.03 2.936(5) 143.5 
N-H⋅⋅⋅⋅Oi 2.06 2.917(5) 176.2 
N-H⋅⋅⋅⋅Oj 1.93 2.898(5) 168.1 
N-H⋅⋅⋅⋅Ok 2.11 2.889(5) 168.3 
N-H⋅⋅⋅⋅Ol 1.98 2.960(5) 171.7 
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Table 5.3 Geometric Parameters of Intermolecular Interactions for 38-41 
 Interaction d(Å) D (Å) θ 
(deg) 
O-H⋅⋅⋅⋅N 1.91 2.7688(19) 167.0 
N-H⋅⋅⋅⋅N 2.10 2.945(2) 174.2 
O-H⋅⋅⋅⋅Oa 1.96 2.894(2) 165.6 
O-H⋅⋅⋅⋅Ob 2.25 3.095(3) 135.8 
N-H⋅⋅⋅⋅Oa 2.09 2.896(2) 167.4 
N-H⋅⋅⋅⋅Ob 2.55 3.194(2) 130.8 
N-H⋅⋅⋅⋅Oc 2.52 3.356(3) 162.1 
N-H⋅⋅⋅⋅Od 2.07 2.947(2) 166.8 
38 
N-H⋅⋅⋅⋅Oe 2.29 3.130(2) 156.3 
O-H⋅⋅⋅⋅N 1.85 2.6715(16) 172.6 
N-H⋅⋅⋅⋅Oa 1.89 2.7549(16) 165.4 
N-H⋅⋅⋅⋅Ob 2.39 3.2056(18) 151.2 
39 
N-H⋅⋅⋅⋅Oc 2.49 3.2745(17) 153.2 
O-H⋅⋅⋅⋅Oa 1.65 2.676(2) 159.6 
O-H⋅⋅⋅⋅Ob 1.59 2.649(2) 173.0 
N-H⋅⋅⋅⋅O 1.92 2.814(2) 171.1 
40 
O-H⋅⋅⋅⋅Oc 1.96 2.831(2) 174.4 
O-H⋅⋅⋅⋅Oa 2.08 2.859(2) 157.3 
N-H⋅⋅⋅⋅O 1.92 2.917(2) 164.5 
O-H⋅⋅⋅⋅Ob 1.78 2.590(2) 163.3 
41 
O-H⋅⋅⋅⋅Oc 1.76 2.582(3) 146.2 
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Table 5.4 Crystallographic Data and structure refinement parameters for compounds 37-41 
 
 
 
                     
 
 
 37 38 39 40 41 
Chemical 
formula 
(C10H12N2O4)3 
• 
C3H6N6 
C10H12N2 O4 
• 
C4H7N5 • H2 O 
C10H12N2O4  
• 
C5H6N2 
C10H12N2O4 
• 
C7H6O3 
C10H12N2O4  
• 
C7H6O3 
stoichiometry 3:1 1:1:1 1:1 1:1 1:1 
Formula .wt. 798.79 367.38 318.33 362.33 362.33 
crystal system monoclinic orthorhombic orthorhombic Monoclinic orthorhombic
space group C2 P212121 P212121 P21 P212121 
a (Å) 28.720(4) 7.2074(10) 7.1242(6) 10.3369(18) 7.114(5) 
b (Å) 16.622(3) 11.9659(17) 13.7996(12) 7.3130(13) 14.460(9) 
c (Å) 15.900(2) 19.940(3) 15.0163(14) 11.065(2) 16.414(10) 
α( °) 90 90 90 90 90 
β(°) 102.909(3) 90 90 94.918(3) 90 
γ(°) 90 90 90 90 90 
volume (Å3) 7398.3(19) 1719.7(4) 1476.3(2) 833.3(3) 1688.6(18) 
Dcalc ( g cm-3) 1.434 1.419 1.432 1.444 1.425 
Z 8 4 4 2 4 
θ range 1.31-26.37 1.98-26.37 2.71-26.37 1.98-26.37 1.88-26.37 
Nref./Npara. 12303/1063 3502/244 3021/214 3192/242 3440/242 
T (K) 100 298 100 298 298 
R1 0.0643 0.0379 0.0343 0.0389 0.0390 
wR2 0.1384 0.0983 0.0851 0.0931 0.0826 
GOF 1.038 1.056 1.110 0.999 0.918 
abs coef. 0.111 0.110 0.106 0.114 0.112 
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6. Summary and Future Directions 
 
6.1.  Summary  
When two or more molecules are co-crystallized the following possibilities exist: 
a physical mixture of the initial components, the formation of polymorphs of either 
component, solvate or hydrate of either component, a co-crystal, a salt (given appropriate 
pKa difference between the components) or a combination of one or more of the 
aforementioned. The exterior functional groups present on the target molecule, their 
ability to form robust supramolecular synthons, the appropriate co-crystal former, 
conformational flexibility of the molecule, mismatched solubility, crystallization 
conditions and methods of preparation are some factors that will ultimately dictate which 
of these possibilities occur.  
The research presented herein focus upon the identification of reliable robust 
supramolecular synthons which has become a pre-requisite in the design process of any 
crystal engineering experiment. This is of importance since it affords a certain level of 
predictability with respect to anticipated pattern formation in the crystal structure and 
facilitates the appropriate selection of co-crystal formers. Specifically, the research 
presented focus on the identification of reliable hydrogen bonded supramolecular 
heterosythons in the generation of co-crystals and ultimately pharmaceutical co-crystals. 
Systematic studies combining CSD analysis and model co-crystal experiments have 
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afforded a better understanding of supramolecular synthons in the solid state. In 
particular, the knowledge acquired has led to the delineation of the reliability of two 
supramolecular heterosynthons namely the carboxylic acid···aromatic nitrogen (III) and 
alcohol··· aromatic nitrogen (VI) heterosynthons. Specifically structural analysis of 
twelve compounds indicate that the carboxylic acid···aromatic nitrogen supramolecular 
heterosynthon (III) forms reliably as compared to the carboxylic acid homosynthon I or 
II.   
Compounds 1-12 formed in predictable stoichiometries in all cases but one, co-
crystal 3, to generate hydrogen bonded discrete, 2D and 3D structures. The co-crystal of 
(trimesic acid)2• (1,2-bis(4-pyridyl)ethane)3 12  exhibits concomitant polymorphism. 
Form II of which displays anticipated (6, 3) networks. Form I however display (10, 3)-a 
networks and exhibits the highest level of interpenetration yet observed in an organic or 
metal-organic network.  The existence of a (10, 3)-a network with such large dimensions 
and the inherent modularity of co-crystals illustrates how co-crystals of TMA might be 
worthy of further investigation in the context of open framework networks.  
Co-crystallization of alcohols with aromatic nitrogen containing molecules 
yielded single crystal data for seven co-crystals all of which are sustained by the alcohol-
aromatic nitrogen supramolecular heterosynthon VI. Based on the statistical analysis and 
experimental results the formation of the alcohol-aromatic nitrogen supramolecular 
heterosynthon appears more dominant to that of the alcohol homosynthon V.  
The strategy for the experiments to evaluate the competition existing between 
carboxylic acids and alcohols for aromatic nitrogen involved two co-crystal formers 
containing different permutation of the functional groups of interest. In an individual 
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experiment two co-crystal formers were combined, one co-crystal former possessed two 
of the three moieties (e.g. COOH/Narom) and the second co-crystal former possessed the 
remaining moiety (e.g. OH). According to this strategy, the individual pairs of co-crystal 
formers are combined as follows: COOH/Narom with OH, COOH/OH with Narom, and 
OH/Narom with COOH. Such an approach to delineate the hierarchies existing between 
two supramolecular heterosynthons is premised on idea that a co-crystal can result only if 
the favored supramolecular heterosynthon is formed between the co-crystal formers. 
Conversely, a co-crystal is not expected to be formed if a dominant supramolecular 
heterosynthon already exists in one of the pure components.  
Of the 16 compounds for which single crystal data was obtained, 14 structures 
were based upon strategy 2 involving COOH/OH with Narom. Of the obtained structures, 
co-crystals 21-23 were sustained by carboxylic acid-aromatic nitrogen supramolecular 
heterosynthon III as well as alcohol-carbonyl(acid) synthon VII, 24-26 exhibited 
alcohol-pyridine supramolecular heterosynthon VI and carboxylic acid dimer I. 27-34 
exhibit both acid-pyridine III and alcohol-aromatic nitrogen VI supramolecular 
heterosynthons.  Solution and solvent drop grinding attempts to obtain co-crystals of 
nicotinic acid and isonicotinic acid with carboxylic acids were unsuccessful; the IR 
spectroscopy and PXRD spectra of the solid obtained revealed a mixture of starting 
materials. Solvent drop grinding and melt experiments involving 3-hydroxypyridine and 
5-hydroxyisoquinoline with carboxylic acids yielded new phases as characterized by 
XRPD and DSC. Single crystals of 3-hydroxypyridinium benzoate, 35 and 3-
hydroxypyridinium isophthalate, 36 obtained within this series exhibited proton 
transfer between the carboxylic acid and the aromatic nitrogen and was sustained by 
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charge assisted interaction, IV.  The ionic version of III results perhaps as a consequence 
of the pKa difference existing between the components. The negative results obtained 
within the series of compounds involving isonicotinic acid and nicotinic acid with 
alcohols, coupled with the positive results obtained within the series involving OH/Narom 
with COOH suggests that the formation of the carboxylic acid-aromatic nitrogen 
supramolecular heterosynthon III appears to dominate over that of the alcohol-aromatic 
nitrogen supramolecular heterosynthon VI.   
The supramolecular organization in crystal structures of four co-crystals and a co-
crystal hydrate of stavudine formed by co-crystallization with 2- aminopyridines and 
carboxylic acids was presented. Stavudine exhibits a range of 1-point, 2-point and 3-point 
recognition heterosynthons via O-H⋅⋅⋅N, O-H⋅⋅⋅O and N-H⋅⋅⋅O interactions to generate 
pharmaceutical co-crystals. The co-crystals of stavudine further illustrate the diversity 
that may be obtained using a supramolecular approach with respect to API forms. 
The susceptibility of co-crystals toward method of preparation alternative to 
solution was also evaluated. Methods of preparation included growth from melt, grinding 
and solvent-drop grinding. The results suggest that solid state methodology are viable 
means of synthesizing co-crystals,  in most instances the same phase was obtained as that 
from solution. Grinding and solvent drop grinding approaches to supramolecular 
synthesis is highly relevant in the context of green chemistry. In general the solvent drop 
grinding technique has proven to be a reliable technique for the reproducible formation of 
multi-component phases requiring less time at achieving conversion than grinding and 
consequently may form the basis of an initial co-crystal screening regiment. With respect 
to growth from melts sublimation or decomposition of the components need to be taken 
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into consideration when large difference in melting point exists between the initial 
components.  
The ultimate goal of crystal engineering is the understanding of intermolecular 
interactions in an effort to design novel crystalline solids for functional applications. The 
presented research has contributed to the overall progress of the field of crystal 
engineering by facilitating a better understanding of hydrogen bonded supramolecular 
synthons. By combining statistical analysis obtained from the CSD analysis and model 
co-crystals studies crystal engineering of pharmaceuticals is feasible. 
Physical and chemical properties are intrinsically dependent on molecular 
arrangement within the crystal structure. Consequently the application of principles of 
crystal engineering towards API’s is inherently related to the modification of their 
physicochemical properties. That pharmaceutical co-crystal represents a significant 
opportunity in the context of drug development and intellectual property consideration is 
without question however the role of pharmaceutical co-crystal within the pharmaceutical 
industry still remains to be explored. Several foreseeable challenges exists including scale 
up, property evaluation of the co-crystalline material,  issues related to regulatory 
procedures, etc.  
 
6.2.  Future Directions  
Attempts to identify reliable supramolecular synthons have for the most part been 
confined to commonly occurring functional groups such as acids, amides, aromatic 
nitrogen, alcohol etc. However further investigation of the reliability of supramolecular 
synthons and hierarchies in a competitive environment may be applied to a wider range 
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of hydrogen bonding and halogen bonding moieties.  
The focus of the presented research has concentrated on the competition between 
two supramolecular synthons, perhaps investigation of the competition of various 
hydrogen bonds in the presence of three, four, or even more functional groups should be 
addressed as well. Great strides have been made with respect to the generation of binary 
co-crystals especially those involving common functional groups, however there is a 
wide landscape for the formation of ternary or quaternary co-crystals, that remains 
largely unexplored. 
 In the context of pharmaceutical co-crystals, the choice of co-crystal formers 
should be expanded to utilize pharmaceutically acceptable molecules including excipients 
already utilized in the formulation process. Thus far, there have been limited reports on 
the physicochemical performance of pharmaceutical co-crystals as compared to the 
parent API. Consequently the evaluation of physicochemical properties of pharmaceutical 
co-crystal is an important area for additional research.   
Milling or grinding has long been utilized in the pharmaceutical industry as an 
effective method of particle size reduction. Many bulk properties such as, flowability 
bulk density, mixing ability, segregation of mixed materials, bulk density etc. are related 
to particle size.  The determination of bulk properties as a consequence of the method of 
preparation specifically grinding and/or solvent drop grinding also needs to be addressed. 
Additionally, there exists a viable opportunity to apply the solvent-grind and grinding 
technique towards initial screening and ultimate large scale preparation of pharmaceutical 
co-crystals. A temperature regulated High Throughput (HT) grinding or solvent grind 
screen can potentially lead to the isolation of new phases-polymorphs, co-crystals, salts- 
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that may not be viable in a tradition HT crystallization screen.  
The phenomenon of polymorphism has long attracted attention, in the case of 
pharmaceuticals the effect range from issues related to bioavailability to intellectual 
property. Exhaustive screen involving an HT approach during the preformulation stages 
could provide more insight toward better understanding the phenomenon and evaluating 
its frequency.  In the context of pharmaceutical co-crystals addressing whether or not 
pharmaceutical co-crystals are more or less prone to polymorphism may lead to important 
scientific and intellectual property implications. Additionally, the origins of the 
polymorphism in pharmaceutical co-crystals and co-crystals in general perhaps require 
further investigation.  
The multi-disciplinary nature of crystal engineering may be expanded to address 
other molecular targets, such as nucleobases, proteins and molecules that mimic 
biologically active compounds etc. Recombinant DNA technology produces a large 
number of proteins and protein products however these solids are typically produced by 
precipitation or lyophillization and tend in most cases to be amorphous or partially 
amorphous. Consequently the stability of protein pharmaceutics presents a problem that 
may be addressed by applying crystal engineering. The approach towards such 
biomolecular co-crystals may be multi-fold addressing issues of stability as well as 
providing models for drug design, and their binding interactions in the solid state. Other 
molecular targets that would also prove attractive and amenable for study include: 
molecules with high polarizability to generate new classes of non-linear-optical materials; 
explosives or propellants with the potential to reformulate and enhance thermal stability 
etc; agrichemicals and volatile organics. The exploration and crystal engineering of 
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hydrogen bonded 2D and 3D polymers and consequently the use of the hydrogen bonded 
synthons as precursors to a range of solid state synthetic reaction are other areas that still 
remain to be chartered. 
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Appendix 1. Experimental Data for (benzoic acid)2•1,2-bis(4-pyridyl)ethane 1. 
 
Infrared Spectrum, DSC thermogram and X-ray powder diffraction pattern of (benzoic 
acid)2•1,2-bis(4-pyridyl)ethane 1 
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Polymorphism screen data for (benzoic acid)2 •1,2-bis(4-pyridyl)ethane, 1. 
X-ray powder diffraction (XRPD) patterns of powders obtained based upon solvent-drop 
grinding with: cyclohexane, toluene, chloroform, ethyl acetate, methanol, DMSO, and 
water 
0 5 10 15 20 25 30 35 40
0
100
200
300
400
500
600
R
el
at
iv
e 
In
te
ns
ity
2-theta/deg
 
    -  trace peaks from benzoic acid. 
 
Incomplete conversion as evidenced by XRPD, resulting in a mixture of co-crystal and trace amounts of 
starting materials-only one form obtained. 
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Appendix 2. Experimental Data for (benzoic acid)2 • trans-1,2-bis(4-pyridyl)ethylene 
2 
 
Infrared Spectrum, DSC thermogram and X-ray powder diffraction pattern of (benzoic 
acid)2 •trans-1,2-bis(4-pyridyl)ethylene 2  
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Polymorphism screen data for (benzoic acid)2 • trans-1,2-bis(4-pyridyl)ethylene, 2.  
 
X-ray powder diffraction patterns of powders obtained based upon solvent-drop grinding 
with: cyclohexane, toluene, chloroform, ethyl acetate, methanol, DMSO, and water 
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Incomplete conversion as evidenced by XRPD, resulting in a mixture of co-crystal and starting materials-
only one form obtained. 
 
 
 
 195
Appendix 3. Experimental Data for benzoic acid •4,4’-bipyridine, 3 
 
Infrared Spectrum, DSC thermogram and X-ray powder diffraction pattern of benzoic 
acid •4,4’-bipyridine 3. 
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Polymorphism screen data for benzoic acid •4,4’-bipyridine, 3 
X-ray powder diffraction patterns of powders obtained based upon solvent-drop grinding 
with: cyclohexane, toluene, chloroform, ethyl acetate, methanol, DMSO, and water 
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Polymorphism screen data for 2:1 (benzoic acid)2 •4,4’-bipyridine  
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Solvent drop grind screen of a 2:1 mole ratio of benzoic acid and 4,4’-bipyridine reveals a new phase that is 
different from the 1:1 co-crystal 3 
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Appendix 4. Experimental Data for sorbic acid•1,2-bis(4-pyridinium)ethane sorbate 
4 
 
Infrared Spectrum, DSC thermogram and X-ray powder diffraction pattern of sorbic 
acid•1,2-bis(4-pyridium)ethane sorbate 4 
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 Polymorphism screen data for sorbic acid •1,2-bis(4-pyridinium)ethane sorbate, 4.  
X-ray powder diffraction patterns of powders obtained based upon solvent-drop grinding 
with: cyclohexane, toluene, chloroform, ethyl acetate, methanol, DMSO, and water 
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Appendix 5. Experimental Data for (naproxen)2 •trans-1,2-bis(4-pyridyl)ethylene 5 
 
Infrared Spectrum and X-ray powder diffraction pattern of (naproxen)2 •trans-1,2-bis(4-
pyridyl)ethylene 5 
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Polymorphism screen data for (naproxen)2•trans-1,2-bis(4-pyridyl)ethylene, 5.  
X-ray powder diffraction patterns of powders obtained based upon solvent-drop grinding 
with: cyclohexane, toluene, chloroform, ethyl acetate, methanol, DMSO, and water 
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Appendix 6. Experimental Data for glutaric acid •1,2-bis(4-pyridyl)ethane, 6 
 
Infrared Spectrum, DSC thermogram and X-ray powder diffraction pattern of glutaric 
acid •1,2-bis(4-pyridyl)ethane, 6. 
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Polymorphism screen data for glutaric acid •1,2 (4-pyridyl)ethane, 6 
X-ray powder diffraction patterns of powders obtained based upon solvent-drop grinding 
with: cyclohexane, toluene, chloroform, ethyl acetate, methanol, DMSO, and water 
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Appendix 7. Experimental Data for glutaric acid• trans-1,2-bis(4-pyridyl)ethylene, 7 
 
Infrared Spectrum, DSC thermogram and X-ray powder diffraction pattern of glutaric 
acid trans-1,2-bis(4-pyridyl)ethylene, 7. 
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Polymorphism screen data for glutaric acid •trans-1,2 (4-pyridyl)ethylene, 7.  
X-ray powder diffraction patterns of powders obtained based upon solvent-drop grinding 
with: cyclohexane, toluene, chloroform, ethyl acetate, methanol, DMSO, and water 
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Solvent drop grind screen results in only one form as evidenced by XRPD. 
 
 
 
 211
Appendix 8. Experimental Data for oxalic acid•tetramethylpyrazine, 8 
 
Infrared Spectrum, DSC thermogram and X-ray powder diffraction pattern of oxalic 
acid•tetramethylpyrazine, 8. 
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Polymorphism screen data for oxalic acid •tetramethylpyrazine, 8 
X-ray powder diffraction patterns of powders obtained based upon solvent-drop grinding 
with: cyclohexane, toluene, chloroform, ethyl acetate, methanol, DMSO, and water 
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XRPD pattern is a mixture of co-crystal 8 and trace amounts of starting material. 
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Appendix 9. Experimental Data for isophthalic acid •1,2-bis(4-pyridyl)ethane, 9 
 
Infrared Spectrum, DSC thermogram and X-ray powder diffraction pattern of isophthalic 
acid •1,2-bis(4-pyridyl)ethane, 9 
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Polymorphism screen data for isophthalic acid •1,2-bis(4-pyridyl)ethane, 9.  
X-ray powder diffraction patterns of powders obtained based upon solvent-drop grinding 
with: cyclohexane, toluene, chloroform, ethyl acetate, methanol, DMSO, and water. 
 
 
0 5 10 15 20 25 30 35 40
0
100
200
300
400
500
600
R
el
at
iv
e 
In
te
ns
ity
2-theta/deg
 
 
Incomplete conversion as evidenced by XRPD, resulting in a mixture of co-crystal and 
trace amounts of starting materials. Only one form obtained. 
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Appendix  10. Experimental Data for (trimesic acid)2 • trans-(1,2-bis(4-
pyridyl)ethylene)3, 11 
 
Infrared Spectrum, DSC thermogram and X-ray powder diffraction pattern of (trimesic 
acid)2 •trans-(1,2-bis(4-pyridyl)ethylene)3, 11 
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Polymorphism screen data for (trimesic acid)2 •trans-(1,2-bis(4-pyridyl)ethylene)3, 
11 
X-ray powder diffraction patterns of powders obtained based upon solvent-drop grinding 
with: cyclohexane, toluene, chloroform, ethyl acetate, methanol, DMSO, and water 
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Solvent drop grinding for 4 minute results in a mixture of trimesic acid •1,2-bis(4-pyridyl)ethylene, 11 and 
trimesic acid in all cases except that of DMSO solvent grind in which complete conversion is achieved. 
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Appendix 11. Experimental Data for trimesic acid•1,2-bis(4-pyridyl)ethane, 12 
 
 Infrared Spectrum, DSC thermogram and X-ray powder diffraction pattern of trimesic 
acid•1,2-bis(4-pyridyl)ethane, 12 
 
 
56
8
97
59
4.
6266
4.
88
68
8.
84
74
6.
7982
3.
45
89
9.
03
95
1.
86
10
18
.5
0
10
90
.4
9
11
70
.3
7
12
21
.8
91
41
8.
95
16
09
.9
117
01
.6
3
34
10
.6
6
ts503c trimesic acid:1,2bis(4-pyridyl)ethane (2:3)
 15
 20
 25
 30
 35
 40
 45
 50
 55
 60
 65
 70
 75
 80
 85
 90
 95
 100
%
T
 1000   2000   3000  
Wavenumbers (cm-1)  
 
 
 221
 
0 5 10 15 20 25 30 35 40
0
2000
4000
6000
8000
10000
In
te
ns
ity
2-theta/deg
 
Form I 
 
 
0 5 10 15 20 25 30 35 40
0
2000
4000
6000
8000
10000
In
te
ns
ity
2-theta/deg
 
Form 2 
 
 
 
 
 
 
 
 
 222
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 5 10 15 20 25 30 35 40
0
100
200
R
el
at
iv
e 
In
te
ns
ity
2-theta/deg
bipethane
TMA
acetone
 
 
 
 
 
 
 
  
0 5 10 15 20 25 30 35 40
0
500
1000
1500
2000
Simulated FormII
R
el
at
iv
e 
In
te
ns
ity
2-theta/deg
bipethane
TMA
Simulated Form I
 223
Polymorphism screen data for (trimesic acid)2 •(1,2-bis(4-pyridyl)ethane)3, 12 
X-ray powder diffraction patterns of powders obtained based upon solvent-drop grinding 
with: cyclohexane, toluene, chloroform, ethyl acetate, methanol, DMSO, and water 
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Two different XRPD patterns are observed in the above solvent drop grind screen 
of 2:3 molar ratio of TMA and 1,2-bis(4-pyridyl)ethane and are grouped accordingly. 
Group A: Solvent drop grinds involving isopropanol, chloroform, dichloromethane, 
cyclohexane, heptane, ethyl acetate, tetrahydrofuran, acetonitrile, isopropyl acetate, 
methanol, heptane, DMA and DMSO. 
Group B: Solvent drop grinds involving toluene, acetone and ethanol. 
The solvent drop grinds were compared to the starting materials as well as co-crystal 12a 
(form I) and 12b (form II).  Based upon this comparison the solvent drop grinds of group 
A were found to be a mixture of starting materials whereas group B appears to be a new 
form. 
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Appendix 12. Experimental Data for (1-naphthol)2 •1,2-bis(4-pyridyl)ethane, 13 
Infrared Spectrum, DSC thermogram and X-ray powder diffraction pattern of (1-
naphthol)2 •1,2-bis(4-pyridyl)ethane, 13. 
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Appendix 13. Experimental Data for (1-naphthol)2 •trans-1,2-bis(4-pyridyl)ethylene, 
14. 
 Infrared Spectrum, DSC thermogram and X-ray powder diffraction pattern of (1-
naphthol)2 •trans-1,2-bis(4-pyridyl)ethylene, 14. 
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Appendix 14. Experimental Data for 4,4’-biphenol •1,2-bis(4-pyridyl)ethane, 15 
 
DSC and X-ray powder diffraction pattern of 4,4’-biphenol •1,2-bis(4-pyridyl)ethane, 15 
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Appendix 15. Experimental Data for 4,4’-biphenol • trans-1,2-bis(4-
pyridyl)ethylene, 16. 
Infrared Spectrum, DSC thermogram and X-ray powder diffraction pattern of 4,4’-
biphenol • trans-1,2-bis(4-pyridyl)ethylene, 16. 
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Appendix 16. Experimental Data for hydroquinone • trans-1,2-bis(4-
pyridyl)ethylene, 17 
Infrared Spectrum, DSC thermogram and X-ray powder diffraction pattern of 
hydroquinone • trans-1,2-bis(4-pyridyl)ethylene, 17. 
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Appendix 17. Experimental Data for hydroquinone• tetramethylpyrazine, 18 
Infrared Spectrum, DSC thermogram and X-ray powder diffraction pattern of 
hydroquinone• tetramethylpyrazine, 18. 
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Appendix 18. Experimental Data for (resorcinol)2•(TMP)3, 19 
Infrared Spectrum, DSC thermogram and X-ray powder diffraction pattern of 
(resorcinol)2•(TMP)3, 19. 
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Appendix 19. Experimental Data for 2,7-dihydroxynaphthalene● (TMP)2, 20  
Infrared Spectrum, DSC thermogram and X-ray powder diffraction pattern of 2,7-
dihydroxynaphthalene● (TMP)2, 20 
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Appendix 20. Experimental Data for (3-hydroxybenzoic acid)2 •pyrazine, 21 
 
Infrared Spectrum and X-ray powder diffraction pattern of (3-hydroxybenzoic acid)2 •1,2-
bis(4-pyridyl)ethane, 21. 
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New Phase obtained upon melt that does not correspond to calc. co-crystal XRPD pattern, has peaks that 
are shifted relative to starting materials and co-crystal. 
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Dry grinding for 6 minutes yields phase that does not correspond to co-crystal, possibly a mixture of Form I 
and Form II 3-hydroxybenzoic acid 
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New Phase obtained that does not correspond to calc. co-crystal XRPD pattern, has peaks that are shifted 
relative to starting materials and co-crystal. 
 
 
Polymorphism screen data for  3-hydroxybenzoic acid)2 •pyrazine 21 
X-ray powder diffraction patterns of powders obtained based upon solvent-drop grinding 
with: cyclohexane, toluene, chloroform, ethyl acetate, methanol, DMSO, and water 
 
 
0 5 10 15 20 25 30 35 40
0
50
100
150
200
250
300
350
R
el
at
iv
e 
In
te
ns
ity
2-theta/deg
 cyclohexane
DMSO
ethyl acetate
water
 toluene
methanol
calc 3HB2 pyrazine xtal
 
(3-hydroxybenzoic acid)2• pyrazine co-crystal reproduced from MeOH grind. Solvent drop grinding 
involving DMSO, ethyl acetate, water and cyclohexane produced a new phase that does not correspond to 
calc. co-crystal XRPD pattern and has peaks that are shifted relative to starting materials and co-crystal. 
Toluene grind appears to give a mixture of 3-hydroxybenzoic acid Form I and Form II exhibiting a similar 
pattern as seen in the dry grind.  
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Appendix 21. Experimental Data for 4-hydroxybenzoic acid •1,2-bis(4-
pyridinium)ethane • 4- hydroxybenzoate, 22 
 
Infrared Spectrum, DSC thermogram and X-ray powder diffraction pattern of  4-
hydroxybenzoic acid •1,2-bis(4-pyridinium)ethane • 4- hydroxybenzoate, 22. 
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Co-crystal obtained from melt, grind and solvent drop grind resulted in mixture of starting materials 
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X-ray powder diffraction patterns of powders obtained based upon solvent-drop grinding 
with: cyclohexane, toluene, chloroform, ethyl acetate, methanol, DMSO, and water 
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A search for crystal forms using solvent drop grinding yield new crystalline phase that contain peaks that 
do not correspond to isolated single crystal or starting materials 
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Appendix 22. Experimental Data for (4-hydroxybenzoic acid)2 •tetramethylpyrazine, 
23 
 
Infrared Spectrum and X-ray powder diffraction pattern of (4-hydroxybenzoic acid)2 
•tetramethylpyrazine, 23 
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Melt, solvent drop grind and dry grind yield the co-crystal as well as starting materials. 
 
 
 
X-ray powder diffraction patterns of powders obtained based upon solvent-drop grinding 
with: cyclohexane, toluene ethyl acetate, methanol, water and DMSO 
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Water, methanol and ethyl acetate grind contain additional peaks that are not present in either co-crystal or 
starting materials. Complete conversion to co-crystal from DMSO grind whereas peaks corresponding to 4-
hydroxybenzoic acid are present in cyclohexane and toluene grinds. 
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Appendix 23. Experimental Data for 4-hydroxybenzoic acid • 4-phenylpyridine, 24 
 
Infrared Spectrum and X-ray powder diffraction pattern of 4-hydroxybenzoic acid • 4-
phenylpyridine, 24. 
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Peak shifts as compared to co-crystal and starting material evident in melt and solvent drop grind. Dry 
grind appears to be a mixture of starting materials 
 
 
X-ray powder diffraction patterns of powders obtained based upon solvent-drop grinding 
with: cyclohexane, toluene, ethyl acetate, methanol, DMSO and water 
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MeOH and EtoAc grinds results in mixture of starting materials, DMSO grinds have peaks corresponding 
to co-crystals however peaks at higher 2θ values are shifted relative to the co-crystal  
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Appendix 24. Experimental Data for (4-hydroxybenzoic acid)2 •pyrazine, 25 
 
Infrared Spectrum, DSC thermogram and X-ray powder diffraction pattern of (4-
hydroxybenzoic acid)2 •pyrazine, 25 
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New crystalline phase obtained that contain peaks that are not present or are shifted relative to co-crystal 
and starting materials. 
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Appendix 25. Experimental Data for 4-hydroxybenzoic acid)2 •tetramethylpyrazine 
acetonitrile solvate, 26 
 
Infrared Spectrum, DSC thermogram and X-ray powder diffraction pattern of  (4-
hydroxybenzoic acid)2 •tetramethylpyrazine acetonitrile solvate, 26 
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Acetonitrile grind does not yield the (4-hydroxybenzoic acid)2  tmp acetonitrile solvate  
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Appendix 26. Experimental Data for 3-hydroxybenzoic acid •(4-phenylpyridine)2, 27 
 
Experimental Data for Infrared Spectrum, DSC thermogram and X-ray powder 
diffraction pattern of 3-hydroxybenzoic acid •(4-phenylpyridine)2, 27 
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The co-crystal is reproduced from the melt. A mixture of the co-crystal and starting material was obtained 
from dry grind and acetone solvent drop grind. 
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X-ray powder diffraction patterns of powders obtained based upon solvent-drop grinding 
with: cyclohexane, toluene, ethyl acetate, methanol, DMSO and water  
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Solvent drop grinding for 4minutes yield a mixture of co-crystal and starting materials, peak shift ca. 27 
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Appendix 27. Experimental Data for 3-hydroxybenzoic acid •1,2-bis(4-
pyridyl)ethane, 28 
 
Infrared Spectrum, DSC thermogram and X-ray powder diffraction pattern of 3-
hydroxybenzoic acid •1,2-bis(4-pyridyl)ethane, 28 
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Co-crystal produced from the melt. 
 
 
 
 
 
 
 
 
 261
X-ray powder diffraction patterns of powders obtained based upon solvent-drop grinding 
with: cyclohexane, toluene, chloroform, ethyl acetate, methanol, DMSO and water  
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Dry grind and solvent drop grinds give a mixture of co-crystal and starting materials 
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Appendix 28. Experimental Data for 3-hydroxybenzoic acid •4,4’-bipyridine, 29 
 
Infrared Spectrum, DSC thermogram and X-ray powder diffraction pattern of  3-
hydroxybenzoic acid •4,4’-bipyridine, 29. 
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Dry grind for 4 minutes gives a mixture of starting materials as well as a peak ca. 27 2θ that is present in 
co-crystal. Co-crystal is produced from the melt. 
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X-ray powder diffraction patterns of powders obtained based upon solvent-drop grinding 
with: cyclohexane, toluene, chloroform, ethyl acetate, methanol, DMSO and water  
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Co-crystal is reproduced from solvent drop grindings involving methanol, cyclohexane, water and dmso, all 
other solvent and dry grind produce the co-crystal as well as starting materials. 
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Appendix 29. Experimental Data for 3-hydroxybenzoic acid •quinoxaline, 30 
 
 Infrared Spectrum, DSC thermogram and X-ray powder diffraction pattern of  3-
hydroxybenzoic acid •quinoxaline, 30. 
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Dry grind gives mixture of co-crystal and starting materials. 
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X-ray powder diffraction patterns of powders obtained based upon solvent-drop grinding 
with: cyclohexane, toluene, ethyl acetate, methanol, DMSO and water 
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Solvent drop grind results in mixture of co-crystal and starting materials 
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Appendix 30. Experimental Data for (3-hydroxybenzoic acid)2 • 
(tetramethylpyrazine)3, 31 
 
DSC thermogram and X-ray powder diffraction pattern of (3-hydroxybenzoic acid)2 • 
(tetramethylpyrazine)3, 31. 
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Melt produces co-crystal 31, grind gives mixture of starting materials 
 
X-ray powder diffraction patterns of powders obtained based upon solvent-drop grinding 
with: cyclohexane, toluene, ethyl acetate, methanol, DMSO and water 
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Ethyl acetate grind gives new crystalline phase, mixture of starting material and co-crystals obtained from 
other solvent drop grinds. 
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Appendix 31. Experimental Data for 6-hydroxy-2-naphthoic acid • trans-1,2-bis(4-
pyridyl)ethylene, 32 
 
Infrared Spectrum, DSC thermogram and X-ray powder diffraction pattern of 6-hydroxy-
2-naphthoic acid • trans-1,2-bis(4-pyridyl)ethylene, 32 
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Appendix 32. Experimental Data for 4-hydroxybenzoic acid • trans-1,2-bis(4-
pyridyl)ethylene, 33 
 
Infrared Spectrum, DSC thermogram and X-ray powder diffraction pattern of 4-
hydroxybenzoic acid • trans-1,2-bis(4-pyridyl)ethylene, 33. 
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Grind results in a mixture of starting materials 
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Appendix 33. Experimental Data for 3-hydroxybenzoic acid • trans-1,2-bis(4-
pyridyl)ethylene, 34 
 
Infrared Spectrum, DSC thermogram and X-ray powder diffraction pattern of 3-
hydroxybenzoic acid • trans-1,2-bis(4-pyridyl)ethylene, 34. 
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Grind results in a mixture of starting materials 
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Appendix 34. Experimental Data for 3-hydroxypyridinium benzoate, 35 
 
Infrared Spectrum, DSC thermogram and X-ray powder diffraction pattern of 3-
hydroxypyridinium benzoate, 35. 
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X-ray powder diffraction patterns of powders obtained based upon solvent-drop grinding 
with: cyclohexane, toluene, ethyl acetate, methanol, DMSO and water 
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Solvent drop grinding yields organic salt of 3-hydroxypyridinium benzoate 
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Appendix 35. Experimental Data for 3-hydroxypyridinium isophthalate, 36 
 
Infrared Spectrum, DSC thermogram and X-ray powder diffraction pattern of 3-
hydroxypyridinium isophthalate, 36. 
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X-ray powder diffraction patterns of powders obtained based upon solvent-drop grinding 
with: cyclohexane, toluene, ethyl acetate, methanol, DMSO and water 
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Appendix 36. X-ray powder diffraction patterns of grinding and solvent drop grinding of 
isonicotinic acid •1-naphthol, nicotinic acid •1-naphthol, (nicotinic acid)2 •4,4’-biphenol, 
(isonicotinic acid)2 •4,4’-biphenol, (isonicotinic acid)3 •phloroglucinol, (nicotinic acid)3 
•phloroglucinol, (isonicotinic acid)2 •resorcinol, (nicotinic acid)2 •resorcinol. 
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Appendix 37. DSC thermograms for the attempted co-crystallizations of  5-
hydroxyisoquinoline•benzoic acid, 5-hydroxyisoquinoline • sorbic acid, (5-
hydroxyisoquinoline)2 • isophthalic acid, (5-hydroxyisoquinoline)2 • glutaric acid, 
(5-hydroxyisoquinoline)3 • trimesic acid, 3-hydroxypyridine • sorbic acid, (3-
hydroxypyridine)2 • glutaric acid, (3-hydroxypyridine)3 • trimesic acid. 
 
 
DSC thermogram for the solvent drop grinding of 1:1 mole ratio of  5-
hydroxyisoquinoline and benzoic acid 
 
 
DSC thermogram comparing the solvent drop grind of 5-hydroxyisoquinoline and 
benzoic acid versus starting materials 
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DSC thermogram for the solvent drop grinding of 1:1 mole ratio of  5-
hydroxyisoquinoline and sorbic acid 
 
 
 
DSC thermogram comparing solvent drop grind 5-hydroxyisoquinoline and sorbic acid 
versus starting materials 
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DSC thermogram for the solvent drop grinding of 2:1 mole ratio of  5-
hydroxyisoquinoline and glutaric acid 
 
 
DSC thermogram comparing solvent drop grind 5-hydroxyisoquinoline and glutaric acid 
versus starting materials 
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DSC thermogram for the solvent drop grinding of 2:1 mole ratio of  5-
hydroxyisoquinoline and isophthalic acid 
 
 
 
 
DSC thermogram comparing solvent drop grind 5-hydroxyisoquinoline and isophthalic 
acid versus starting materials 
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DSC thermogram for the solvent drop grinding of 3:1 mole ratio of  5-
hydroxyisoquinoline and trimesic acid 
 
 
 
 
DSC thermogram comparing solvent drop grind 5-hydroxyisoquinoline and trimesic acid 
versus starting materials 
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DSC thermogram showing comparison of solvent drop grind of 3-hydroxpyridine and 
benzoic acid versus single crystals of 3-hydroxypyridinium benzoate 
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DSC thermogram for the solvent drop grinding of 2:1 mole ratio of  3-hydroxypyridine 
and isophthalic acid 
 
 
DSC thermogram comparing solvent drop grind 3-hydroxypyridine and isophthalic acid 
versus starting materials 
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DSC thermogram for the solvent drop grinding of 1:1 mole ratio of  3-hydroxypyridine 
and sorbic acid 
 
 
 
DSC thermograms comparing solvent drop grind 3-hydroxypyridine and sorbic acid 
versus starting materials 
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DSC thermogram for the solvent drop grinding of 2:1 mole ratio of  3-hydroxypyridine 
and glutaric acid 
 
 
 
DSC thermograms comparing solvent drop grind 3-hydroxypyridine and glutaric acid 
versus starting materials 
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X-ray powder Diffraction of attempted co-crystallization of 3-hydroxypyridine and sorbic 
acid 
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Histogram showing contact distance for alcohol-carbonyl (acid) interactions 
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There are 1495 entries that contain both a carboxylic acid and an alcohol. Of this number 
566/1495 (37%) exhibit the alcohol-carbonyl heterosynthon. The interaction was found to 
occur within the range 2.6-3.0Å, Mean: 2.80(8) Å 
 
Search Filters: CSD 5.28, Jan 2007 update: Organics only, 3D coordinates determined, 
R>7.5%.  
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Tabulated  pKa values of existing CSD structures containing 3-hydroxypyridine 
 
REFCODE Compound Pka (acid) Pka (base) ΔPka(base-
acid) 
IDUNEA 3-hydroxypyridinium_ 5-
nitrofuran-2-carboxylate 
2.06 8.51 
4.86 
6.45 
IDUNIE 3-hydroxypyridinium_ 4-
nitrobenzoate 
3.42 8.51 
4.86 
5.09 
IDUNOK 3-hydroxypyridinium_ 2,4-
dinitrobenzoate 
1.43 8.51 
4.86 
7.08 
IDUNUQ 3-hydroxypyridinium_3,5-
dinitrobenzoate 
2.77 8.51 
4.86 
5.74 
JOJJUN 3-hydroxypyridinium_2,4,6-
trinitrobenzoate 
0.42 8.51 
4.86 
8.09 
KOKBOC 3-hydroxypyridinium_(2,4-
dichlorophenoxy acetate 
2.98 8.51 
4.86 
5.53 
LEJROH 3-hydroxypyridinium_ pyrazine-
2,6-dicarboxylate  
2.24 
-4.01 
8.51 
4.86 
6.27 
OCAKAF 3-hydroxypyridinium_3-
(carboxymethoxy)phenoxy acetate 
2.83 8.51 
4.86 
5.68 
PAHZAA 3-hydroxypyridinium_2-
hydroxypropanedioate 
1.98 8.51 
4.86 
6.53 
RACBED 3-hydroxypyridinium_2,5-
dihydroxybenzoate 
3.01 8.51 
4.86 
5.50 
VITXUR 3-hydroxypyridinium tartrate 3.07 8.51 
4.86 
5.44 
YETLUE 3-hydroxypyridinium_L-malate 3.61 8.51 
4.86 
4.90 
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Tabulated pKa values for components used in attempted co-crystallization involving molecules 
containingOH/Narom with COOH melecules 
 
 pKa (base) pKa(acid) ΔpKa 
3-hydroxypyridine and sorbic 
acid 
8.51 
4.86 
4.59 3.92 
3-hydroxypyridine and glutaric 
acid 
8.51 
4.86 
4.33 4.18 
3-hydroxypyridine and trimesic 
acid 
8.51 
4.86 
2.98 5.53 
5-hydroxyisoquinoline and 
benzoic acid 
8.31 
5.31 
4.2 4.11 
5-hydroxyisoquinoline and 
sorbic acid 
8.31 
5.31 
4.59 3.72 
5-hydroxyisoquinoline and 
glutaric acid 
8.31 
5.31 
4.33 3.98 
5-hydroxyisoquinoline and 
isophthalic acid 
8.31 
5.31 
3.53 4.78 
5-hydroxyisoquinoline and 
trimesic acid 
8.31 
5.31 
2.98 5.53 
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Appendix 39. Experimental Data for (stavudine)3 •melamine, 37 
 
DSC thermogram, FT-IR spectrum and X-ray powder diffraction patterns of bulk sample 
and calculated from the single crystal structure for (stavudine)3 •melamine, 37 
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Polymorphism screen data: X-ray powder diffraction patterns of powders obtained 
based upon solvent-drop grinding with: cyclohexane, toluene, ethyl acetate, methanol, 
DMSO, and water.   
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Comparison of X-ray powder diffraction patterns of bulk sample obtained via slurry in 
water and calculated from the single crystal structure 
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Appendix 40. Experimental Data for stavudine •2,4,6-triaminopyrimidine hydrate, 38. 
 
X-ray powder diffraction patterns calculated from the single crystal structure for 
stavudine •2,4,6-triaminopyrimidine hydrate, 38. 
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Comparison of X-ray powder diffraction patterns of bulk sample obtained via slurry in 
water and calculated from the single crystal structure 
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Appendix 41. Experimental Data for stavudine•2-aminopyridine, 39 
DSC termogram, FT-IR spectrum and X-ray powder diffraction patterns of stavudine•2-
aminopyridine, 39. 
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Polymorphism screen: X-ray powder diffraction patterns of powders obtained based 
upon solvent-drop grinding with: cyclohexane, toluene, chloroform, ethyl acetate, 
methanol, DMSO, and water. 
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Comparison of X-ray powder diffraction patterns of bulk sample obtained via slurry in 
water and calculated from the single crystal structure 
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Appendix 42. Experimental Data for stavudine•4-hydroxybenzoic acid, 40 
DSC termogram, FT-IR spectrum and X-ray powder diffraction patterns of stavudine•4-
hydroxybenzoic acid, 40. 
 
61
6.
8479
8.
93
81
7.
18
85
0.
71
10
73
.5
5
12
41
.2
9
12
80
.9
9
15
96
.8
8
16
89
.0
8
 72
 74
 76
 78
 80
 82
 84
 86
 88
 90
 92
 94
 96
 98
 100
 102
%
T
 1000   2000   3000   4000  
Wavenumbers (cm-1)  
 
 
 308
0 5 10 15 20 25 30 35 40 45
0
2000
4000
6000
8000
10000
In
te
ns
ity
2-theta/deg
 
 
 
0 5 10 15 20 25 30 35 40
-100
0
100
200
300
400
500
600
700
800
R
el
at
iv
e 
In
te
ns
ity
2-theta/deg
4-hydroxybenzoic acid
stavudine
simulated XRPD stavudine
_4-hydroxybenzoic acid xtal
 
 
 
 
 309
0 5 10 15 20 25 30 35 40
0
100
200
300
400
500
600
700
R
el
at
iv
e 
In
te
ns
ity
2-theta/deg
grind
solvent grind
melt
simulated stavudine
_4-hydroxybenzoic acid xtal
 
 
Polymorphism screen data for stavudine•4-hydroxybenzoic acid, 40 
X-ray powder diffraction patterns of powders obtained based upon solvent-drop grinding 
with: cyclohexane, toluene, chloroform, ethyl acetate, methanol, DMSO, and water. 
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Comparison of X-ray powder diffraction patterns of bulk sample obtained via slurry in 
water and calculated from the single crystal structure 
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Appendix 43. Experimental Data for stavudine• salicylic acid 41 
DSC termogram, FT-IR spectrum and X-ray powder diffraction patterns of bulk sample 
and calculated from the single crystal structure of stavudine• salicylic acid, 41 
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Polymorphism Screen for stavudine •salicylic acid, 41: X-ray powder diffraction patterns 
of powders obtained based upon solvent-drop grinding with: cyclohexane, toluene, 
chloroform, ethyl acetate, methanol, DMSO and water 
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Comparison of X-ray powder diffraction patterns of bulk sample obtained via slurry in 
water and calculated from the single crystal structure 
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